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Abstract 
Alzheimer’s disease (AD) is the most common form of dementia among the elderly. 
The disease is characterized by amyloid-β (Aβ) plaques, neurofibrillary tangles, 
loss of synapses and neurons, and chronic neuroinflammation. The significance 
of neuroinflammatory processes in the on-set and progression of AD have been 
debated, as activated and reactive glial cells demonstrated protective and 
damaging properties. However, patients with AD treated with anti-inflammatory 
drugs demonstrated a lesser than average extent of disease development, 
indicating an important role of neuroinflammation in AD. Current strategies for the 
treatment of Alzheimer’s disease are minimally effective, as we lack the methods 
of diagnosis at an early stage. Numerous cases present significant neuronal loss 
prior to diagnosis and, as restoration of function is unlikely, treatment options focus 
on limiting further neuronal loss. It is my hypothesis that deposition of Aβ peptide 
can activate the innate immune system via pattern recognition receptors (PRRs), 
including complement, and evoke Alzheimer's pathology. In the current study, we 
focused on the role of the innate immunity system of the brain in the initiation and 
the propagation of inflammatory process in AD and the interplay between 
TLRs/NLRs and the complement system.  
Silencing the expression of various receptors demonstrated the involvement of 
NLRP3 in Aβ recognition, and use of confocal microscopy confirmed the 
association of Aβ interactions with this inflammasome and complement receptors. 
These results were confirmed in human astrocytes stimulated with Aβ and in brain 
tissue slides of patients with AD. Using human astrocytes and fluorescence 
resonance energy transfer (FRET), the associations of cell surface TLRs (such as 
TLR2, TLR4) with CRs (C5aR1, C3aR) were investigated; TLR2 and TLR4 were 
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found to interact with C5aR1. In addition, Aβ-induced responses were augmented 
in the presence of complement and Aβ appeared to induce the interactions of 
TLR4 and C5aR1 on the cell surface. The trafficking of PRRs and Aβ in human 
astrocytes was further investigated to determine whether internalization and 
trafficking of Aβ is crucial for triggering a proinflammatory response. The results 
demonstrated that, along with Aβ and TLR4, complement internalized in the 
Rab5+ endosomes, and recruited NF-kB-inducing kinase (NIK) to these 
endosomes in a complement-dependent manner. MAC complexes were 
previously demonstrated to activate an Akt+NIK+ signalosome in human 
endothelial cells. To the best of our knowledge, this is the first to identify such 
signalosomes in Rab5+ endosomes in response to complement and Aβ. These 
results suggest a novel possibility of a therapeutic target in the case of an Aβ-
induced neuroinflammation.  
C5a is the most potent anaphylatoxin, thus upon the identification of the 
complement-inflammasome interactions, the role of C5a in the Aβ recognition was 
investigated in human astrocytes. The results demonstrated that C5a augmented 
the Aβ-induced IL-1β production, activated pro-IL-1β and was caspase-1-
dependent. In addition, a C5a-induced IL-1β release was observed following 
Signal 2 stimulation by Ca2+ and lysosomal damage.  Since the signal activation 
resulting in inflammation in AD appears to involve multiple receptors, the therapy 
should be combinational and not targeting single molecules. Thus, C5aR1 
blocking antibodies and PMX53 were utilized to identify a combinatory therapeutic 
approach in human astrocytes. The results demonstrated that the secretion of IL-
1β was further reduced in the combinatory treatment of PMX53+MCC950 
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compared with their single treatments, suggesting a combinatory treatment to 
tackle the effect of Aβ in human cells. 
The results of the present study add on to the current knowledge of the molecular 
mechanisms involved in AD, regarding Aβ association, and may lead to the design 
of targeted therapeutic interventions for AD. 
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1.1 Neurodegenerative Diseases 
The clinical characterization of neurodegenerative diseases is based on the 
pathological loss of neurons and the loss of neurological functionality. The loss of 
neurons in some of these diseases is often accompanied by certain 
histopathological findings, including Lewy bodies and Alzheimer’s plaques 
(Arvanitakis et al. 2011; Bennet et al. 2006). On the other hand, other 
neurodegenerative diseases demonstrate gradual neuronal loss and atrophy 
without a specific pathology, or entail certain interconnected sets of neurons or 
anatomical systems. In the latter, the focal pathology is symmetric and bilateral or 
otherwise diffused and such diseases are relentlessly progressive (Crews and 
Masliah 2010). Neurodegenerative diseases often affect the elderly however, 
certain may affect children and young individuals (Bierer et al. 1995; Bussière et 
al. 2003). Researchers have established the biochemical basis of 
neurodegenerative diseases and a great number of them are inherited. Certain 
genes associated with these diseases were identified and DNA-based diagnosis, 
such as prenatal diagnosis, is available (Cozaru et al. 2016). To attain specific 
treatments for these diseases, an insight into their pathological mechanisms and 
gene products is required. Alzheimer’s and Parkinson’s diseases are the two most 
common neurodegenerative diseases.  
1.1.1 Dementia 
Dementia is a generic term referring to the loss of one’s mental capacity. It may 
be the result of any pathology which can cause substantial brain damage (Uboga 
and Price 2010). Certain causes of dementia are neuropsychiatric disorders, 
effects of medication, severe organ failure or medical illness, neurodegenerative 
diseases (Huntington’s disease, diffuse Lewy Body dementia, Parkinson’s disease 
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or Alzheimer’s Disease), multiple sclerosis (demyelinative diseases), metabolic 
central nervous system (CNS) disorders (peroxisomal diseases and lysosomal 
storage), CNS infections (HIV encephalitis), hydrocephalus, head trauma (chronic 
traumatic encephalopathy, diffuse axonal injury, subdural hematomas), 
hippocampal sclerosis, and ischemic encephalopathy and stroke (vascular or 
multi-infarct dementia) (Scott and Barrett 2007).  
1.1.2 Alzheimer’s Disease 
Alzheimer’s disease (AD) was first described in 1906 by Dr Alois Alzheimer, a 
German neuropathologist and psychiatrist. His patient (a woman over 50 years of 
age) named Auguste D was suffering from poor cognitive function and language 
skills, altered behaviour, and memory impairment (Berrios 1991). The post-
mortem neuropathological assessment of the patient revealed neurofibrillary 
tangles, senile plaques, and histopathological lesions, which are now known as 
the pathological characteristics of AD (Guillozet et al. 2003; Serrano-Pozo et al. 
2011; Selkoe et al. 2012).  AD was recognized as the leading cause of dementia 
during the late 1960s and early 1970s due to the work done by Gary Blessed, 
Bernard Tomlinson, and Martin Roth (Blessed et al. 1968). During that time, 
researchers discovered that individuals with AD exhibited acute loss of cholinergic 
neurons that synthesize the so-called neurotransmitter acetylcholine. This 
discovery facilitated the efforts aimed at increasing acetylcholine levels in the 
patient’s brain. Currently, most of the drugs for AD treatment are based on this 
concept. Further studies demonstrated that AD influences various 
neurotransmitter systems and this explained the existing drugs’ modest effect. 
Researchers have focused their efforts on the disease’s molecular mechanisms 
over the past two decades and they have gained further understanding of the 
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disease through characterization and examination of the brain lesions, based on 
Dr Alzheimer’s initial description (Ghoshal et al. 1999; Gómez-Isla et al. 1997; 
Serrano-Pozo et al. 2011). The clinical characteristics of AD include delusions, 
depression, indifference, inability to perform calculations, loss of language 
function, loss of memory, a deranged view of space, and inability to learn about 
new things (Knudsen et al. 2001; Bird 2015). Such deficits impair the social 
functioning of the patients and hinder them from carrying out their daily activities. 
Patients with AD often die of various complications associated with chronic illness. 
While the disease often affects the elderly (>60 years old), it sometimes affects 
individuals aged between 40 and 50 years old. The prevalence of AD increases 
with age; ~10% of individuals >70 have significant memory loss and more than 
half of these individuals have AD. An estimated of 25-45% individuals >85 years 
old have dementia. The incidence of AD increases from 2.8 per 1,000 individuals 
between 65 and 69 years old, to 56.1 per 1,000 individuals over 90 years old 
(Kukull et al. 2002).  
The two major lesions in AD are neurofibrillary tangles (NTs) and senile plaques 
(SPs) (Pike et al. 1995; Braak et al. 2006). The latter refers to the spherical lesions 
within the cerebral cortex which measures up to approximately 100 microns. The 
two types of senile plaques are neuritic plaques (NPs) and Aβ plaques (AβPs) 
(Hyman et al. 1993; Serrano-Pozo et al. 2011). The former refers to the 
extracellular Aβ deposits which are spherical in shape (Figure 1.1.2.1). On the 
other hand, NPs refers to the AβPs that consist of degenerating neuronal 
processes having tau-paired helical filaments (Crowther 1991). They also consist 
of reactive microglia and astrocytes. The Aβ found in NPs often forms small 
clumps or a central core, is Congo Red positive, and contains a fibrillary fine 
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structure (Glabe 2005; Greenberg et al. 1997; Grutzendler et al. 2007). AβPS do 
not cause disruptions to the neuropil. In certain cases, elderly non-demented 
individuals may have increased numbers of AβPs, however these are not 
associated with AD. A neuritic plaque scoring mechanism was developed by the 
Consortium to Establish a Registry for Alzheimer’s disease (CERAD) which is 
used for ranking the neuritic plaques’ density within the neocortex, as identified by 
the Bielschowski silver stains (Mirra et al. 1991).  
NTs refer to the tau filaments found within the neuronal body. In addition, similar 
deposits are found within the dendrites and in the NPs’ dystrophic processes 
(Bondareff et al. 1991; Augustinack et al. 2002). The hippocampus in advanced 
AD often consists of extracellular NTs that are embedded within the neuropil, like 
neurons’ fossilized skeletons (Hoozemans et al. 2009). However, the mechanism 
through which the tau accumulates in the NTs is unclear. It is believed that Aβ 
deposition is the primary lesion in AD, while NTs are the secondary (Braak et al. 
1994; Braak and Del Tredici 2011). Nevertheless, the development of NTs is 
independent of Aβ. Additionally, the cognitive decline has a higher association to 
the NTs than the SPs’ number (Mandelkow and Mandelkow 1998; Guillozet-
Bongaarts et al. 2005). Both the environmental and genetic risks of AD are strongly 
associated with the amyloid. In addition to AD, NTs are also found in several other 
neurodegenerative diseases, including prion diseases, chronic traumatic 
encephalopathy, and frontotemporal dementias. These cases are a clear 
indication that NTs may independently result in neurodegeneration without an Aβ 
deposition (Iqbal and Grundke-Iqbal 2002; Giannakopoulos et al. 2003; Ingelsson 
et al. 2004). However, SPs are demonstrated in AD only. 
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While certain cases of AD have a predominance of either NTs or SPs, most of 
them demonstrate a combination of both. The analysis of NTs deposition’s pattern 
indicates that such changes initially appear within the temporal lobes’ 
transentorhinal area prior to spreading to other regions, including the neocortex, 
hippocampus, and the entorhinal cortex (see Figure 1.1.2.2) (Gómez-Isla et al. 
1996; Guillozet-Bongaarts et al. 2005; Harris et al. 2010). Therefore, there are 
three stages involved in the development of the AD’s neurofibrillary pathology: 
isocortical, limbic and transentorhinal. These stages form the foundation for the 
AD Braak and Braak staging system (Braak and Braak 1991). This system’s initial 
stages (stages I and II) correlate to the so-called transentorhinal involvement, the 
next two (stages III and IV) correlate to the limbic, and the last two (stages V and 
VI) correlate to the isocortical involvement. Neocortical NTs are associated with 
cognitive decline, whereas NTs in the entorhinal cortex and hippocampus are 
associated with memory impairment (Braak and Braak 1991).  
SPs are commonly present in the association cortex. However, in very acute cases 
of patients, NTs and SPs are additionally observed in the brainstem and deep 
cerebellar nuclei, whereas the white matter does not contain such lesions. Each 
SP is a representation of the neuropil’s focus of damage, including numerous 
neurons’ dendrites and axon terminals, and possibly thousands of synapses 
(Geddes et al. 1997). Therefore, formation of SPs results in acute disconnection. 
The clinical pathology is associated with the lesions’ distribution. The hippocampal 
damage justifies the memory impairment, while the association cortex’s 
involvement is correlated with the patient’s higher-level intellectual functions. Both 
NTs and SPs correlate with brain atrophy, the loss of synapses and neurons, as 
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well as the lateral ventricles’ dilation because of brain tissue loss (DeKosky and 
Scheff 1990; DeKosky et al. 1996; Erten-Lyons et al. 2009). 
 
 
 
 
 
 
 
Figure 1.1.2.1 Histopathological lesions in Alzheimer’s Disease. Amyloid plaque in the 
hippocampus area of an Alzheimer’s Disease patient (image obtained during staining analysis of 
a tissue slide provided for this project). 
 
 
Figure 1.1.2.2 Diagram of the brain. 
Neocortex 
The thin outer layer of tissue 
Entorhinal cortex 
Hippocampus 
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1.2 APP processing  
Amyloid precursor protein (APP) refers to a transmembrane protein that is largely 
availed in various tissues. There are three varying secretases that mediate the 
proteolytic processing of APP:  α-, β- and γ-secretases. The site of α-secretase 
cleavage is found between residue 16 and 17 in the centre of the Aβ sequence, 
sending out α-APPs from the cell membrane. The C-terminal fragment C83 is in 
the left membrane, and the β-secretase cleaves APP into β-APPs and the C-
terminal fragment C99. γ-secretase cleaves C83 and C99, releasing p3 and Aβ, 
respectively (Figure 1.2). Therefore, Aβ is not produced by cleavage with γ-
secretase and α-secretase and this pathway is called the non-amyloidogenic 
pathway. It thus follows that the amyloidogenic pathway creating the Aβ is 
mediated by β-secretase and γ-secretase (Esler and Wolfe 2001).  
β-secretase cleavage in the brain has been observed to be interceded by a single 
protein, the aspartyl protease β-site APP cleaving enzyme-1 (BACE-1) (Vassar et 
al. 1999). This transmembrane protein is carried through the secretory pathway to 
the plasma membrane and clustered with APP in lipid rafts (membrane 
microdomains containing cholesterol). The primary sites of β-secretase activity are 
the lipid rafts and endosomes (Vassar et al. 1999; Ehehalt et al. 2003). Τhe ideal 
pH for BACE-1 activity is 5.5 (Sinha et al. 1999), hence, the acidic environment of 
endosomes supports the β-secretase action. The biological significance of BACE-
1 has been indistinct until recently; BACE-1 action was observed to be vital for the 
myelination of axons (Willem et al. 2006).  
γ-secretase cleavage is performed by a protein complex comprising of 4 proteins: 
nicastrin, presenilin, APH-1 (frontal pharynx-deficient phenotype 1) and PEN-2 
(presenilin-enhancer 2) (Edbauer et al. 2003). The γ-secretase complex cleaves 
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inside the transmembrane space of APP, and γ-secretase has been demonstrated 
to be present and active in numerous cell compartments, such as the endoplasmic 
reticulum, trans-Golgi system, endosomes, and the plasma membrane (Vetrivel 
and Thinakaran 2006; Kaether et al. 2006). Additionally, similarly to β-secretase, 
γ-secretase has been observed to be limited to lipid rafts (Vetrivel et al. 2004). 
Furthermore, the γ-secretase complex cleaves APP at ε-site (~10 residues 
downstream of the γ-site) to release the APP intracellular domain (AICD) 
(Weidemann et al. 2002).  
The secretases required in APP processing are essential therapeutic targets due 
to their activities and scientists are researching for β- and γ-secretase inhibitors. 
Nevertheless, BACE-1 is difficult to target due to the considerable great active site 
and localization to endosomes. In addition, BACE-1 may be involved in 
myelination. As mentioned above, the γ-secretase complexes cleave numerous 
substrates, such as notch, thus inhibiting γ-secretase could result in potential side 
effects.  
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Figure 1.2 APP processing pathways. APP is cleaved by either β- or α-secretase, leaving C99 
and C83 in the plasma membrane. Cleavage by the α-secretase (non-amyloidogenic pathway) 
results in the generation of sAPP-α and C83 (left arrow). Cleavage by the β-secretase 
(amyloidogenic pathway) leads to the generation of sAPP-β and C99 (right arrow). C83 is finally 
cleaved by the γ-secretase to generating AICD and Aβ. 
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1.3 The Αβ peptide 
The properties of the Aβ peptide were investigated by researchers following the 
distinguishing proof that the peptide was the fundamental protein component of 
the amyloid plaques in AD. At the time, Aβ demonstrated no homology to known 
proteins and the amyloid cores of senile plaques were difficult to dissolve to further 
investigate, thus initially Aβ was believed to exist in senile plaques only. Further 
studies demonstrated that Aβ was detected in the plasma of healthy individuals 
(Seubert et al. 1992) and that numerous types of cells, not only neurons, were 
producing the peptide (Hartmann et al. 1997). Similarly to the fibre structures 
present in plaques in vivo, small segments of the Aβ amino-acid sequence were 
identified forming amyloid fibres in vitro (Kirschner et al. 1987).  
Even though Aβ40 is the major Aβ species produced by neuronal cells (Suzuki et 
al. 1994), the amyloid plaques primarily contain Aβ42. Thus, the elongated peptide 
appeared to serve a role a great role in AD. A previous study demonstrated that 
the longer carboxyl terminus of Aβ influenced the amyloid formation and the 
subsequent aggregation of soluble Aβ peptides. For example, the rate of peptide 
formation was accelerated due to the additional Aβ including the C-terminal 
residues (Jarrett et al. 1993).   
The precise number of molecules existing in the smallest nuclei of Aβ has not been 
identified yet, however a previous study hypothesized that a pentamer/hexamer 
may be the smallest unit utilized to result in fibril formation (Klein et al. 2004). The 
wild type of Aβ1-42 may create this unit during the initial stages of aggregation, 
whereas the wild type Aβ1-40 is formed by monomers to tetramers (Bitan et al. 
2003). To investigate the effects of Aβ fibrils, the concentration of Aβ needed for 
fibrillization should be established. In general, previous studies suggest ~10 μM 
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as the optimal concentration for synthetic Aβ peptide in vitro. However, this is not 
the case for in vivo applications, as the concentrations of Aβ in plasma and 
cerebrospinal fluid are in the nM or pM range. In in vivo cases, the concentration 
of Aβ may be higher in certain cells or other factors may allow fibril formation with 
decreased Aβ concentration (Fezoui et al. 2002).  
A previous study proposed that Aβ may create an unfolded helix with intermediate 
that assists in the acceleration of fibrillization. Nonetheless, the fully unfolded 
peptide may create fibrils at a slower rate. In in vitro studies, the procedure of fibril 
formation entails the formation of soluble oligomers. These studies identified 
numerous formed oligomeric Aβ species, such as protofibrils and ADDLs (Aβ 
derived diffusible ligands) (Walsh et al. 1997; Harper et al. 1997). The protofibrils 
of Aβ were characterized as curved structures of a diameter between 4 and 10 
nm, and approximately 200 nm long (Walsh et al. 1997; Harper et al. 1997). In 
addition, fibrils were identified as insoluble structures of more than 200 nm long 
and a diameter of 4-10 nm, alike the protofibrils (Walsh et al. 1997). A previous 
study demonstrated that the fibrils consist of 6 protofilaments with β-strands, 
following a perpendicular to the fiber axis direction and held together by hydrogen 
bonding (Serpell 2000). Upon centrifugation at an average speed, fibrils form 
pellets and may bind β-sheet binding-dyes, such as Congo-Red and Thioflavin 
(Serpell 2000).   
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1.3.1 Aβ mediated neurotoxicity  
Numerous studies have demonstrated that aggregated Aβ serves an important 
role as a pathogen in AD, thus further research was conducted to identify the Aβ 
aggregate with the most pathogenic ability. Previous studies utilizing synthetic Aβ 
demonstrated that protofibrils and fibrils were toxic to the cultured neurons (Hartley 
et al. 1999; Walsh et al. 1999; Ward et al. 2000) and influenced the 
electrophysiological parameters (Hartley et al. 1999; Walsh et al. 1999). The same 
effects were not detected for the monomeric Aβ (Hartley et al. 1999; Walsh et al. 
1999; Ward et al. 2000). Despite these observations, other studies demonstrated 
that fibrillar Aβ was either non-toxic (Heinitz et al. 2006; Hoshi et al. 2003) or had 
a less effective result (Deshpande et al. 2006) in comparison to the oligomeric 
form. A possible explanation for these contradictory observations may be that the 
Aβ oligomers and fibrils provoke neurotoxicity via various mechanisms 
(Deshpande et al. 2006).  
Furthermore, Aβ-mediated cell death was hypothesized to be dependent on 
continuous polymerization and not on only one specific aggregate (Wogulis et al. 
2005). In addition, numerous toxic incidents, including oxidative stress, calcium 
overload, mitochondrial dysfunction, and pore/channel formation, have been 
demonstrated to result in necrotic or apoptotic events (Canevari et al. 2004). The 
various molecular mechanisms leading to these events may be interconnected 
and take place at the same time, and certain toxic incidents may be minor in 
comparison to the original toxic attack. For example, a previous study 
demonstrated that mitochondrial dysfunction is an early Aβ-mediated toxic incident 
preceding cell death (Deshpande et al. 2006).  
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1.3.2 Aβ plaques 
Amyloid or Aβ plaques are extracellular accumulations of protein, consisting of the 
hydrophobic Aβ peptide, and various proteins and cell components, such as 
apolipoprotein E (ApoE), clusterin and numerous constituents of the complement 
system (Liao et al. 2004).  An association and activation of the immune system in 
Aβ plaques was proposed due to the activated astrocytes and microglia cells 
surrounding the plaques (Eikelenboom et al. 2006). The formation of the Aβ 
peptide occurs following the processing of APP, via either the amyloidogenic or 
non-amyloidogenic pathway (Figure 1.3.2), as determined by the secretase 
enzyme implicated in the sequential cleavage stages.      
The two APP processing pathways generate the amyloid precursor protein 
intracellular domain (AICD). AICD was hypothesized to serve a role in 
transcriptional control, however the genes affected by this process are not yet 
identified (Chang and Suh, 2010). An initial cleavage by β-secretase, followed by 
γ-secretase in the amyloidogenic pathway produces the aggregated Aβ peptide. 
The number of amino acid residues in the Aβ peptide species depends on the γ-
secretase cleavage. Aβ40 and Aβ42 are frequently produced, ~90% and <10%, 
respectively, however species of less residues were identified (Selkoe and Wolfe, 
2007).  Aβ42 is particularly hydrophobic and prone to aggregation.  
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1.3.3 Neurofibrillary tangles 
Tau is a microtubule-related protein and the principle segment of NTs. It serves a 
role in the adjustment and control of microtubule bundles required for the 
cytoskeletal integrity and axonal transport (Roy et al. 2005). The regular activity of 
tau is managed by a fine balance amongst phosphorylation and 
dephosphorylation. Disruption in this balance may result in hyperphosphorylation 
of tau, which further leads to the interruption of regular functioning, inclining the 
molecule to form paired helical filaments. These filaments are insoluble and 
aggregate in blocks, forming the NTs inside the cytoplasm of neuronal cells during 
AD (Goedert et al. 1995). The tau protein is involved in numerous 
neurodegenerative diseases apart from AD, including frontal temporal dementia 
(Neumann et al. 2009). Frontal temporal dementia may be a result of a series of 
mutations in the microtubule associated protein tau (MAPT) gene which encodes 
tau (Goedert and Jakes 2005), leading to neuronal cell death and further cognitive 
decline.  
In the case of AD, tau tangles are believed to form after the Aβ plaques. 
Furthermore, APP mutations result in amyloid plaques and NTs, however tau 
mutations lead to NTs only (Lovestone 2000). 
1.3.4 Aβ and tau in AD 
Deposits of aggregated Aβ are present in the neuritic plaques and cerebral vessels 
(cerebrovascular amyloid angiopathy) of patients with AD (Akiyama et al. 2000).  
An innate immune response, including activated glial cells and augmented levels 
of cytokines, is associated with the Aβ deposits present in the brain of patients 
with AD (Akiyama et al. 2000). Previous studies demonstrated that Aβ deposits in 
the AD brain may activate glial cells, commencing a pro-inflammatory cascade that 
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leads to the production and release of cytotoxic molecules, cytokines, proteases 
and complement compartments, thus triggering neurodegeneration (Akiyama et 
al. 2000; Heneka and O'Banion 2007). Based on these observations, nonsteroidal 
anti-inflammatory drugs (NSAIDs) were suggested to be utilized to reduce the risk 
and possibly postpone the onset of AD (Breitner et al. 1995; Breitner et al 1994; 
McGeer et al. 1990; Stewart et al. 1997; Szekely et al. 2004; Veld et al. 2000).  
A previous study demonstrated that amyloid plaques were generated by an 
overexpression of the APP in its mutant form in the brains of transgenic mice [9]. 
Reactive astrocytes and activated microglia were identified near those plaques, 
and the levels of interleukin (IL)-1, IL-6 and tumour necrosis factor (TNF) -α were 
upregulated compared with the mice lacking overexpressed APP (Morgan et al. 
2005). These observations are similar to the ones demonstrated in patients with 
AD. Previous studies demonstrated that treatment of Tg2576 mice (AD mouse 
model) overexpressing APP with Ibuprofen (an NSAID), led to decreased levels of 
reactive astrocytes, Aβ deposition and IL-1β production (Lim et al. 2000; Lim et al. 
2001).  Furthermore, the process of gene deletion in transgenic mice is utilized in 
research to understand AD and prevent the pathology. A previous study 
demonstrated that removal of the TNF Type I receptor gene in a different mouse 
model of AD, APP23, resulted in reduced plaque formation, inhibition of Aβ and 
normal learning and memory activity (He et al. 2007). Another study revealed that 
the deletion of interferon (IFN) –γ receptor Type I gene in Tg2576 mice resulted in 
reduced gliosis and amyloid plaques (Yamamoto et al. 2007). In the wild type mice 
of the study, INF-γ elicited TNF-α production leading to increased levels of the β-
site APP-cleaving enzyme (BACE1) in astrocytes, which further resulted in Aβ 
formation (Yamamoto et al. 2007).  
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The data of these studies suggest that upregulation of proinflammatory cytokines 
and activation of glial cells may promote AD progression. 
1.3.5 The amyloid cascade hypothesis 
The amyloid cascade hypothesis was proposed more than 20 years ago. The 
hypothesis proposes that Aβ deposition results in NT formation and numerous 
toxic events, which ultimately leads to AD (Mudher et al. 2002). The hypothesis, 
which is considered to be the foremost one in the field of AD, was initially proposed 
based on genetic evidence and has been contested over the years. Primarily, 
concerns were raised regarding the association of the plaque load and AD (Haass 
and Selkoe 2007). Further concerns were that the neurological deficits, which were 
similar to AD, were present prior to the deposition of the plaques (Williams 2006).  
The amyloid hypothesis states that increased Aβ42 production as a result of a 
mutation or other factors, including faulty Aβ clearance, leads to Aβ42 
oligomerization and deposition. This process results in the pathogenic events 
correlated with AD, such as neuronal dysfunction, thus leading to dementia. Based 
on previous concerns and novel data coming forward over the last decade, certain 
amendments of the hypothesis were recommended. For example, evidence 
emerged on the pathological role of the soluble oligomeric Aβ species, which 
precede amyloid plaque formation, and on the role of intracellular Aβ (Francis et 
al. 1999). Aβ in its soluble form associates with synapse loss Terry et al. 1999) 
and memory impairment (Haass and Selkoe 2007).  
The role of amyloid in neuronal dysfunction has been extended by the discovery 
of small, soluble, oligomers of the Aβ peptide, some forms of which have been 
termed ADDLs (Aβ-derived diffusible ligands) (Lambert et al. 1998). These Aβ 
oligomers are not only potential intermediates in the formation of amyloid 
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filaments, but they also have been shown to be neurotoxic themselves and to 
inhibit long-term potentiation (LTP), a cellular model of memory, in hippocampal 
slices (Klein 2002). Thus, the essential role of Aβ oligomers in the 
neurodegeneration process is now taken into account in the Amyloid Cascade 
Hypothesis. Despite its strength, the Amyloid Cascade Hypothesis is incomplete 
without including the essential role of amyloid- associated inflammatory proteins.  
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1.4 Diagnosis of AD 
As mentioned above, the two hallmark pathologies required for a diagnosis of AD 
are the extracellular plaque deposits of the β-amyloid peptide and the NTs of the 
microtubule binding protein tau. Progressive dementia that has evolved over a 
period of time, lacking focal neurological deficits, and presents no abnormal 
imaging findings may be AD. Helpful biomarkers, such as the increase in tau 
protein or decrease of Aβ in the CSF, are tested however, a definitive diagnosis of 
AD occurs with a histopathological examination of the brain. Previous autopsy 
studies demonstrated that the brains of individuals over 65 years old without 
clinical dementia were positive for SPs and NTs within the hippocampus and the 
entorhinal cortex (Reitz et al. 2009). This observation implies that SPs and NTs 
are partly formed due to normal ageing. Nevertheless, in the brains of AD 
individuals, increased levels of SPs and NTs were demonstrated in the limbic 
cortex, the neocortex and other brain regions, compared with the non-demented 
individuals (Lacor et al. 2007).  
The brains of patients with AD demonstrate reduced levels of acetylcholine (ACh), 
loss of cholinergic neurons in the basal forebrain and decreased acetylcholine 
synthesizing enzyme choline acetyltransferase in the cerebral cortex (Kar et al. 
2004). In addition to the human individuals, animal models reveal that ACh serves 
an important role in memory and thought processing. Besides ACh, 
neurotransmitters, including noradrenalin, serotonin, and somatostatin, have been 
demonstrated in reduced levels in AD. In the case of neurotransmitter deficiency, 
the cognitive impairment was correlated with the loss of the cholinergic input 
(Martorana and Koch (2014).   
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Based on the above observations, acetylcholinesterase inhibitors, such as tacrine, 
and ACh receptor agonists, such as nicotine, were utilized as treatment for AD. 
However, the results indicated a minor success of this treatment, suggesting that 
other factors combined with ACh deficiency have an effect on cognitive function.   
Identification of AD-like pathology in individuals without dementia raised concerns, 
as cases were characterized to be demented due to the presence of few SPs and 
NTs, whereas clinical dementia was not present. The CERAD criteria regarding 
the neuropathological assessment of AD gave emphasis to the senile or neuritic 
plaques, age, and clinical history of the patient (Mirra et al. 1991). An additional 
system has been suggested by the National Institute on Aging (NIA)-Reagan 
Institute to assess the topographic staging of neurofibrillary changes, as well as 
neuritic plaques (Newell et al. 1999). Following the above criteria for AD, a patient 
may be diagnosed considering the number of SPs and NTs, age, and cognitive 
function.  
The increased formation of SPs and NTs in individuals reveals that the 
biochemical abnormalities occurring in AD have been initialized. For certain 
patients with AD, the progression of the disease is rapid and severe, whereas in 
others the disease progresses in a slow-rate leading to memory impairment and 
deterioration of mental power. 
Further research is required to understand the association of neurotransmitter 
deficiencies and neuronal plasticity. In addition, the effect of the environment on 
brain interactions should be investigated. This would allow for the design of future 
therapies in AD.  
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1.5 Neuroinflammation in the Central Nervous System 
1.5.1 Neuroinflammation 
Inflammation is associated with all neurodegenerative diseases. During the last 
decade, scientists have started to understand the effect of the immune system on 
these various neurodegenerative disorders. Based on better technology, there is 
a strong research focus on investigations of the impact of microglia. However, 
there is specific information regarding the impact of astrocytes in 
neuroinflammation.  
AD-related neuroinflammation is considered to be the resulting reaction of Aβ 
deposit formation in the brain and the subsequent neuronal cell death. It is not fully 
understood whether this neuroinflammatory response is the inducer itself and not 
a secondary response to Aβ deposition. Inflammation in general has been 
suggested to serve a vital role in the progression of late-onset AD. 
Neuroinflammation has been proposed to have both a beneficial and detrimental 
role in AD. For example, reactive astrocytes and activated microglia have a 
positive effect in the clearance of Aβ (Simard et al. 2006; Koistinaho et al. 2004), 
and an undesirable production of cytotoxic elements resulting in the development 
of AD (Akiyame et al. 2000). Microglia phagocytosis is required for the clearance 
of Aβ (Richard et al. 2008), however, an overstimulation of the process might result 
in neuronal cell death. In addition, increased production of inflammatory molecules 
by the glial cells has an effect on the development of AD.  
The amyloid plaques consist not only of Aβ, but of acute phase proteins (Abraham 
et al. 1989), such as α1-antichymotrypsin and α2-macroglobulin (Abraham et al. 
1990; Bauer et al. 1991), and complement components, such as C1q, C3, C5, C6, 
C7, C8 and C9 (Eikelenboom and Stam 1982).  These Aβ-associated proteins 
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(AAPs) were demonstrated to have an effect on the fibrillization, deposition and 
transport of Aβ (Veerhuis et al. 2005; Eikelenboom et al. 2011), thus disrupting the 
clearance of Aβ. For instance, AAPs, such as apolipoproteins, heat-shock proteins 
and heparan sulfate proteoglycans co-deposit with Aβ (Veerhuis et al. 2005; 
Wilhelmus et al. 2007).  Furthermore, Aβ may form soluble complexes with several 
AAPs, such as the Aβ-ApoE complex in the cerebrospinal fluid (Tai et al. 2013). In 
addition, alpha1-antichymotrypsin and certain heat-shock proteins affect the 
aggregation and fibril formation of Aβ (Janciauskiene and Wright 1998).  
IL-1 is an immunoregulatory cytokine that is overexpressed within the cerebral 
cortical regions of the AD-affected brain. The early overexpression of IL-1 in AD, 
coupled with the increased number and staining intensity of IL-1-immunoreactive 
microglia indicates that IL-1 serves an important role in the development of the 
plaques. Previous in vitro studies have additionally demonstrated that the IL-1 
cytokine had an effect on the increased production and deposit formation of Aβ via 
processing (Buxbaum et al. 1992) and promoting the synthesis of APP (Goldgaber 
et al. 1989). In the case of unsuccessful Aβ clearance by glial cells, the cells 
remain chronically activated, as observed in late-onset AD (Koenigsknecht-Talboo 
and Landreth 2005; Edison et al. 2008).  
Approximately 60% of variation in cognitive decline in late-onset AD was 
hypothesized to be inherited, however previous studies investigated various 
inflammatory markers associated with the late stage of AD (Gatz et al. 2006). One 
of these studies investigated middle-age individuals whose parents had a history 
of late-stage AD. The data of the study demonstrated that augmented levels of 
inflammatory markers were a risk factor for the individuals to develop AD later in 
life (van Exel et al. 2009). The data were further compared with age-matched 
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individuals whose parents had no history of AD. For the experimental analysis, 
whole blood samples were collected and stimulated with lipopolysaccharide (LPS) 
ex vivo, and the data demonstrated that individuals with parents suffering from AD 
had increased levels of IL-1β, IL-6 and TNF-α. Another study suggested that the 
inflammatory response observed in the blood may be analogous across the blood 
brain barrier (BBB) (Ek et al. 2001). Based on these results, it may be that 
inflammation serves a critical role and could be considered a risk factor in 
developing AD. 
1.5.2 White matter 
White matter is present within the CNS of vertebrates. The volume of white matter 
in the human body accounts for more than 50% of the entire brain volume (Fields 
2008). This is a significant proportion in comparison to other animals, such as 
mice, in which the proportion is as small as 25% of the whole brain volume (Fields 
2008). 
The role of white matter was believed to be insignificant and its function was 
neglected by scientists in the past. White matter was initially studied by Rudolf 
Virchow (Peters et al. 1991) and was presumed to be a type of connective tissue. 
This presumption continued for decades, until the pathologists Ramon y Cajal and 
Rio Hortega illustrated the 3 primary cells types white matted consisted of: 
microglia, astrocytes, and oligodendrocytes (Pérez-Cerdá et al. 2015). In addition 
to these cell types, scientists demonstrated that white matter contains numerous 
blood vessels and axons (connections among nerve cells). Axons function as 
energy transporters (cell signalling) among cells; they stretch from neurons of the 
grey and white matters and assist with information transport (Clark et al. 2009).  
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Figure 1.5.2a Location of white and grey matter in the brain. Schematic of a horizontal section 
of a human brain showing location of grey and white matter [adapted from American Accreditation 
HealthCare Commission (www.urac.org)]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5.2b Components of white and grey matter. Components of grey matter (cell bodies) 
and white matter (oligodendrocytes, astrocytes, microglia, and axons). [adapted from The McGraw-
Hill Company, Inc. (www.mcgraw-hill.co.uk)].  
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1.5.3 Astrocytes 
Chemical interactions result in the activation of astrocytes, which may lead to 
phagocytosis and production of cytotoxic molecules. Astrocytes have not been 
researched in depth, compared with the microglia cells, as initially they were 
hypothesized to only connect with other astrocytes and act in an organizational 
matter. Nevertheless, this perception has changed, as irregular astrocytic activity 
has been demonstrated to associate with various neuropathologies, such as focal 
brain ischemia, perinatal asphyxia, retinal ischemia, diabetic retinopathy, AD, 
Parkinson’s disease, and multiple sclerosis (Allaman et al. 2011). Astrocytes 
account for approximately 50% of the cells of the CNS, thus being the most 
common type of cell within this system. They originate in the neuroectoderm, have 
the shape of a star and great plasticity (Volterra and Meldolesi 2005). Astrocytes 
utilize gap junctions as their communication system and are structured in domains 
to have the least overlap, while being aware of their surroundings and swiftly 
respond to any alterations in their environment (Liu et al. 2011). Due to their 
arrangement in domains, any astrocyte may act on its own within the domain as a 
link with other cells of the CNS (Liu et al. 2011).  
Astrocytes serve a critical role in the brain homeostasis, specifically in neuronal 
survival and function. For example, astrocytes offer energy to neurons via the 
lactate shuttle structure, they maintain ion, glutamate, and water homeostasis, are 
an important element of the defense system, and assist to form and maintain the 
BBB (Allaman et al. 2011; Sofroniew et al. 2010). Upon activation of astrocytes, 
the levels of intracellular Ca2+ rise creating a Ca2+ signal which proliferates to the 
surrounding astrocytes. This response leads to the activation of signalling 
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pathways within the astrocytes, which further results in morphological alterations 
and cell motility (Akiyama et al. 2000).  
Activation of astrocytes does not necessarily correlate with proliferation, thus the 
term “reactive astrocytes”, instead of “active astrocytes” was proposed to describe 
their activation process. Following activation, astrocytes may express numerous 
inflammatory elements, such as complement components, iNOS, IL-1 and IL-6 
(Akiyama et al. 2000).  
1.5.4 Astrocytes in AD  
The term astrogliosis refers to the abnormal increase in the number of astrocytes 
due to the destruction of surrounding neurons and, in AD, astrogliosis is observed 
in areas of the brain consisting of amyloid plaques (Akiyama et al. 2000). In 
addition, deposition of Αβ leads to increased intercellular calcium expression and, 
simultaneously, overactivity of astrocytes in vitro and in vivo (Kuchibhotla et al. 
2009; Abramov et al. 2003). 
As a response to Aβ, astrocytes produce cytotoxic compounds, such as IL-1β, IL-
6 and IFN-γ, which have been suggested to activate microglia and lead to chronic 
inflammation, thus serving a role in the pathogenesis of AD (Garwood et al. 2011). 
Furthermore, a previous study demonstrated that in a culture consisting of rat 
primary neurons and astrocytes, following Aβ induction, the astrocytes were a 
factor in the resulting neurotoxicity and tau phosphorylation (Garwood et al. 2011). 
Following activation by Aβ, astrocytes have an effect on neuronal cultures; 
astrocytes accelerate Aβ-induced neurotoxicity. The so called ‘neuro-neglect 
hypothesis’ implies that astrocytes activated by Aβ neglect the support they would 
normally provide to neurons, thus leading to the vulnerability of neurons towards 
toxic responses (Fuller et al. 2010).  
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Previous studies demonstrated that, in Tg2576 mice, astrocytes surrounding the 
Aβ plaques produce and express BACE1. BACE1 expressed by astrocytes is 
additionally demonstrated in the neocortex of patients with AD (Hartlage-
Rubsamen et al. 2003; Rossner et al. 2001). The above findings and the fact that 
astrocytes account for more than half of the brain parenchyma suggest that the 
contribution of astrocytes to the Aβ plaque formation requires further research.  
1.5.5 Effect of chronic neuroinflammation on microglia and 
astrocytes 
Chronic neurodegenerative diseases, such as AD or Parkinson’s disease, are 
often age-related and primarily associated with extensive neuroinflammation 
(Hauss-Wegrzyniak et al. 2002; Wersinger and Sidhu 2002; Blasko et al. 2004). 
Various studies have shown that in chronic brain inflammation, cells of the innate 
immune system modify their phenotype and specifically change their receptor 
expression (Streit et al. 2004; Liu et al. 2005; Letiembre et al. 2007). Thus, it can 
be presumed that microglia and astrocytes may change to a more reactive state. 
In most diseases, associated with chronic brain inflammation, the expression of 
PRRs in microglia and astrocytes is up-regulated.  PRRs and cell types of the CNS 
involved in the innate immune system and sensing of fibrillar Aβ need to be 
identified, and the correlation between PRRs and Aβ needs in depth research. 
In a healthy brain, microglia and astrocytes release molecules that keep the brain 
running normally. In AD, microglia and astrocytes can become deregulated, 
causing neuroinflammation that can promote the development and progression of 
neurodegeneration. 
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Figure 1.5.5 The effect of chronic neuroinflammation on a human brain with Alzheimer 
Disease. Combination of two brain diagrams comparison. On the left a normal brain without AD, 
and on the right an AD brain showing clear shrinkage of the cerebral cortex, hippocampus, and 
severely enlarged ventricles due to cerebral and hippocampal atrophy. This was caused by the 
multiple primary lesions which lead to the death of motor cells, overtime leading to shrinkage 
(adapted from ADEAR: "Alzheimer's Disease Education and Referral Center, a service of the 
National Institute on Aging, www.patient.info/education/alzheimers-disease). 
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1.6 Innate Immunity and Pattern Recognition Receptors 
1.6.1 Overview 
The immune system is composed of two subdivisions: the innate (non-specific) 
and adaptive (acquired) immune systems. The two subdivisions can identify 
foreign invaders, such as microorganisms, triggering an immune response to 
remove them from the body. The innate immune system is the first line of defence 
against invading organisms and the adaptive immune system operates as a 
second line of defence, providing protection against re-exposure to the same 
pathogen due to immunological memory (Janeway et al. 2001).  
The primary function of the immune system is to differentiate between itself and 
non-self components. This function is required for protection of the body against 
invading pathogens and to eradicate malignant cells (altered cells). Numerous 
pathogens, such as viruses, replicate intracellularly and others, such as fungi and 
bacteria, replicate extracellularly. Therefore, the various parts of the immune 
system have developed in a manner of protection against these pathogens 
(Janeway et al. 2001).  
An infection may be cleared by the immune system prior to becoming a disease. 
A disease may arise following un-prevented infection, increased virulence of a 
pathogen or a serious compromise within the immune system. The immune 
system may be harmful or beneficial, depending on the scenario. For example, 
after inflammation (immune response), local irritation and impairment to healthy 
tissue occur due to the toxic components being released. In addition, the immune 
system may attack itself in the case of autoimmune diseases, as it does not 
differentiate between the healthy tissue and antigens (Edwards and Cambridge 
2006).  
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Pattern recognition receptors (PRRs) serve an important role in the innate immune 
response by detecting pathogen-associated molecular pattern motifs (PAMP), 
such as LPS, bacterial lipoteichoic acid (LTA), peptidoglycans, bacterial flagellin 
and bacterial DNA. PAMPs are unique to each pathogen, essential molecular 
structures required for the pathogens survival, and exist on Gram-positive and 
Gram-negative bacteria, fungi, and viruses (Akira et al. 2006). PRRs are receptors 
on lymphocytes which recognise antigens. Extracellular PRRs detect mainly 
PAMPs in bacteria and fungi, compared with the intracellular PRRs which primarily 
detect viral components. PRRs are separated into endocytic, such as the mannose 
and scavenger receptors, and signalling receptors, such as the TLRs and NOD 
proteins.  Endocytic PRRs promote the attachment of microorganisms to 
phagocytes and their subsequent engulfment and destruction.  
In addition to PAMPs, PRRs recognize damage-associated molecular pattern 
motifs (DAMP), which are either cytosolic or nuclear proteins with diverse 
intracellular activities (Rubartelli and Lotze 2007).  Upon recognition of various 
bacterial components by the innate immune system, a pro-inflammatory response 
occurs. Pro-inflammatory mediators, including TNF-α, IL-6 and IL-1, are released, 
leading to uncontrollable cytokine production and subsequent cardiovascular 
collapse, hemodynamic instability and eventually sepsis. 
1.6.2 Toll-like receptors 
Toll-like receptors (TLRs) were named for their similarity to Toll, a receptor 
recognised in Drosophila melanogaster. Following the identification of TLR4, the 
first mammalian TLR, by Charles Janeway and Ruslah Medzhitov in 1997, 
numerous proteins were further recognized which were structurally associated 
with it. These proteins are now known as TLRs (Rock et al. 1988). Janeway and 
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Medzhitov demonstrated that TLR4 was capable of inducing the activation of the 
adaptive immune system and further investigated the involvement of TLRs in the 
innate immune system. 
The family of TLRs in mammals is composed of at least 11 TLRs, and individual 
TLRs may detect specific microbial elements originating in pathogens, such as 
fungi, protozoa, viruses and bacteria (Poltorak et al. 1998). For example, TLR2 
recognises Gram-positive bacteria products, such as LTA, peptidoglycan, 
spirochetes, mycobacteria, and yeast. TLR3 recognises viral double-stranded 
RNA (dsRNA) (Poltorak et al. 1998), TLR4 serves an important role in the 
detection of LPS (Poltorak et al. 1998), TLR5 recognises bacterial flagellin 
(Hayashi et al. 2001), TLRs 7 and 8 recognise single stranded RNA and viral 
ssRNA (Krieg and Vollmer 2007) and TLR9 is responsible for mediated immune 
responses to CpG DNA (Ashkar and Rosenthal 2002).  
TLRs have leucine-rich repeats (LRR) in their extracellular domains, and are 
spread within the cell. For example, TLRs 1, 2 and 4 are located on the cell 
surface, compared to TLRs 3, 7, 8 and 9 which are located in intracellular 
compartments, including the endosome (Heil et al. 2003; Matsumoto et al. 2003; 
Ahmad-Nejad et al. 2002; Latz et al. 2004).  
The Toll/interleukin-1 receptor (TIR) homology domain is an intracellular signalling 
domain observed in the IL-1 receptor and TLRs. Regardless of this resemblance 
between the two types of receptors, IL-1 has an immunoglobulin-like domain 
instead of LRRs, and the extracellular domains of the receptors do not share the 
same structure (Poltorak et al. 1998).  
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Table 1.6.2 Innate immune recognition by mammalian Toll-like receptors. (Janeway’s 
Immunobiology, 8th edition, Garland Science, 2012). 
 
Toll-like receptor Ligand Cellular distribution 
TLR-1:TLR-2 heterodimer Lipomannans (mycobacteria), 
lipoproteins, lipoteichoic acids, 
cell-wall β-glucans, zymosan 
Monocytes, dendritic cells, 
mast cells, eosinophils, 
basophils 
TLR-2:TLR-6 heterodimer 
TLR-3 Double-stranded RNA (viruses) NK cells 
TLR-4 (plus MD-2 and CD-
14) 
LPS, Lipoteichoic acids macrophages, dendritic cells, 
mast cells, eosinophils 
TLR-5 Flagellin Intestinal epithelium 
TLR-7 Single-stranded RNA (viruses) plasmacytoid dendritic cells, 
NK cells, eosinophils, B cells 
TLR-8 Single-stranded RNA (viruses) NK cells 
TLR-9 DNA with unmethylated CpG 
(bacteria and herpesviruses) 
plasmacytoid dendritic cells, 
NK cells, eosinophils, B cells 
TLR-10 Unknown plasmacytoid dendritic cells, 
NK cells, eosinophils, B cells 
TLR-11 (mouse only) Profilin and profilin-like 
proteins 
Macrophages, dendritic cells, 
liver, kidney and bladder 
epithelial cells 
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Figure 1.6.2.1 TLR localisation. TLR1, TLR2, TLR4, TLR5, TLR6, and TLR11 recognise their 
ligands on the cell surface, whilst TLR3, TLR7, TLR8, and TLR9 are located intracellularly, in 
endosomes and lysosomes (adapted from Yamamoto and Takeda 2010).  
 
1.6.3 TLR signalling pathways 
Microbial parts or damage-associated molecular pattern motifs (DAMP) are able 
to stimulate various TLRs and this leads to the expression of numerous genes 
playing a role in the immune response. The signalling pathways mediated by TLRs 
are investigated to reveal the molecular mechanisms utilised in TLR-induced gene 
expression (Akira and Takeda 2014). Upon activation, the dimerization of TLRs 
may take place. For example, a previous study demonstrated that TLR2 forms a 
heterodimer with TLR1 or 6, whereas other TLRs are hypothesized to create 
homodimers (Saitoh et al. 2004).  The formation of dimers can initiate numerous 
signalling pathways that include a cytoplasmic TIR domain and MyD88 (myeloid 
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differentiation primary-response protein 88; TIR-domain-containing adaptor) 
located downstream of these pathways was demonstrated to serve a key role in 
the production of inflammatory cytokines, including TNF-α and IL-12 (Hayashi et 
al. 2001; Hemmi et al. 2002; Takeuchi et al. 2000; Kawai et al. 1999; Schnare et 
al. 2000; Hacker et al. 2000).  
Following the investigation of the TLR-mediated pathways, two distinct pathways 
emerged: the MyD88-independent and -dependent pathways (Figure 1.6.3).  
 
 
Figure 1.6.3 Visualization of the MyD88 dependent and independent TLR signalling 
pathways. TIR containing adaptor molecule MyD88 is essential for downstream signalling for the 
secretion of inflammatory cytokines through TLR signalling and the MyD88 independent pathway 
leads to IRF3 activation via IKKε/IKKί. Signalling through the MyD88-dependent pathway leads to 
the activation of MAPKK and IKK complex resulting in activation and nuclear translocation of AP-
1 and NF-κB, respectively. TRIF is the main adaptor protein in the MyD88-independent pathway 
and can associate with TRAF6 to activate AP-1 and NF-κB (adapted from Patel et al. 2012).  
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1.6.4 Future prospects of TLRs 
As mentioned above, microbial components or DAMPs can stimulate TLRs and 
initiate the production of various inflammatory cytokines, including TNF-α, and 
interleukins 6 and 12. Upon increased production of the proinflammatory 
cytokines, systemic disorders are initiated, accompanied with increased mortality 
rates. Thus, the human body and other organisms have developed the molecular 
mechanisms required for the adaptation of the immune responses provoked by 
TLRs (Beeson 1947). Previous studies have demonstrated an association of TLRs 
and inflammatory and immune diseases. An example is the continuous production 
of IL-10 due to flawed TLR signalling leading to chronic enterocolitis. Another study 
demonstrated that mutating TLR4 in mice with flawed IL-10 production has 
improved the intestinal inflammation, therefore suggesting that a specific TLR is 
mediating the microbial identification resulting in chronic enterocolitis (Kobayashi 
et al. 2003).  
Further to enterocolitis, mice with an APOE-deficiency demonstrated less 
pathology of atherosclerosis following the induction of a MyD88 deficiency, thus 
suggesting that TLRs play an important role in the progression of the disease 
(Bjorkbacka et al. 2004; Michelsen et al. 2004). These studies indicate that TLRs 
are capable of mediating certain pathways initiating an immune response, 
regardless of the presence or not of an infection. Therefore, identifying the 
mechanisms to balance the TLR-mediated immune response may reduce the 
effect of the response in various disorders. 
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1.6.5 PRRs in AD 
PRRs recognise a restricted collection of microbial signatures (PAMPs), and 
permit sensing of different types of microbial pathogens ranging from bacteria and 
viruses to fungi and spirochetes as well as danger-associated molecular patterns 
(DAMPs). Families of PRRs include the TLR family, the RIG-like receptor family 
(RLR), the NOD-like receptor family (NLR) as well as the complement system.  
The precise roles of PRRs in detecting and mounting responses against Aβ, and 
their roles in AD are not clear. TLR expression is upregulated in the AD brain, and 
in murine models of AD, TLR2 and TLR7 were found to be upregulated compared 
to controls (Letiembre et al. 2007). Furthermore, multiple TLR genes (1-8) (Weiner 
and Frenkel 2006; Meyer-Luehmann et al. 2008; Akiyama et al. 2000; McGeer et 
al. 2006; Letiembre et al. 2009; Bsibsi et al. 2002) were found to be present in 
microglia in post-mortem tissue from AD patients, with varying levels of expression 
(Bsibsi et al. 2002). The increased expression of TLRs in AD has positioned them 
as potential key players in neurodegenerative mechanisms and disease 
progression.  
In particular, the TLR4 gene has emerged as a candidate for susceptibility for AD. 
A common miss-sense polymorphism resulting in an adenine to guanine 
substitution 896 nucleotides downstream of the transcription start site causes the 
replacement of glycine for aspartic acid at amino acid 299 (Asp299Gly) and alters 
the extracellular structural domain of TLR4. This mutation attenuates TLR4 
signalling in response to LPS (Arbour et al. 2000). Since its discovery, this 
polymorphism has been associated with decreased cardiovascular disease risk 
(Balistreri et al. 2004), aging (Balistreri et al. 2009) as well as decreased risk of 
late-onset AD in an Italian cohort (Minoretti et al. 2006; Balistreri et al. 2008), 
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suggesting that pro-inflammatory responses triggered via TLR4 are crucial for 
disease progression. Recently, Tang et al. (2014) using primary neuronal cultures 
from TLR4 mutant mice have shown that neurons expressing TLR4 have an 
increased sensitivity to Aβ and are vulnerable to degeneration in AD. 
In addition to the implication of TLR4 in susceptibility to neurodegeneration, recent 
studies have suggested that TLR4 activation is required for clearance of Aβ in AD. 
Mice carrying a point mutation in TLR4 exhibit augmented deposition of Aβ in both 
the neocortex and hippocampus (Tahara et al. 2006). The mechanism by which 
TLR activation aids Aβ clearance is unclear. 
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1.7 Inflammasomes 
Inflammasomes are intracellular macromolecular complexes which represent a 
major line of innate defence. They form upon recognition of PAMPs or DAMPs. 
The exact structure of an inflammasome depends on the activator/receptor that 
will cause the inflammasome to assemble (Davis et al. 2011). PAMPs are detected 
by PRRs and are separated to non-viral (bacterial) and viral PAMPs. Non-viral 
ones include bacterial LPS and peptidoglycan, and viral PAMPs include 
endosomal dsRNA (double-stranded RNA), uncapped ssRNA (single-stranded 
RNA), cytosolic DNA and several viral fusion glycoproteins. The PRRs family 
detecting these PAMPs is separated into four main classes; Toll-like receptors 
(TLRs), {NOD}-like receptors (NLRs), the IFI200 family member absent in 
melanoma 2 (AIM2) and {RIG-I}-like receptors (RLRs).  TLRs sense PAMPs in the 
extracellular space and endosomes and NLRs, RLRs and AIM2 sense pathogens 
in intracellular compartments. 
Inflammasomes are caspase-1 and caspase-5 activators. Caspase-1 controls the 
activation of the proforms (precursors) of IL-1β and IL-18 cytokines, by cleaving 
the proforms to release the cytokines (Latz et al. 2013). These cytokines lack a 
leader sequence and are expressed as biologically inactive proforms in the 
cytoplasm of the cells. Caspase-1 is expressed in an inactive proform in the 
cytoplasm too and it is activated by proteolytic self-processing (Latz 2010).  
Caspase-1 appears to be uniquely involved in participating in the inflammatory 
response by cleaving the precursors of IL-1 beta and IL-18. Inactive pro-caspase-
1 is converted to an active enzyme via dimerization, followed by an autocatalytic 
reaction that generates an active molecule composed of two large and two small 
subunits (termed p20 and p10) (Lamkanfi et al. 2007). The precise molecular 
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mechanisms for the activation of the inflammasome are still unclear, however it is 
certain that for the maturation and release of IL-1β and IL-18 at least two signals 
are required; Signal 1 and Signal 2 (Latz 2010). Mechanisms triggering signal 2 
for inflammasome activation are induction by reactive oxygen species (ROS), 
lysosomal damage (possibly coming from ROS), pore formation and K+ efflux and 
possibly PAMP influx (Davis et al. 2011). A fourth mechanism was identified 
recently which is the calcium mobilization regarding the activation of the NLRP3 
inflammasome. Findings support NLRP3 inflammasome activation by calcium-
mediated mitochondrial damage (Murakami et al. 2012).   
 
Figure 1.7 Schematic Diagram of an Inflammasome. The NLRs, ASC and Caspase-1 
assembles to form the penta- or heptameric structure called the inflammasome resulting in the 
maturation of IL-1β and IL-18, as well as inflammatory cell death, by either pyroptosis or 
pyronecrosis (adapted from Davis et al. 2011). 
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1.7.1 NOD-like-receptors (NLRs) 
The NLR family consists of three subfamilies; NODs, NLRPs and IPAF. NLRP1, 
NLRP3, NLRC4 (IPAF) family members assemble the inflammasomes which are 
responsible for the activation of caspase-1, hence cleavage of pro-IL-1β and pro-
IL-18 for secretion of IL-1β and IL-18 cytokines. On the other hand, NLRX1, 
NLRC5 and NODs family members in general, inhibit NF-κB and type I IFN-
mediated signaling pathways attenuating an inflammatory response. NLRs have a 
conserved NOD motif characterization and their domain organization consists of 
an amino-terminal effector binding region (CARD, PYD, and BIR domains), the 
intermediary NOD and an array of carboxy-terminal LRR (Leucine-rich repeat) 
motifs. The intermediary NOD is needed for nucleotide binding and self-
oligomerization and the array of LRR motifs is presumed to detect conserved 
microbial patterns and modulate NLR activity (Kanneganti 2010). 
1.7.1.1 NLRP1 (or NALP1) Inflammasome 
The NLRP1 inflammasome consists of NALP1, ASC, caspase-1 and caspase-5. 
Human NALP1 is a multi-domain scaffold protein, containing an N-terminal PYRIN 
(PYD) domain, a centrally located NACHT domain, five tandem LRR domains, a 
FIIND domain and a C-terminal CARD (Chu et al. 2001; Hlaing et al. 2001). The 
mechanisms of activation of NLRP1 inflammasome are not yet clear, although it is 
proposed that it is a two-step activation; bacterial cofactor muramyl dipeptide 
(MDP) induces a conformational change in NLRP1, which then allows the protein 
to bind NTPs and oligomerize, thus creating a platform for caspase activation 
(Faustin et al. 2007).  The mechanism by which MDP primes NLRP1 for 
subsequent NTP-dependent oligomerization is a matter for speculation (Faustin et 
al. 2007). NLRP1 activity is regulated by anti-apoptotic proteins Bcl-2 and Bcl-x(L) 
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which can inhibit NLRP1 activity, by inhibiting ATP binding to NLRP1 (Bruey et al. 
2007). Cell death and IL-1β secretion induced by NLRP1 depend on K+ efflux and 
the lysosomal protein cathepsin B (Davis et al. 2011). 
 
Figure 1.7.1.1 Minimal model for NLRP1 inflammasome. Depicted above in an unoligomerized 
inflammasome complex. CARD, caspase recruitment domain; LRR, leucin rich repeats; NACHT, 
nucleotide-binding and oligomerization domain; PYD, pyrin domain, FIIND, domain with function to 
find; HIN, HIN-200/IF120x domain (adapted from Tschopp and Schroder 2010). 
1.7.1.2 NLRP3 (or NALP3) Inflammasome 
The NLRP3 inflammasome is activated by a wide range of danger signals that 
derive not only from microorganisms, but also from metabolic dysregulation. 
Thanks to its wide distribution in different tissues and organs, the NLRP3 
inflammasome protein complex may represent a crucial signalling pathway that 
facilitates organ crosstalk and local injury in tissues target of metabolic damage. 
The NLRP3 inflammasome is activated in response to the widest array of stimuli, 
leading to the theory that the dissimilar agonists induce similar downstream events 
that are sensed by NLRP3 (Schroder et al. 2010). In most cell types, NLRP3 must 
be primed and priming has long been known to increase cellular expression of 
NLRP3 through NF-κB signalling (Bauernfeind et al. 2009). Priming is initiated with 
an NF-κB–activating stimulus, such as LPS binding to TLR4 (Kolb et al. 2014), 
which induces elevated expression of NLRP3 (as well as IL-1B), resulting in the 
increased expression of the NLRP3 protein (Murakami et al. 2012; Hirota et al. 
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2011). Furthermore, the adaptor protein ASC becomes linearly ubiquitinated and 
phosphorylated resulting in inflammasome assembly. Following priming, a second 
signal activates NRP3 during the canonical NLRP3 inflammasome activation, 
which results to the formation of the NLRP3 inflammasome complex. 
The mechanisms for NLRP3 activation are the extracellular ATP binding to its 
receptor P2X7, triggering K+ efflux and pannexin-1 membrane pore formation, 
leading activators in (Tschopp and Schroder 2010). Another mechanism is through 
phagocytosis causing lysosomal damage, releasing the lysosomal content into the 
cytosol. The third mechanism associates with ROS generation causing activation 
to NLRP3, while the fourth mechanism is the Calcium mobilization as calcium 
signalling promotes mitochondrial damage which triggers NLRP3 inflammasome 
(Murakami et al. 2012; Tschopp and Schroder 2010).  
 
Figure 1.7.1.2a Minimal model for NLRP3 inflammasome. Depicted above in an unoligomerized 
inflammasome complex. CARD, caspase recruitment domain; LRR, leucin rich repeats; NACHT, 
nucleotide-binding and oligomerization domain; PYD, pyrin domain (adapted from Tschopp and 
Schroder 2010). 
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Table 1.7.1.2 Proposed signalling pathways for NLRP3 inflammasome activators (adapted 
from Tschopp and Schroder 2010). 
Figure 1.7.1.2b Schematic Diagram of NLRP1, NLRP3 and NLRC4 inflammasomes and their 
activators. The NLRs, ASC and Caspase-1 assemble to form the inflammasome resulting in the 
maturation of IL-1β and IL-18. For the activation and release of IL-1β, two distinct signals are 
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required. The nature of these signals during infection or inflammation is not completely defined. 
Signal 1 is triggered by various PAMPs following Toll-like receptor (TLR) activation which induces 
the synthesis of pro-IL-1β. Signal 2 is provided by the activation of the inflammasome and caspase-
1, resulting in IL-1β processing (www.invivogen.com/review-inflammasome).  
 
 
Figure 1.7.1.2c Schematic Diagram of NLRP1, NLRP3 and NLRC4 inflammasome signalling 
upon activation (http://www.adipogen.com/inflammasomes/?___store=gb).  
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1.7.1.3 NLRC4 (or IPAF) Inflammasome 
NLRC4 is activated by bacteria. The inflammasome assembled by the NLR protein 
NLRC4 responds to bacterial flagellin and a conserved type III secretion system rod 
component. How the NLRC4 inflammasome detects the two bacterial products and 
the molecular mechanism of NLRC4 inflammasome activation are not fully 
understood. When bacterial flagellin enters through the cell membrane it is 
detected by NRLC4 and activates it causing caspase-1 activation (Franchi et al. 
2006). 
 
Figure 1.7.1.3 Minimal model for IIPAF (NLRC4) inflammasome. Depicted above in an 
unoligomerized inflammasome complex. CARD, caspase recruitment domain; LRR, leucin rich 
repeats; NACHT, nucleotide-binding and oligomerization domain; PYD, pyrin domain (adapted 
from Tschopp and Schroder 2010). 
1.7.1.4 NLRC5 Inflammasome 
NLRC5 contains an N-terminal CARD-like domain and it is commonly expressed 
in numerous tissues and cell types in human and mouse. It is considered to be 
negative and positive regulator in both NF-κΒ and type I IFN signaling pathways 
(Lamkanfi et al. 2011) and regulates MHC Class 1 (Major Histocompatibility Class 
I) (Meissner et al. 2010). It is still not clarified what is the exact role of NLRC5 in 
regulating immune signalling as the literature appears to be controversial 
(Lamkanfi et al. 2011). 
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Figure 1.7.1.4 Structural Domain of NLRC5. NLRC5 has typical tripartite domains including the 
N-terminal atypical caspase activation and recruitment domain (CARD), the centrally located 
NACHT (named after NAIP, CIITA, HET-E, and TP-1 proteins) and multiple leucine rich repeats 
(LRRs) at the C-terminal (adapted from Yao and Qian 2013). 
1.7.1.5 NLRP6 Inflammasome 
NLRP6 regulates caspase-1 and NF-κB activity and it correlates with ASC to 
activate caspase-1 and release IL-1β. It is expressed in non-hematopoietic cells, 
maintaining intestinal homeostasis through regulation of the intestinal flora (Anand 
et al. 2012).  Deficiency in NLRP6 in mouse colonic epithelial cells resulted in 
altered intestinal microbiota. This is because NLRP6 inflammasome regulates IL-
18 and not IL-1β and deficiency in IL-18 or NLRP6 distorts the composition of the 
microbiome toward a colitogenic type (Anand et al. 2012; Chen et al. 2011; Elinav 
et al. 2011; Chen and Nunez 2011). This distortion, along with CCL5 chemokine 
production and recruitment of inflammatory cells stimulates a spontaneous 
inflammation, causing colitis.  Studies support that this process and inflammation 
could be the initiating event in some cases of human inflammatory bowel disease 
(Rathinam et al. 2012). Therefore, therapeutic inhibition of NLRP6 activation could 
benefit in treating infectious diseases (Anand et al. 2012). 
 
 
Figure 1.7.1.5 Minimal model for NLRP6 inflammasome. Depicted above in an unoligomerized 
inflammasome complex. LRR, leucin rich repeats; NACHT, nucleotide-binding and oligomerization 
domain; PYD, pyrin domain. 
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1.7.1.6 NLRP7 Inflammasome 
NLRP7 has an N-terminal pyrin (MEFV) domain (PYD), followed by a NACHT 
domain, a NACHT-associated domain (NAD), and a C-terminal LRR region 
(Messaed et al. 2011a).  NLRP7 functions as a PRR in primary human 
macrophages and the NLRP7 inflammasome senses microbial infection via 
recognition of acLP (acylated lipopeptides) (Messaed et al. 2011b). The cytosolic 
microbial acLP activates NLRP7, causing the assembly of the inflammasome, 
caspase-1 activation via ASC recruitment to the inflammasome and the release of 
IL-1β and IL-18. In macrophages both NLRP7 and TLR2 are required for the acLP-
mediated release of IL-1β and they both play a role in the host defence against 
intracellular Gram-positive bacteria (Khare et al. 2012). 
1.7.2 AIM2 Inflammasome 
AIM2 belongs to the same family as IFI200 or HIN200 proteins which are IFN-
inducible proteins.  They have a 200-amino-acid repeat at the C-terminus, known 
as HIN domain, and an N-terminal PYD. Same as NLRP3, AIM2 N-terminal PYD 
recruits ASC to the inflammasome, thus causing the activation of pro-caspase-1 
into caspase-1. The AIM2 inflammasome can be activated by cytosolic dsDNA 
from viruses or bacteria, therefore having a crucial role in the recognition of 
cytosolic DNA and of infection with vaccinia virus and MCMV (Kanneganti 2010).  
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Figure 1.7.2 Minimal model for AIM2 inflammasome. Depicted above in an unoligomerized 
inflammasome complex. CARD, caspase recruitment domain; PYD, pyrin domain; HIN, HIN-
200/IF120x domain (adapted from Tschopp and Schroder 2010). 
1.7.3 RIG-I Inflammasome 
RIG-I induces type I IFN production through MAVS (mitochondrial antiviral 
signalling protein) and activates IRF3 and IRF7 (IFN response factor 3 and 7 
respectively). MDA5 and RIG-I are both members of the RLR family. MDA5 
recognizes RNA virus infection that is specific dsRNA intermediates produced 
during infection with positive-strand RNA viruses (Kanneganti 2010; Poeck et al. 
2010). MDA5 cannot interact with ASC which is needed for activation of caspase-
1, thus cannot activate the inflammasome. RIG-I might be responsible to mediate 
both Signals 1 and 2 needed for inflammasome activation (Kanneganti 2010; Yu 
and Levine 2011). RIG-I triggers IL-1β and/or IL-18 production through caspase-1 
and caspase-3 activation. The transfected 5’-triphosphate RNA causes RIG-I 
activation, leading to MAVS-CARD9-NF-κΒ signaling giving pro-IL-1β. ASC 
recruitment activates caspase-1 which causes the inflammasome pathway 
activation (Kanneganti 2010).  
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1.7.4 Therapeutic potential 
A high number of viruses activate caspace-1 inducing IL-1β and IL-18 cytokines 
secretion, thus the inflammasomes have a potential role in the immune response 
to viruses (Kanneganti 2010).  Even though the mechanisms regulating the 
inflammasomes activity are not clear, various proteins were identified that may 
interfere with inflammasome activation. Inflammasome activation and chronic 
inflammation are responsible for metabolic disorders progression, such as obesity, 
type 2 diabetes mellitus and atherosclerosis, and are a factor in carcinogenesis 
and control the adaptive immune response (Davis et al. 2011).  For these reasons 
the molecular mechanisms leading to the activation of inflammasomes need to be 
further investigated to enable for specific treatments preventing sterile or microbial 
attacks. Some human hereditary or acquired diseases are correlated with elevated 
IL-1β or NLRP3 mutations, like Gout, Type 2 Diabetes Mellitus, and Alzheimer 
Disease (Leemans et al. 2011).  
 
 
 
 
 
 
 
 
 
71 | P a g e  
 
1.8 Complement System 
1.8.1 Overview of complement activation and function 
An important component of the immune system is the complement system. This 
system boosts or ‘complements’ the bactericidal activity of antibodies in serum 
(Janeway et al. 2001). The complement system acts as an element of the innate 
immune system, nevertheless, the adaptive immune system may adapt it to 
function if required. The term ‘complement’ was coined by Paul Ehrlich in 1899 to 
describe the required supplementary molecule with the function of inducing 
bacterial lysis (Chaplin 2005). 
Originally, in 1891, the term ‘alexin’ (means ‘to ward off’ in Greek) was used by 
Hans Ernst August Buchner to describe the heat labile part in the blood that was 
capable of killing bacteria (as reviewed by Nesargikar et al. 2012). To eliminate 
the killing activity, the serum was heated, however, upon injection of heat-
inactivated serum into animals, the serum sustained its killing properties and 
protected the animal from diseases. In addition to the alexin factor, further studies 
by Jules Bordet demonstrated that that a ‘sensitizer’ was another required factor 
to have cell lysis (Morgan 1990; Nesargikar et al. 2012). The ‘sensitizer’ is now 
known as the antibody and, following a century from the initial description of the 
complement, its abilities and function demonstrate something more than just a 
supplementary molecule.     
Following penetration of a pathogen in the epithelial barrier, the defense 
mechanisms of the innate immune system are activated. The complement system 
is one of the initial factors activated, and serves an important role in the search for 
pathogens and antigens, as well as, acting in response to PAMPs and DAMPs 
(Janeway et al. 2001). The complement system is a complex of pre-cursors and 
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proteins that assist antibodies and phagocytic cells to eliminate bacteria and other 
foreign invaders from an organism. The complement proteins are in the blood and 
lymph, thus a molecular defense mechanism, including the complement activation, 
could be used immediately following infection. The activation of the complement 
leads to a series of enzymatic reactions, in which proteolytic cleavage and 
activation of successive complement proteins occur. Following activation of the 
proteins, complement fragments are fixed on the pathogen surface. This leads to 
the uptake and destruction of complement-coated microbes by phagocytes 
carrying the complement receptors (Wagner and Frank 2010). Following 
inflammation, the target cells are opsonized by the complement components C1q, 
C3b (iC3b) and C4b. Opsonisation occurs via deposition of antibodies, known as 
the classical pathway, carbohydrate-binding proteins, known as the lectin pathway 
or the alternative pathway (Hoffman et al 2000). The membrane attack complex 
(MAC) is responsible for the lysis of the targeted cell and, due to the vast functions 
of the complement system, it is required to maintain homeostasis in the body. To 
sustain this role, the complement system eradicates macromolecular aggregates, 
apoptotic and necrotic cells, and assists with the healing of the body by attraction 
and activation of cells (Janeway et al. 2001).  
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1.8.2. Complement activation pathways 
C1q binds to the antigen-antibody complex resulting in the activation of the C1-
complex, thus leading to the activation of the classical pathway. This pathway may 
additionally be activated by other molecules, such as Aβ, C-reactive protein and 
various apoptotic fragments. The lectin pathway has a rather similar activation to 
the classical pathway, with the opsonin mannose-binding lectin (MBL) and ficolins 
1, 2 and 3, as an alternative to C1q. The above-mentioned lectin molecules are 
capable of binding to various sugars, including mannose and fucose, which are 
uncovered by the pathogens.  Activation of the lectin pathway occurs following the 
MBL binding to mannose deposits on the pathogen surface. This binding leads to 
the activation of MBL-associated serine proteases (MASP) 1 and 2, which 
cleavage C4 into C4a and b, and additionally cleavage C2 into C2a and b (Figure 
1.8.2) (Orsini et al. 2014).  The binding of C2a with C4b creates the C3-convertase. 
The alternative pathway is activated following the spontaneous hydrolysis of 
circulating C3 into C3(H2O) on the surface of the cells. A fourth pathway was 
proposed, the extrinsic one, which is determined by the serine protease 
components of the coagulation cascade. A previous study suggested there is 
interplay between the complement and coagulation systems in cerebrovascular 
diseases (Huber-Lang et al. 2006). 
The complement pathways converge on the C3-convertase, except for the 
extrinsic one. All four pathways, however, converge on the C5-convertase and 
activate the final pathway, known as the terminal pathway, by cleaving C5 into C5 
a and b (Figure 1.8.2). C5a and C3a are potent anaphylatoxins and are capable 
of provoking inflammatory responses. On the other hand, C5b is binding on the 
targeted cell which forms a pore, named the Membrane Attack Complex of 
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complement (MAC), by assembling C6, 7, 8 and 9. If small amounts of MAC are 
generated, then signalling events take place in host cells instead of cell lysis. 
However, lytic amount of MAC results in cell lysis and clearance of the pathogen 
or altered cell.  
 
 
Figure 1.8.2 Overview of the complement system (Orsini et al. 2014).  
 
Complement activation produces numerous cleavage fragments, including C3b 
and C4b, which act as opsonins and initiate a phagocytic response. Furthermore, 
complement molecules are capable of initiating an immune response via signalling 
to various receptors on immune cells (Ricklin and Lambris 2007). Due to the 
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importance of maintaining the complement balance, regulatory molecules, such 
as C1 inhibitor (C1-INH), exist. These molecules are separated into membrane-
bound and fluid phase regulators (Tandon et al. 1994; Zipfel and Sherka 2009). 
Complement regulators include factor H and properdin (alternative pathway), and 
C1q and C1INH (classical and lectin pathways). Soluble inhibitors include clusterin 
and vitronectin (terminal pathway), and membrane-bound regulators include CR1, 
CD46, CD55 and CD59 (Zipfel and Sherka 2009). 
C1-INH is a well-characterized complement inhibitor, and is a serine-protease 
inhibitor capable of deactivating the C1q-C1r-C1s and MBL-MASP1-MASP2 
complexes (Wagner and Frank 2010). In addition, increased quantity of CI-INH 
deactivates the C3b fragment produced in the alternative pathway (Wagner and 
Frank 2010), and various molecules of the coagulation cascades (Ehrnthaller et 
al. 2011). The numerous roles of the complement receptors are yet to be 
determined, as further research is required to investigate their potential.  
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1.8.3 Regulation of complement  
The proteins involved in the complement system make ~4% of all blood proteins 
and the majority of these proteins derive from the liver, normally circulating as 
inactive precursors (pro-proteins). Upon stimulation of the Complement system by 
e.g. binding of C1q to IgG or IgM, or MBL to mannose residues, changes in 
conformation of C1q and MBL results in activation of associated enzymes and a 
cascade of enzymatic activation reactions (resulting in the release of C3a and 
C5a), conformational changes and complex formations of the various complement 
components results in the formation of the membrane attack complex of 
complement (MAC). Hepatocytes were demonstrated to produce various types of 
these proteins (Morgan and Gasque 1997; Brennan et al. 2012), and epithelial, 
endothelial, glial cells and neurons can produce various complement factors.  
The human brain has the ability to protect itself from numerous threats due to an 
advanced immune system specialized for the brain cells, unlike other organs in 
the body. Glial cells, oligodendrocytes and neurons are competent enough to 
produce locally receptors, regulators, and factors for the complement components 
(Woodruff et al. 2010). Specifically, glial, and neuronal cells are capable to 
synthesize C3, C1q, C1-INH and CD59, and additionally certain brain cells 
produce other complement components (Stevens et al. 2007).  
The complement system serves an important role in neurodegenerative diseases. 
In a healthy brain, the production of complement proteins is minimal and is 
hypothesized to play a role in brain maturity and homeostasis (Woodruff et al. 
2010). On the other hand, impairment or injuries of cells results to a rise in the 
levels of the complement components. An amplification in the production of 
complement proteins leads to inflammation and tissue destruction (Woodruff et al. 
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2010).  Previous studies demonstrated that in chronic neurodegenerative and 
acute CNS diseases, the complement system was activated, with neuronal cells 
specifically showing complement-mediated damage. This specific damage may be 
because neurons have a low expression of membrane-bound complement 
regulators, such as CD46 and CD55 (Singhrao et al. 2000).  
Initially, the complement system was hypothesized to be activated only upon 
injury/penetration of the BBB. Over the last decades, studies have demonstrated 
that complement proteins are widely expressed within the CNS and are involved 
in innate immune responses and signalling cascades (Stephan et al. 2012). For 
example, Shinjyo et al. demonstrated that interplay between C3a and C3aR has 
an effect on the adult neuronal development, by controlling the migration and 
differentiation of neuronal stem cells (Shinjyo et al. 2009). Furthermore, previous 
studies demonstrated that astrocyte-induced expression of complement proteins 
in neurons was necessary for the clearance of redundant synapses in the CNS 
while expanding (Schafer et al. 2012).  
Complement regulators and factors are located in glial cells, and the complement 
system appears to carry out major inflammatory responses within the brain 
(Veerhuis et al. 2011). In addition, astrocytes and microglia are capable of 
secreting oxidative products, pro-inflammatory cytokines or have phagocytotic 
functions following activation of the complement system (Fu et al. 2012). Finally, 
brains of mice and patients with AD demonstrated an increase in the levels of 
complement proteins, further supporting the association of AD and complement 
(Stoltzner et al. 2000; Loeffler et al. 2008). More specifically, complement proteins 
of both the classical and alternative pathways, such as C1q, C4, C3, and Factor 
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B, have been co-localized with fibrillar amyloid plaques and cerebral vascular 
amyloid in the cerebral cortex and hippocampus of AD patients.  
 
  Complement Components 
Cell type Classical Alternative Terminal C-
receptors 
C-
regulators 
Soluble 
Membrane
-bound 
Astrocytes C1q, C1r, 
C1s, C2, 
C3, C4 
C3, fB, fD C5, C6, 
C7, C8 
C1qR, 
CR2, 
C3aR, 
C5aR 
C1-inh, fH, 
fI, clusterin 
CD59, DAF, 
MCP, CR1 
Microglia C1q, C1r, 
C1s, C2, 
C3, C5 
C3, fB, fD - C1qR, 
CR3, 
C3aR, 
CR4, C5aR 
C1-inh CD59, CR1 
 
Table 1.8.3 Expression of C proteins by human astrocytes and microglia (adapted from 
Veerhuis et al. 2011). 
 
Regarding genetic factors, clusterin (complement regulator) (Harold et al. 2009) 
and CR1 (Lambert et al. 2009) were demonstrated to be genetic risk factors of AD, 
and play a role in the activation of complement during AD.  
Lian et al. revealed that, in agreement with previous studies, Aβ provokes the 
activation of complement in astrocytes, microglia, and neurons (Lian et al. 2015; 
Haga et al. 1993; Fu et al. 2012), nevertheless the consequence of complement 
activation in vivo continues is not fully understood. A previous study demonstrated 
that deletion of C1q led to the development of amyloid plaques and loss of 
synapses in an AD-mouse model (Fonseca et al. 2004). Furthermore, C1q was 
additionally demonstrated to protect from amyloid toxicity (Pisalyaput and Tenner 
2008).  
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Complement system has a therapeutic potential and various antagonists and 
agonists available should be further investigated in in vitro and in vivo studies to 
understand their full potential.  
1.8.4 Complement system and TLRs 
TLRs and complement system play a major role in the first line host defence and 
various PAMPs can activate both systems. How these systems cooperate when 
co-activated it is not clear yet, however infections can induce simultaneous 
activation of both systems, indicating the systems are inter connected 
(Hajishengallis and Lambris 2010; Hawlisch and Kohl 2006; Mollnes et al. 2008). 
It is believed that TLR signalling is regulated by the complement system 
(Hajishengallis and Lambris 2010). Moreover, there are evidence indicating that 
TLRs can target the second C5a receptor, C5aR2, by reducing C5aR2 activity 
(Raby et al. 2011) and in general TLR activation interacts with C5a (Damman et 
al. 2011). C5aR1 and C5aR2 are seven transmembrane G-protein coupled 
receptors. As mentioned above, complement activation ultimately leads to the 
formation of the anaphylatoxins C3a, C4a, and C5a.  Of these, C5a is one of the 
most phlogistic peptides involved in diverse immune and non-immune responses. 
Human C5a (approximately 15 kDa) is glycosylated, consists of 74 amino acids 
and has an N-linked glycosylation site at Asn 64 that is not essential for biological 
activity, although it has been suggested to regulate the C5a activity in vivo (Monk 
et al. 2007. C5a is a potent anaphylatoxin that at low nanomolar concentrations 
acts as a chemoattractant for myeloid cells, including neutrophils, monocytes, 
macrophages, basophils, and eosinophils. At higher concentrations, C5a can elicit 
superoxide generation and enzyme release responses (Gerard and Gerard 1994). 
The biological activity of C5a is greatly reduced by the removal of the carboxyl-
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terminal residue (Arg) by carboxypeptidases, which is then known as C5adesArg 
(Manthey et al. 2009). The potent inflammatory functions of C5a (see Table 1.8.4) 
indicate that inhibition of this ligand, or its receptor(s), might alleviate certain 
inflammatory conditions. There are two receptors known to bind to C5a; C5aR1 
(CD88) and C5aR2 (GPR77) (Llee et al. 2008). 
Cell type Activity 
Neutrophils Enhanced expression of adhesion molecules; 
Chemotaxis; Oxidative burst (O2 consumption); 
Phagocytosis; Release of granule enzymes; Delayed 
apoptosis 
Eosinophils Release of granule enzymes; Chemotaxis 
Basophils Histamine release 
Mast cells Histamine secretion; Chemotaxis 
Plasmacytoid dendritic cells Chemotaxis 
Macrophages/monocytes Chemotaxis; Cytokine release 
Thymocytes Enhances apoptosis 
Endothelium Vasodilation; Chemokine release 
Hepatocytes Enhanced regeneration 
Microglia Chemotaxis 
 
Table 1.8.4 Functional activity of C5a on different cell types (as reviewed in Llee et al. 2008). 
 
Okusawa et al. (1987) demonstrated that when human monocytes were exposed 
to both C5a and LPS, the IL-1β induction levels were increased compared with 
when the monocytes were stimulated with either agonist alone. Their results 
suggested a synergistic interaction between C5aR1 and TLR4 receptors. It may 
well be that in vivo the two systems are activated simultaneously upon recognition 
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of a pathogen. Zhang et al. (2007) has also demonstrated that while LPS-mediated 
IL-12 production is suppressed by the C5a-C5aR1 interaction, C5a had enhanced 
the LPS-induced TNFα, IL-1β, and IL-6 production in mice.  
C5a was additionally demonstrated to synergize with TLR2, which reacts with 
Porhyromonas gingivalis, resulting in increased TLR2-mediated cAMP production 
in macrophages. Due to this synergistic effect, the nitric oxidedependent killing of 
P. gingivalis is inhibited (Wang et al. 2010). TLRs appear able of enhancing C5a-
mediated responses (Raby et al. 2011). Stimulation of human peripheral blood 
monocytes with TLR ligands, such as LPS and zymosan, and a subsequent 
stimulation with C5a indicated an enhanced expression of IL-8, suggesting that 
TLR activation can modulate C5aR1-mediated responses (Raby et al. 2011).  
The same complement receptors regulating TLR signalling, like CR3, C5aR1, 
gC1qR and CD46, can be controlled by bacterial or viral pathogens to interfere 
with the hosts’ protective immunity (Hajishengallis and Lambris 2010).  The more 
associations between TLR and complement signalling pathways are discovered 
and researched, the more enhanced protective immunity is offered by the host as 
therapeutic drugs will be developed based on specific signalling cascades. 
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1.8.5 Complement system and Alzheimer Disease 
The complement system is implicated in various diseases, among them some of 
the central nervous system such as AD. It is detected that an up-regulation of the 
expression of the complement proteins of the classical pathway occurs in AD 
affected brain regions (Van Beek et al. 2000; Veerhuis 2010). The levels of 
complement mRNAs for C1q, C1r, C1s, C2, C3, C4, C5, C6, C7, C8, and C9 were 
detected in the 11 regions of brain that were investigated. The mRNA levels were 
markedly up-regulated in affected areas of AD brain, such as the entorhinal cortex, 
hippocampus, and midtemporal gyrus, as C1q mRNA was increased 11- to 80-
fold over control levels, and C9 mRNA 10- to 27-fold. Protein analysis of AD-
affected hippocampus established the presence of all the native complement 
proteins as well as their activation products C4d, C3d, and the membrane attack 
complex. These data indicate that high levels of complement are being produced 
in affected areas of AD brain, that full activation of the classical complement 
pathway is continuously taking place, and that this activation may be contributing 
significantly to AD pathology (Yasojima et al. 1999). 
The correlation of complement factors and amyloid deposits in AD was first 
described in immunohistochemical studies by Eikelenboom and Stam in 1982 
(Eikelenboom and Stam 1982). Detection of complement activation via 
monoclonal antibodies and use of knockout mice to validate these antibodies to 
be used in mice with neurodegeneration, has strengthened the validity of the 
reports of complement component association with fibrillar amyloid containing 
plaques Amyloid plaques was proved to activate complement in vivo, and this 
suggested a role for complement in AD pathophysiology (Veerhuis et al. 2011; 
Gasque et al. 1995; Lambert et al. 2009). 
83 | P a g e  
 
Neuronal and glial cells express TLRs and complement receptors, and nearly all 
complement components can be locally produced in the brain, usually after injury 
or developmental cues. Complement proteins promote proliferation and 
regeneration in various tissues (Ricklin et al. 2010) and this could also be applied 
in similar functions in the Central Nervous System, since neuronal stem cells 
differentiate and migrate in response to complement. For example, it is observed 
that C3a-C3aR interactions are a positive regulator of adult neurogenesis 
(Bogestal et al. 2007; Shinjyo et al. 2009). Neurons and astrocytes express several 
serine protease inhibitors, including C1-Inh, nevertheless, in neurodegenerative 
diseases like AD, expression levels of several regulatory proteins, including C1-
Inh and alternative pathway C-regulators fH and fI, remain low or are decreased 
(such as protease nexin 1), causing probable uncontrolled actions of the proteases 
(as reviewed in Veerhuis et al. 2011). The functions of some regulatory proteins, 
such as α2M which regulates thrombin, can be taken over by others since many 
proteases and protease inhibitors act in the complement, like C1-Inh, which is not 
only a physiological regulator of C1 activation, it is also a major inhibitor of MASP2 
of the lectin pathway (Beinrohr et al. 2008).  
In AD Aβ initiate the complement cascades and the Aβ-induced activation could 
lead to a disturbed protease - protease inhibitor balance, particularly when the 
synthesis of the proteases increase too, as it has been observed in AD. These 
imbalances could be the cause of initiation of the consequent steps in 
neurodegenerative processes in AD (Veerhuis et al. 2011). Moreover, in Alzheimer 
Disease patients, both TLR2 and CD14-positive microglia were associated with 
Aβ plaques, and many CD14-positive cells were found surrounding diffuse plaques 
compared to dense-core plaques (Letiembre et al. 2007; Landreth and Reed-
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Geaghan 2009). This indicates that the increased expression of CD14 and TLRs 
is associated with increased inflammation, which is associated with aging.  When 
all these are joined with various Alzheimer Disease risk factors, the disease 
progresses through an inflammatory response (Landreth and Reed-Geaghan, 
2009), thus more research is needed into this field. 
In conclusion, polymorphisms of complement factors and TLR signalling are 
coupled with neurodegenerative diseases. Therefore, by controlling the 
complement activation via use of inhibitors of the complement cascade events we 
could avoid the consequences of this activation and positively affect the rate of 
progression of these diseases (Veerhuis et al. 2011).  
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1.9 Aims of the project 
Neuroinflammation plays a key role in neurodegeneration in AD. Complement, 
TLRs and NLRs are swiftly activated in response to infection or damage: there is 
increasing evidence for extensive bidirectional cooperation between the two 
systems. Aβ linked with AD can activate both types of these receptors, but whether 
and how these two innate immune systems interact with each other in the context 
of AD has not been studied before. It is my hypothesis that deposition of Aβ 
peptide can activate the innate immune system via PRRs, including 
complement, and evoke Alzheimer's pathology. Deposition of Aβ in the brain 
might activate astrocytes and microglia, initiating a pro-inflammatory cascade that 
results in the release of potentially cytotoxic molecules, such as cytokines, 
complement, proteases and other acute phase proteins, ultimately causing 
neurodegeneration. In the current study, I focused on the role of the innate 
immunity system of the brain in the initiation and the propagation of 
inflammatory process in AD and the interplay between TLRs/NLRs and the 
complement system.  
To test my hypothesis, the following questions were examined:  
1. Which PRRs are involved in the innate immune sensing of fibrillar Aβ?  
2. How do PRRs - Aβ associate and how is signalling being triggered? Is interplay 
between complement and TLR/NLR receptors the key to the chronic 
inflammatory response observed in AD? 
3. Is the clearance of fibrillar Aβ through its internalization and trafficking crucial 
for triggering a pro-inflammatory response? 
4. Can we inhibit inflammatory responses by antagonizing PRRs involved in 
neuroinflammation? 
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Chapter II 
Materials and methods 
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2.1 Materials 
2.1.1 Chemicals 
All fine chemicals were obtained from Sigma-Aldrich (UK). 
2.1.2 Antibodies 
Primary Abs Species Company 
Catalogue 
no. 
anti-NLRP1 
(B2) 
Mouse 
Monoclonal 
Santa Cruz Biotechnology 
SC-
166368 
anti-NLRP3 
(Cryopyrin-H 
66) 
Rabbit 
Polyclonal 
Santa Cruz Biotechnology SC-66846 
anti-NLRC5 
(NOD4 - N-17) 
Goat 
Polyclonal 
Santa Cruz Biotechnology 
SC-
248091 
Anti NLRP3 
Goat 
polyclonal 
Santa Cruz Biotechnology SC-58902 
anti C9 
neoantigen 
Mouse 
Monoclonal 
Hycult HM2264 
anti-CR1 
Rabbit 
Polyclonal 
Santa Cruz Biotechnology SC 20924 
anti-CR3 
Rabbit 
Polyclonal 
Santa Cruz Biotechnology SC 28664 
anti-C5aR1 (S 
5/1) 
Human, 
mAb 
HyCult Biotechnology (Netherlands) HM2094 
anti-C3aR (H-
300) 
Rabbit 
Polyclonal 
Santa Cruz Biotechnology SC-20138 
anti-CD55 (H-
319) 
Rabbit 
Polyclonal 
Santa Cruz Biotechnology SC-9156 
anti C9  
Rabbit 
Polyclonal 
Kindly donated by Prof Paul Morgan 
and Dr T.Hughes 
(Triantafilou  et al. J Cell Sci 2013) 
 
anti-CD59 Rabbit 
Kindly donated by Prof Paul Morgan 
and Dr T.Hughes 
(Triantafilou  et al. J Cell Sci 2013) 
N/A 
anti  Phospho-
IKappaBAlpha 
Rabbit  New England Biolabs 2859L 
anti Beta 
amyloid 
Mouse 
monoclonal 
Santa Cruz Biotechnology SC28365 
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Table 2.1.2a List of primary antibodies utilized for experiments. This table summerizes the 
primary antibodies used in this study. 
 
 
 
 
 
 
 
 
 
anti TLR4  
Mouse 
Monoclonal 
Santa Cruz Biotechnology SC293072 
anti-Factor H Rabbit 
Kindly donated by Prof Paul Morgan 
and Dr T.Hughes 
N/A 
anti-TLR2 (C-
18) 
Goat 
Polyclonal 
Santa Cruz Biotechnology SC-8690 
anti amyloid  
Rabbit 
polyclonal 
Thermofischer Scientific  700254 
anti NIK 
Mouse 
Monoclonal 
Santa Cruz Biotechnology SC8417 
 antiTLR2 
Mouse 
Monoclonal  
Abcam TLR2.1 
Anti NIK 
Rabbit 
polyclonal 
New England Biolabs 4994S 
anti EEA1 
Goat 
polyclonal 
Santa Cruz Biotechnoly SC34567 
anti EEA1 
Mouse 
Monoclonal 
Santa Cruz Biotechnoly SC11176 
anti Rab5 
Goat 
Polyclonal 
Santa Cruz Biotechnoly SC42376 
anti LAMP1 
Goat 
polyclonal  
Santa Cruz Biotechnoly SC23114 
anti-TLR4 (C-
19) 
Goat 
Polyclonal 
Santa Cruz Biotechnology SC-8694 
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Secondary Abs Species Company Catalogue no. 
Rabbit anti-mouse IgG- FITC DAKO 00044532 
Goat anti-rabbit  IgG- FITC JaksonImmunoresearch 111-095-045 
Donkey anti-Goat IgG (H+L), 
Alexa Fluor 488 
Thermofischer Scientific A-11055 
 
 
Donkey anti-Rabbit IgG (H+L) 
Alexa Fluor 488 
Thermofischer Scientific A-21206 
Donkey anti-rabbit IgG (H+L) 
Alexa Fluor 546 
Thermofischer Scientific A-11157 
 
 
Donkey anti-Goat IgG (H+L) 
Alexa Fluor 546 
Thermofischer Scientific A-11056 
Goat anti-Rabbit IgG (H+L) 
Alexa Fluor 546 
Thermofischer Scientific A-11010 
Donkey anti-mouse IgG (H+L), 
Alexa Fluor 555 
Thermofischer Scientific A-31570 
Donkey anti-mouse IgG (H+L), 
Alexa Fluor 488 
Thermofischer Scientific A-21202 
Donkey anti-mouse IgG (H+L), 
Alexa Fluor 647 
Thermofischer Scientific A-31571 
Donkey anti-rabbit IgG (H+L), 
Alexa Fluor 647 
Thermofischer Scientific A-31573 
Donkey anti-Goat IgG (H+L), 
Alexa Fluor 633   
Thermofischer Scientific A-21082 
Rabbit anti-goat   IgG- FITC DAKO 00053061 
Goat anti-rabbit  IgG- FITC JaksonImmunoresearch  111-095-045 
Goat anti-rabbit IgG-FITC JaksonImmunoresearch  111-095-045 
Rabbit anti-mouse IgG- FITC DAKO 00044532 
Goat anti-rabbit IgG-FITC JaksonImmunoresearch 111-095-045 
Goat anti-rabbit IgG-FITC JaksonImmunoresearch  111-095-045 
Goat anti-rabbit IgG- FITC JaksonImmunoresearch  111-095-045 
Goat anti-rabbit IgG- FITC   JaksonImmunoresearch 111-095-045 
Rabbit anti-goat  IgG- FITC DAKO 00053061 
Goat anti mouse IgG-HRP Thermofischer Scientific A10551 
Goat anti Rabbit IgG-HRP Thermofischer Scientific 31460 
Rabbit anti-goat IgG FITC DAKO 00053061 
 
Table 2.1.2b List of secondary antibodies utilized for experiments. 
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2.2 Tissue culture 
To ensure sterile conditions during tissue culture a Microflow Advanced Biosafety 
Class II laminar flow hood was used. Plasticware, glassware and solutions were 
autoclaved for tissue culture. Hood and equipment was sterilized with 1% aqueous 
Virkon (Antec International). Cells were incubated at 37˚C with 5% CO2 humidified 
atmosphere. 
2.2.1 Cell line investigated 
The cell line used for experiments is a Human brain astrocytoma cell line from 
ECACC (European Collection of Cell Cultures, a Public Health England Culture 
Collection); 1321N1. The adherent cell line, astrocyte cells (glial morphology, 
human species), was cultured in RPMI 1640 medium + 10% FCS (Sigma-Aldrich), 
0.25% Trypsin/EDTA (Sigma-Aldrich) and maintained in an incubator at 5% CO2 
at 37°C. 
2.2.2 Trypsinization 
Foetal calf serum (FCS; growth factor) was added to the growth medium (10% to 
final volume) to provide the required nutritions and viable environment for cell 
growth. Upon high confluency (cells cover >90% of the flask), cells required either 
propagation or maintenance. Cell propagating ensures that the cells have the 
necessary space to grow and the cell line is maintained indefinitely.  
For trypsinization, the supernatant was discarded from the flasks containing the 
monolayer of cells. The single layer of cells was then washed using 2 ml of 1X 
phosphate buffered saline (PBS) to remove the cellular debris.  PBS was 
discarded and 2 ml of trypsin (Sigma-Aldrich) were then added to the cells (2x106 
cells), and incubated for 5 min at 37oC at 5% CO2. Trypsin is a serine protease 
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that is utilized to hydrolyse the cell-adherent proteins at the bottom of the flask. 
After 5 min of incubation, 2 ml of growth medium (equal volume to trypsin) were 
added to the cells to neutralize the effect of the trypsin. 
The cells were equally divided and growth medium was added bringing the flasks 
up to a total volume of 5 ml. The flasks were left in the incubator at 37oC at 5% 
CO2. 
2.2.3 Cryogenic preservation 
To freeze the adherent cells for preservation, the confluent monolayer of cells 
(2x106 cells) was washed with 1X PBS and trypsinized as described above. The 
cell volume, including trypsin, was then transferred into a 15 ml Falcon tube, and 
centrifuged at 1200 rpm for 5min at room temperature (RT). The supernatant was 
aspirated and discarded, and 1 ml of freezing medium was added to the pellet and 
resuspended. The mixed sample was quickly transferred into appropriately 
labelled CryoTube vials (Nunc; Sigma-Aldrich) and stored at -80oC.   
The CryoTube vials were transferred into liquid nitrogen (-196oC) after 24 h for 
long-term storage. Depending on the cells (transfected or wild type), the freezing 
medium consists of 10% dimethyl sulfoxide (DMSO) in FCS. In the case of 
transfected cells, the freezing medium consists of 10% DMSO, 30% FCS and 60% 
selection medium (with antibiotics; see transfection subchapter). The freezing 
medium is necessary for the preservation of cells to avoid cell damage and is 
acting by forming ice crystals around the cells. The DMSO/FCS-resuspended 
pellet of cells was transferred into CryoTube vials and stored in the freezer in less 
than 10 min, as DMSO is a cryo-protectant, however toxic to the cells in room 
temperature following exposures longer than 15 min.  
92 | P a g e  
 
2.2.4 Thawing Cells 
CryoTube vials stored in liquid nitrogen may be carefully removed and utilize as 
required in experiments. To use the frozen cells, they require thawing first. The 
DMSO/FCS/cell mixture from the vials was transferred into 15 ml Falcon tubes as 
soon as it was defrosted and 10 ml of appropriate growth medium were quickly 
added. The sample was centrifuged at 1200 rpm for 5 min at RT and the 
supernatant was discarded. Growth medium (5 ml) was added to the pellet of cells 
and resuspended carefully. The cell mixture was then transferred into a flask and 
left in a 37oC at 5% CO2 incubator. 
2.2.5 Amyloid 
A peptide of amino acids 1–42 of Aβ (DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA), 
as well as revAβ (AIAEGDSHVLKEGAYMEIFDVQGHVFGGKIFRVVDLGSHNVA) (control nonfibrillary 
peptide with identical sequence in reverse order), were obtained from Anaspec. 
To induce fibril formation, Aβ1–42 was resuspended in H2O at 1 mg/ml and 
incubated for 1 week at 37°C (Moore et al 2002). Fibril formation from our 
preparation was confirmed by atomic force microscopy staining performed by 
Professor Louise Serpell (University of Sussex) who is an expert in amyloid 
structure, as previously described (Gosal et al 2005). Aβ preparations were tested 
for endotoxin with a limulus amebocyte lysate assay. Aliquots of Aβ were frozen 
and then they were used as needed to prevent microbial growth and degradation 
of fibrils. Aβ1–42 and revAβ were used at 10uM in all studies unless otherwise 
stated. 
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2.2.6 Brain tissue samples 
Brain tissue samples used in this study were obtained from The Oxford Brain 
Bank as well as the University College London Brain Bank by a Material transfer 
agreement.  Tissue was supplied as paraffin-embedded slides. Alzheimer's 
Disease subjects and non-demented controls were recruited through the Oxford 
Brain Tissue Research Center or the UCL Brain Bank. Each subject was 
diagnosed at intake and each brain underwent an extensive neuropathology 
examination. A table indicating the tissue samples is listed below. 
 
Sample 
number 
Gender Age 
Pathological 
diagnosis 
 
Limbic region 
section 
Neuropathological 
record 
Controls 
Cs00017 Female 57 Normal hippocampus  
Controls 
Cs22348 Female 76 Normal hippocampus  
Controls 
Cs0099 Female 61 Normal hippocampus  
Controls 
Cs00567 Female 67 Normal hippocampus  
Controls 
Cs11123 Male 54 Normal hippocampus  
Controls 
Cs00765 Male 37 Normal hippocampus  
Controls 
Cs11123 Male 54 Normal hippocampus  
Controls 
Cs341 Female 48 Normal hippocampus  
Controls 
Cs00978 Male 57 Normal hippocampus  
Controls 20111016 
Male 60  hippocampus  
Controls 19960207 
Female 49 Normal hippocampus  
Controls 20000059 
Female 55 Normal hippocampus  
Controls 20020062 
Male 70 Normal hippocampus  
Controls 20090017 
Male 18 Normal hippocampus  
Controls 20100098 
Female 63 Normal hippocampus  
Controls 20100320 
Male 33 Normal hippocampus  
Controls 20100987 
Male 62 Normal hippocampus  
Controls 20110561 
Male 64 Normal hippocampus  
Controls 20100486 
Female 27 Normal hippocampus  
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Controls 20121029 
Male 52 Normal hippocampus  
Controls 20131902 
Male  Normal hippocampus  
Controls 19820196 
Female  Normal hippocampus  
Controls 19891029 
Male  Normal hippocampus  
Controls 19910252 
Female 67 Normal hippocampus  
Controls 19920202 
Female   hippocampus  
Dementia Cs05479 Female 89 Alzheimer hippocampus Stage IV 
Dementia Cs34578 Male 80 Alzheimer hippocampus Stage III 
Dementia Cs1198 Male 77 Alzheimer hippocampus Stage IV 
Dementia Cs12345 Female 78 Alzheimer hippocampus Stage V 
Dementia CS111 Male 81 Alzheimer hippocampus Stage V 
Dementia CS1118 Female 77 Alzheimer   
Dementia Cs0087 Female 83 Alzheimer hippocampus Stage VI 
Dementia Cs0056 Male 55 Normal hippocampus Stage IV 
Dementia Cs1234 Male 70 Alzheimer hippocampus Stage IV 
Dementia Cs0096 Female 65 Normal hippocampus Stage III 
Dementia Cs5809 Female 74 Alzheimer hippocampus Stage IV 
Dementia Cs2456 Male 86 Alzheimer hippocampus Stage VI 
Dementia Cs3478 Male 75 Alzheimer hippocampus Stage V 
Dementia Cs3477 Male 70 Alzheimer hippocampus Stage IV 
Dementia Cs0091 Female 68 Alzheimer hippocampus Stage IV 
Dementia Cs34567 Female 71 Alzheimer hippocampus Stage IV 
Dementia CS1239 Male  Alzheimer hippocampus Stage III 
Dementia Cs11888 Male 89 Alzheimer hippocampus Stage VI 
Dementia 
19940092 
Male  Alzheimer hippocampus  
Dementia 
19940144 
Female 92 Alzheimer hippocampus Stage IV 
Dementia 
20040091 
Female 87 Alzheimer hippocampus Stage IV 
Dementia 
20050087 
Male 73 Alzheimer hippocampus Stage III 
Dementia 
20050102 
     
Dementia 
20070049 
Female 69 Alzheimer hippocampus Stage IV 
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Dementia 
20090067 
Male 72 Alzheimer hippocampus Stage IV 
Dementia 
20100729 
Male 70 Alzheimer hippocampus Stage III 
Dementia 
20110891 
Female 88 Alzheimer hippocampus Stage IV 
Dementia 
20040091 
 77 Alzheimer hippocampus Stage VI 
Dementia 
20050087 
Male 83 Alzheimer hippocampus Stage V 
Dementia 
20050102 
Female 87 Alzheimer hippocampus Stage VI 
Dementia 
20070049 
Female 66 Alzheimer hippocampus Stage IV 
Dementia 
20090067 
Male 81 Alzheimer hippocampus  
Dementia 
20100729 
Female 84 Alzheimer hippocampus  
Dementia 
20110891 
Female 86 Alzheimer hippocampus Stage V 
Dementia 
20111016 
Male 90 Alzheimer hippocampus Stage V 
Dementia 
19960207 
Male 76 Alzheimer hippocampus Stage VI 
Dementia 
20000059 
Female 70 Alzheimer hippocampus Stage V 
Dementia 
20020062 
Male 69 Alzheimer hippocampus Stage VI 
Dementia 
20090017 
Female 82 Alzheimer hippocampus Stage V 
Dementia 
20100098 
Female 75 Alzheimer hippocampus Stage VI 
Dementia 
20100320 
Female  Alzheimer hippocampus Stage VI 
Dementia 
20100987 
Female 78 Alzheimer hippocampus Stage IV 
Dementia 
20110561 
Female  Alzheimer hippocampus Stage V 
Dementia 
20100486 
Male 69 Alzheimer hippocampus Stage III 
Dementia 
20121029 
Female 72 Alzheimer hippocampus Stage IV 
Dementia 
20131902 
Male 72 Alzheimer hippocampus Stage V 
Dementia 
19820196 
Female  Alzheimer hippocampus Stage VI 
Dementia 
19891029 
Male 85 Alzheimer hippocampus Stage IV 
Dementia 
19910252 
Female 78 Alzheimer hippocampus Stage V 
Dementia 19920202 
Male 71 Alzheimer hippocampus Stage VI 
 
Table 2.2.6 A table indicating the samples from patients with Alzheimer’s Disease and 
healthy controls used for this study. 
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2.3 Immunofluorescence 
2.3.1 Underlying principles 
Immunofluorescence is a technique that utilizes light microscopy with a 
fluorescence microscope to detect and quantify an antigen present on the cell 
membrane or intracellularly. Antibodies have specificity towards certain antigens, 
thus a fluorophore (fluorescent dye) is attached to an antibody to bind the antigen 
of interest. The fluorophore assists in the visualization of the distribution of the 
targeted antigen and the fluorescence detected corresponds to the quantity of the 
antigen of interest. Immunofluorescence may be used on cell lines or tissue 
sections to investigate the distribution of molecules (Bauer and Jaccoberger 
1994).  
Fluorophores are fluorescent chemical compounds which absorb light energy of a 
certain wavelength and emit energy at a different wavelength. Depending on the 
fluorophores’ structure and environment, the energy transfer efficiency, absorbed 
wavelengths and time prior to emission change accordingly. Two of the most 
commonly used fluorophores are the derivatives of fluorescein, FITC (fluorescein 
isothiocyanate), and rhodamine, TRITC (tetramethylrhodamine isothiocyanate). 
FITC has an excitation wavelength of 495nm (cyan) and an emission wavelength 
of 519nm (green), whereas TRITC has an excitation wavelength of 547nm (green) 
and an emission wavelength of 572nm (yellow) (Haugland 1995; Liu et al. 2013). 
Alexa 488 (excitation wavelength of 495nm and an emission wavelength of 
519nm), Alexa 594 (excitation wavelength of 590nm and an emission wavelength 
of 617nm) and Alexa 405(excitation wavelength of 401nm and an emission 
wavelength of 421nm) are additional fluorescent dyes chosen for this project. 
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Additional fluorescent dyes, such as TOPRO (excitation at 642 nm and emission 
at 661 nm), or DAPI (excitation at 350 nm and emission at 470 nm), are nuclear 
and chromosomal counterstains that infiltrate compromised membranes 
(characteristic of dead cells), thus used as an indicator of cell death within a cell 
population. The fluorescence of TOPRO, a long-wavelength light-absorbing dye, 
is not normally concealed due to tissue auto-fluorescence, thus it is an ideal dye 
for tissue counterstaining. In addition, TOPRO stain has very strong binding affinity 
for dsDNA, with dissociation constants in the μM range, therefore offers a robust 
and selective nuclear staining in tissue sections or cultured cells (Tavecchio et al. 
2008). 
The two main methods of immunofluorescence are direct (primary) and indirect 
(secondary). 
2.3.2 Direct immunofluorescence 
In direct immunofluorescence (IF) a single antibody is directed against the antigen 
of interest and it is chemically conjugated to a fluorescent dye (Figure 2.3.3). The 
experimental procedure of direct IF is simpler and shorter compared with the 
indirect IF, as only one labelling step is required. However, the signal detected in 
direct IF may appear weak compared with indirect IF. This is because signal 
amplification provided using secondary antibodies does not occur in direct IF. 
Nevertheless, non-specific binding is reduced in direct IF via the use of conjugated 
primary antibodies. Finally, direct IF allows for the investigation of ligand binding 
properties, in addition to labelling specific antigens (Coons et al. 1941; Bacallao et 
al. 2006).  
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2.3.3 Indirect immunofluorescence 
Indirect IF uses two antibodies: a primary antibody that is un-conjugated and 
specific for the antigen of interest, and a fluorophore-conjugated secondary 
antibody directed against the primary antibody to detect it (Figure 2.3.3). This 
method is highly specific, as the positive and negative samples create very 
different signals, thus are easily differentiated. Each bound antibody demonstrates 
a typical fluorescence pattern depending on the location of the individual antigens. 
The technique of IF allows for simultaneous detection of antibodies against 
numerous biochemically different antigens on one single biological substrate. 
Therefore, indirect IF is chosen in cases for which the test antigens would be 
difficult to be individually prepared for enzyme immunoassays. The selection of 
primary antibodies is a crucial step in IF. The secondary detection of two different 
targets in the same sample depends on the primary antibody for each target being 
raised in different host species to avoid cross-reactivity between the secondary 
antibodies.  
To detect different targets in the same sample, the structure of antibodies serves 
an important role. An antibody consists of two regions: An Fc region (fragment 
crystallisable region) and a Fab region (fragment antigen-binding region). The Fab 
region contains variable sections that determine which antigen is bound and the 
Fc region is constant in a class of the same species. Antibodies may be designed 
to contain the same Fc region and different Fab regions. Therefore, primary 
antibodies with the same Fc region may be used to detect various antigens (due 
to different Fab regions), and still be detected by a single fluorescently-conjugated 
secondary antibody specific to the Fc region of the primary antibody. 
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Figure 2.3.3 Two types of immunofluorescence (IF). In direct IF, the antibody (orange) is 
labelled with fluorophores (green) and binds the epitope (grey). In indirect IF, the primary antibody 
(orange) binds the epitope (grey) and a fluorophore-labelled secondary antibody (purple) binds 
specifically to the primary antibody (Thermofisher Scientific, Inc., URL). 
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2.4 Flow Cytometry 
2.4.1 Underlying principles 
Flow cytometry is utilized in cell counting, cell sorting, biomarker detection and 
protein engineering. A flow cytometer defines and counts cells passing in a stream 
through a laser beam, and it can identify and isolate different populations of cells 
within a sample. To identify the different cell populations, it is detecting the 
fluorescence from tagged primary or secondary antibodies (Janeway et al. 2001). 
The cells are forced though a narrow nozzle with a much larger volume of saline 
solution, to release cells individually, hence the laser beam will excite them 
singularly. The laser beam excites the fluorescent tags and then sensitive 
photomultiplier tubes detect the fluorescence. The size and granularity of each cell 
and the fluorescence of bound labelled monoclonal antibodies are calculated, 
providing information on the expression of the cell-surface proteins of each cell.  
This method is used to investigate numerous processes, including cell cycle, 
apoptosis, and detection of biomarkers. The method assesses the physical and 
chemical characteristics of cells (between 0.2 and 150μm in size), which are 
fluorescently labeled. As the fluorescing cell passes through the laser beam, it 
creates a peak or pulse of photon emission over time. These are detected by the 
photomultiplying tube sensors and converted to a voltage pulse, known as an 
event. The flow cytometer measures the total pulse height and area. The 
measured voltage pulse area will correlate directly to the intensity of fluorescence 
for that event.  
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A.       B.  
 
 
Figure 2.4.1 (A) Overview of a flow cytometer. (B) Photomultiplying tube sensors 
measurement. Measurement of the pulse area of the voltage created each time by a fluorescing 
cell releasing photons (Abcam PLC, URL). 
The flow cytometer, also known as a Fluorescence Activated Cell Sorter (FACS), 
can quantify and distinguish between molecules according to their fluorescence 
and physiological structure. In this study, fluorescently labelled cells/cytokines 
were analysed using a Becton Dickinson Fluorescent Activated Cell Sorter 
(FACSCalibur) with the software supplied by Cell Quest. 
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2.5 Determining PRR expression levels 
2.5.1 Trypan blue viability test 
As the quality of the cell sample was vital for potential downstream experiments, 
viability measurements were routinely performed. The Trypan blue exclusion test 
is used to determine the number of viable cells present in a cell suspension. It is 
based on the principle that live cells possess intact cell membranes that exclude 
certain dyes, such as Trypan blue, Eosin, or propidium, whereas dead cells do not. 
In this test, a cell suspension is simply mixed with 1% trypan blue (ThermoFisher 
Scientific) and then visually examined under a microscope to determine whether 
cells take up or exclude the dye. In the protocol used, a viable cell had a clear 
cytoplasm whereas a nonviable cell had a blue cytoplasm.  
2.5.2 Cell stimulation and assays analyses 
Indirect immunofluorescence and flow cytometry were utilised to elucidate NLRs, 
TLRs and complement receptors expression in astrocytes. To perform the indirect 
immunofluorescence assay, confluent cells (1x106) were either unstimulated, or 
stimulated with 10μM of Aβ or scrambled peptide (identical sequence to Aβ, but 
scrambled) for 2, 4 or 6 hours.  
At each time point, the supernatants were collected from the flasks and transferred 
to appropriately labelled eppendorf tubes. The tubes were stored in the -20oC to 
be used at a later point for the cytometric bead array assay. The monolayer of cells 
in the flasks was washed with 2 ml 1X PBS and 1 ml of 1X PBS was added to each 
flask to scrape of the cells and collect them into eppendorf tubes. The samples 
were then centrifuged at 13000 rpm for 5 minutes at RT and the PBS was aspirated 
without disturbing the pellet of cells. Cells were fixed using 300 μl of 4% 
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paraformaldehyde (PFA; Sigma-Aldrich) for 15 minutes at RT and 500 µL of 1X 
PBS were added to wash the cells by centrifugation at 13000 rpm for 5 minutes at 
RT. The PFA and PBS were aspirated and 100 µL of 1X 
PBS/0.02%BSA/0.02%NaN3/0.02%Saponin were added to the cells and left to 
incubate for 5 minutes at RT. BSA is used as a carrier protein to antibodies and 
as a general protein blocking agent. The amphipathic nature of Saponin makes it 
act as a surfactant, enhancing the penetration of proteins through the cell 
membrane. NaN3 prevents the internalization of surface antigens, which could 
produce a loss of fluorescent intensity. The appropriate primary antibodies (1 ug) 
were added and samples were incubated at room temperature for 1 hour. Samples 
were washed twice with PBS/BSA/NaN3/Saponin and the appropriate secondary 
antibody conjugated to FITC was added. The cells were incubated with the 
secondary antibody (0.5 ug) for 45-60 min in the dark (to avoid photobleaching), 
washed twice and resuspended in 500μl PBS/BSA/NaN3/Saponin. The samples 
were transferred to flow tubes and analyzed using the Becton Dickinson 
Fluorescent Activated Cell Sorter (FACSCalibur) and the Cell Quest software. 
10,000 not gated cells were analyzed for each sample.  
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2.6 SDS-PAGE 
2.6.1 Underlying principles 
Polyacrylamide gel electrophoresis (PAGE) is a method used in combination with 
western blotting to separate proteins according to their size, shape, and net 
charge. Sodium dodecyl sulphate (SDS)-PAGE separates the proteins according 
to their size only, as proteins migrate in the gel in response to the electric field 
applied.  This is because SDS, as a denaturing detergent, dissolves the 
hydrophobic molecules to become linear. SDS makes the protein negatively 
charged for the proteins to migrate through the gel from negative to positive 
charge. Therefore, depending on their molecular weight (MW), small proteins will 
move faster in the gel than the ones with higher MW. 
After the separation of the proteins on the gel, the proteins are transferred to 
nitrocellulose membranes and probed with antibodies along with enzymatic 
chemiluminescent to detect the proteins. The advantage of using SDS-PAGE 
instead of ELISA is the denaturing condition where under proteins are quantified, 
which is of high relevance when analysing highly fibrillogenic proteins, such as Aβ. 
2.6.2 Continuous SDS-PAGE 
For continuous SDS-PAGE, the same buffer ions are present at constant pH in the 
gel and electrode reservoirs. Therefore, it is much quicker and easier to prepare, 
compared with the discontinuous SDS-PAGE. For this method, the DNA (or RNA) 
samples should be sufficient to run for enough resolutions of electrophoresis, 
where as to simply observe whether a protein is present in a sample the 
discontinuous method is preferred. 
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2.6.3 Discontinuous SDS-PAGE 
For discontinuous SDS-PAGE, different buffer ions are present in the gel and 
electrode reservoirs. By using different buffers in the gel and in the electrode 
solutions and adding a stacking gel to the resolving gel, samples are compressed 
into a thin starting band and individual proteins are finely resolved and separated. 
The gel consists of two parts: the upper stacking gel and the lower resolving gel. 
The 4% stacking gel has larger pores (low percentage) and a low pH of 6.8, 
whereas the lower 10% resolving gel has smaller pores with a higher pH of 8.8. 
The protein samples are loaded at the interface between the two gel layers, in very 
thin and sharp wells (made with a 1 mm comb). Following the application of an 
electrical field, the proteins travel through the resolving gel and are separated 
according to their MW, as described above.  
2.6.4 Experimental procedure 
The gels were made up in liquid form to be poured into appropriate casts to set. 
The polymerisation of the gel occurs upon addition of ammonium persulfate (APS) 
and N,N,N’,N’-tetra-methylethylenediamine (TEMED), as the gels form cross-links 
creating the sieve-like matrix required. For the SDS-PAGE analysis in the present 
study the Mini-PROTEAN Tetra Handcast System (Bio-Rad Laboratories, Inc.) 
was utilised (Figure 2.6.4). 
To prepare the gel cast to load the proteins, the resolving gel mixture (see Table 
2.6.4) was prepared and immediately poured into the cast. Isobutanol (~1 ml) was 
added to the top to make the gel surface smooth and flat. The gel was left to set 
at RT for 45 min and then isobutanol was rinsed with dH2O and removed. The 4% 
stacking gel mixture (see Table 2.6.4) was poured on top of the resolving gel and 
a 1mm comb was placed in it to form the wells. The stacking gel was left to set at 
106 | P a g e  
 
RT for 45 min and then the comb was carefully removed. The gels were placed 
into the electrophoresis tank and 1X running buffer [25Mm Tris, 192mM glycine 
and 0.1% (w/v) SDS, pH 8.3] was poured on top to cover it. 
 Figure 2.6.4 The Mini-PROTEAN Tetra handcast system (Bio-Rad Laboratories, URL). 
 
 
 
 
 
Table 2.6.4 Composition of resolving and stacking gels used in SDS-PAGE. 
 
To prepare the samples for running on the gel, X2 SDS-PAGE Reducing Sample 
Buffer (100ml; 10.0g Glycerol, 20ml 0.5M Tris pH 6.8, 16ml 10% SDS, 4ml 14.3M 
β-mercaptoethanol, few mg of Bromophenol Blue) was added to cells that had 
been either unstimulated, or stimulated with Aβ or scrambled for 2, 4, or 6 hours. 
The SDS in the reducing sample buffer is an anionic surfactant which both 
denatures secondary and non-disulphide-linked tertiary structures in proteins, and 
places a negative charge onto each protein in proportion to its mass. This ensures 
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that each protein is linear and separated only by its molecular weight. The β-
mercaptoethanol present further denatures proteins by cleaving their disulphide 
bonds, thereby disrupting the tertiary and quaternary structure of them. The 
glycerol helps preserve the proteins at low temperatures, and weighs down the 
samples when loading them into the wells, and the Tris present acts as a buffer. 
The addition of Bromophenol Blue allows the samples to be visualised as they 
pass through the gel. Each sample (100μl) was added to separate eppendorfs and 
boiled for 10 minutes, along with biotinylated SDS-PAGE standards (2μl + 40μl X2 
SDS-PAGE Reducing sample buffer), to help denature the proteins further. The 
standards are a mixture of biotinylated proteins with consistent molecular weights, 
allowing for accurate molecular weight determination of immune detected proteins. 
40μl of the samples (10μl of standards) were then loaded into the wells, and the 
apparatus was run at a constant voltage of 200V for approximately 45 minutes.  
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2.7 Western blot analysis 
2.7.1 Underlying principles 
Western blotting refers to the transfer of biological samples from a gel to a 
membrane and their subsequent detection on the surface of the membrane. 
Towbin et al. (1979) was the first to demonstrate the method that it is now widely 
used to analyze proteins. The specificity of the antibody-antigen interaction allows 
for a target protein to be identified within a complex protein sample.  
The SDS-PAGE is used to electrophoretically separate the proteins, which are 
then transferred to a nitrocellulose membrane via electroblotting. The proteins are 
transferred into a portion of nitrocellulose membrane in the same formation as they 
were in the gel. Electroblotting was used to pull proteins from the poly-acrylamide 
gel onto the nitrocellulose membrane using the Mini Trans-Blot Cell system (Bio-
Rad Laboratories, Inc.; Figure 2.7.1). 
 
 
 
 
 
 
 
 
 
Figure 2.7.1 The Mini Trans-Blot cell system. The Mini Trans-Blot cell transfers up to two gels 
in an hour and the self-contained Bio-Ice cooling unit absorbs the heat generated during transfer 
(Bio-Rad Laboratories, URL). 
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Following SDS-PAGE, the resolving gel was placed in a transfer cassette on top 
of a porous pad, two pieces of blotting paper and a nitrocellulose membrane, all 
soaked in transfer buffer (20mM Tris acetate, 0.1% SDS, 20% isopropanol, pH 
8.3). Two pieces of blotting paper and a porous pad were then placed on top of 
the gel, and the cassette was closed and placed in the transfer tank. A blue cooling 
unit was placed inside the tank along with the cassette and then it was filled to the 
top with transfer buffer. Transferring was performed at a constant current of 
220mA for 60 minutes.  
2.7.2 Probing the membranes with antibodies 
Subsequent to protein transfer, the membrane was placed in blocking buffer (20g 
milk powder dissolved in 100ml 1X PBS) on rotary for 1 h. The nitrocellulose 
membrane has a high binding affinity and allows all proteins to bind strongly, in 
addition to antibodies. The blocking mixture has high quantities of proteins to 
prevent the unspecific binding of antibodies, thus blocking the membrane ensures 
that these proteins will bind to the rest of the membrane to block the antibodies 
from binding (Abcam, URL).  
Subsequent to blocking, the membrane was washed for 2x15 min in 1X PBS with 
0.1% Tween 20 on a rotary and then incubated with the appropriate primary 
antibody diluted in 1X PBS-Tween for the specific protein of interest. Primary 
antibody incubation was performed on rotary at RT for 1 h and then the membrane 
was left in the fridge overnight.  The following day, the membrane was washed for 
2x15 min in 1X PBS-Tween on a rotary. The membrane was then incubated with 
a secondary antibody specific to the primary antibody and conjugated to 
horseradish peroxidise (HRP). Secondary antibody incubation was performed on 
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rotary at RT for 45 min and the membrane was then washed for 2 h in 1X PBS-
Tween whilst changing the washing buffer every 15 min.  
Subsequent to the washes, the membrane was placed in a developing cassette, 
treated with an enhanced-chemiluminescence (ECL) Prime reagent (Amersham, 
UK) in a dark room and high performance chemiluminescence film (Hyperfilm; GE 
Healthcare) was placed onto the membrane. The ECL reagent enables the HRP 
to emit light only where the protein bands are present. The film was finally exposed 
for a short time, depending on the intensity of the luminescence.  
 
 
Figure 2.7.2 Principles of western blotting. The proteins are electrophoretically transferred from 
the sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) gel onto the 
nitrocellulose membrane. The membrane is then blocked, and primary and secondary antibody 
incubations take place. Subsequent to the incubations, a substrate is added for the proteins to be 
visualised utilizing enhanced chemiluminescence (Komabiotech, URL). 
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Figure 2.7.3 Principle of electro-chemiluminescence in western blotting. The nitrocellulose 
membranes are treated with an electro-chemiluminescence (ECL) reagent, causing the HRP to 
emit light only where the protein bands are present. HRP catalyses the oxidation of luminol to its 
excited state and decays back to the ground state via a light emitting pathway (GE Healthcare Life 
Sciences, URL).  
2.7.3 Stripping and re-probing membranes 
Following the initial use of nitrocellulose membranes with bound proteins and 
antibodies, the membrane may be stripped and re-probed with different antibodies. 
To strip the membrane of previous bound antibodies and keep only the proteins 
bound, the membrane is incubated in stripping buffer at 50oC, on a shaker 
incubator for 5-7 min. Following incubation, the membrane was washed with 1X 
PBS-Tween for 20 min on a shaker and then blocked for 1 h. Subsequent to 
blocking the membrane may be re-probed with the same or different antibodies, 
as described above (see 2.7.2 Probing membranes with antibodies section). 
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2.8 Plasmid DNA 
2.8.1 Preparation of plasmid DNA  
2.8.1.1 Transformation 
All procedures were carried out using sterile tips near a Bunsen burner to ensure 
sterility. Agar plates were previously prepared with 25 ug/ml Zeocin. psiRNA-
plasmids (Invivogen) were transformed into a competent E. Coli strain (E. Coli 
GT116). 1 ug of the plasmid was added to 100 μl of E. Coli competent cells and 
incubated on ice for 30 min. This was followed by heat shocking the tubes at 42oC 
for 45 sec, then placing them back on ice for 2 min. Luria Broth (500 μl; 
Bactopeptone, Yeast extract, NaCl, dH20) was added to the transformed cells and 
the tubes were incubated at 225 rpm at 37oC for 1 h. The transformed cells (100 
µl) were then placed on Zeocin (25µg/ml) incorporated agar plates. Plates were 
left to grow overnight in an incubator shaker at 37ºC at 125 rpm. The plasmids 
contained a Zeocin-resistance gene, so that only the E. Coli that have taken up 
the plasmid would survive on the Zeocin agar plates. Following the growth of the 
E. Coli colonies, separate colonies were selected with sterile toothpicks and 
placed in different 25 ml vials of Zeocin (25μg/ml) incorporated luria broth, and 
incubated overnight at 225 rpm at 37oC. 
2.8.1.2 DNA Isolation  
The luria broth mixture containing the E. Coli culture was centrifuged at 4000rpm 
in 50ml Falcon tubes for 30 min at RT and the supernatant was then swiftly 
discarded without agitating the pellet of cells. STET buffer (400 μl) was added to 
the pellet and was vortexed to lyse the E. Coli cell walls. The mixture was then 
transferred to sterile eppendorf tubes and 10 μl lysozyme (50mg/ml) (Sigma 
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Aldrich, UK) was added to each eppendorf. The eppendorfs were placed in a 
100oC waterbath for 1 min and subsequent on ice for 5 min. The samples were 
then centrifuged for 30 min at 13000 rpm at RT and the pellet was removed using 
a sterile toothpick. RNAse A (5 μl; 20μg/ml; degrades RNA) (Sigma Aldrich, UK) 
was added to each sample and left to incubate at 42oC for 30 min. Following 
incubation, 400 μl phenol/chloroform/isoamyl alcohol (P3803; Sigma-Aldrich UK) 
were added to the samples, vortexed carefully and centrifuged for 15 min at 13000 
rpm at RT. The supernatant was carefully collected and transferred to a new set 
of sterile eppendorfs, while the rest was discarded. Chloroform/isoamyl alcohol 
(400 μl) (25666; Sigma-Aldrich UK) was added to the samples, vortexed and 
centrifuged as before for 30 min at 13000 rpm at RT. The supernatants were again 
carefully collected and transferred to another set of sterile eppendorfs. A mixture 
consisting of: 20 μl (1/20th of total volume) sodium acetate 2M pH 6.5 and 1 ml (2.5 
times the total volume) 100% ethanol, was added to each sample, vortexed and 
placed in the -80oC freezer for at least 1 h.  
After 1 h, the samples were immediately centrifuged from frozen at 13000 rpm for 
20 min at RT. The supernatants were carefully discarded, keeping the tiny pellets 
of purified DNA in the eppendorfs. Samples were centrifuged at 13000 rpm for 1 
min at RT to remove any excess supernatant and sterile water (60 μl) was then 
added to each sample. DNA concentration was measured using the NanoDrop 
2000 UV-Vis Spectrophotometer. Samples were stored in -80oC for future 
experiments.  
2.8.1.3 Agarose gel electrophoresis for purity control 
Agarose gel electrophoresis was used to separate a mixed population of DNA 
through a matrix made of agarose. The DNA samples were separated according 
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to the size of the sample fragments; smaller fragments translocated further than 
the longer fragments, through the agarose gel. An electrical gradient was applied 
on both ends of the gel, for the negatively charged molecules to translocate and 
separate the fragments. To verify the purity of the prepared plasmid (see 2.8.1.2 
section), the samples were run on a 1% w/v agarose gel with 1% GelRed DNA 
stain. The samples were mixed with the ELFO loading buffer (10 μl sample + 5 μl 
buffer) and run at 100V constant voltage for 45 min. Once run, the bands were 
observed using the Stratagene Eagle Eye II still video system (Stratagene; Agilent 
Technologies Inc.) to detect whether the DNA was purified, thus could be used in 
future experiments. 
2.8.2 Silencing (RNA interference) 
RNA interference (RNAi)i involves the control of genes at the level of RNA. In this 
study astrocytes were transformed with NLRP1, NLRP3, TLR2, TLR4 and NLRC5 
psiRNAs to knock down their expression. 
The psiRNA is transcribed producing shRNA this is processed by the Dicer class 
of RNase III enzymes into siRNA, removing the hairpin and leaving a two 
nucleotide long 3' overhang. The siRNA is then bound by siRNA-induced silencing 
complex (siRISC) which has an RNase component (argonaute) which is activated 
and sets about degrading one of the siRNA strands. The strand left intact, with 
RISC attached, is complimentary to and binds endogenous mRNA. This complex 
not only prevents transcription of the mRNA, but also when bound the RNAse 
component of RISC leads to cleavage and degradation of the mRNA (Figure 
2.8.2).  
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Figure 2.8.2.1 Gene silencing by shRNA. Transfection of a psiRNA plasmid into a mammalian 
cell leads to the cleavage and degradation of the target mRNA. This results in the knock down of 
gene expression (Santa Cruz Biotechnology, Inc., URL). 
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The TLR2 and TLR4 shRNAs were produced by the psiRNA-h7SKGFP::Zeo 
plasmid from the human 7SK RNA pol III promoter (Figure 2.8.2.2; InvivoGen). 
The plasmids feature a GFP::Zeo fusion gene that allows simple monitoring of 
transfection efficiency and selection in both E. Coli and mammalian cells. 
 
. 
 
 
 
 
 
 
 
 
 
Figure 2.8.1.2 TLR2 psiRNA plasmid. This is a schematic representation of the psiRNA-
h7SKGFP::Zeo plasmids from the human 7SK RNA pol III promoter. The siRNA region (red) 
encodes TLR2 interfering RNA (Invivogen psiRNA 2009 manual). 
Different psiRNA clones were generated using the psh7SK vector from Invitrogen 
the most efficient was against the sequence: for NLRP3 
GGAAGTGGACTGCGAGAAGTT, for NLRC5, GAACCTGTGGAGCTGTCTTGT and 
GCAACAGCATCTGCGTGTCAA, for NLRC4, GGATGCTGCTAGAGGGATCAT and 
GACAACTGGGCTCCTCTGTAA for NLRP1, GAAGGAGGAGCTGAAGGAGTT and 
GGCCTGATTATGTGGAGGAGA. For TLR4 GCCAGGAGAACTACGTGTGAA and for 
TLR2 GTCAATTCAGAACGTAAGTCA. 
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2.8.3 Transfection 
During the experimental process of transfection, foreign DNA enters the cells and 
the protein expression is examined and investigated. In the present study, the 
method of transient transfection was chosen. In transient transfection, the cells 
temporarily express the gene in the introduced plasmid, as it is not integrated into 
the host chromosomes and would be lost upon a certain number of cycles of cell 
division. This type of transfection has the advantage of being a quick and easy 
technique to express a gene of interest into a cell population. In the other type of 
transfection, the stable one, the plasmid is integrated into the hosts’ DNA and 
becomes a stable part of the transfected cells’ genetic material, however, the 
procedure takes between 6 and 8 weeks. For both types of transfection, the 
transfected cells are detected and selected using a selection growth medium with 
antibiotics. In this study lipofectamine was used as a transfection agent. 
Liposomes are synthetic analogues of the phospholipid bilayer, the building block 
of the cellular membrane. These transfection compounds share several 
characteristics with their natural counterparts, including the presence of 
hydrophobic and hydrophilic regions of each molecule which allow for the 
formation of spheroid liposomes under aqueous conditions. In the presence of free 
DNA or RNA, liposomes encapsulate the nucleic acids to create an efficient 
delivery system. The charge, composition and structure of the liposome defines 
the affinity of the complex for the cellular membrane. Under specific conditions, 
the liposome-nucleic acid complex can interact with the cell membrane to gain 
access into the cell by endocytosis and subsequently release the nucleic acids 
into the cytoplasm. 
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Briefly, in the experimental process, plates, or flasks of astrocytes (1x106 cells) 
were prepared for transfection using 4ug of plasmid shRNA and Lipofectamine 
2000 (following the manufacturer's instructions). 
4ug of plasmid siRNA were re-suspended in 30μl GIBCO Opti-MEM (31985-062, 
Life Technologies Ltd. UK), complexed with 10μl Lipofectamine 2000 (11668027, 
Life Technologies Ltd. UK) + 40μl Opti-MEM. 1x106 cells were washed with 6ml 
GIBCO Opti-MEM, the supernatant was aspirated and then 800μl of Opti MEM 
was added per plate. After the addition of Lipofectamine 2000-complexed DNA, 
cells were incubated overnight. The following day the medium was removed and 
cells were, re-suspended in GIBCO RPMI 1640 GlutaMAX™-I + 100ug/ml Zeocin 
to apply antibiotic selection pressure. Control plates with untransfected cells, cells 
with just the psh7SK vector and psh7SK with scrambled sequence were also used.  
Flow cytometry determined efficiency of transfection, since the plasmids 
expressed GFP, as well as western blotting for the receptor of interest. The 
procedure was repeated until 85% knockdown efficiency was achieved and then 
the cells were used for stimulations. 
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2.9 Cytometric Bead Array 
2.9.1 Underlying principles 
The cytometric bead array (CBA) system allows for the simultaneous 
measurement of multiple analytes in sample volumes too small for traditional 
immunoassays. In addition, the assay enables the evaluation of multiple analytes 
in a single sample and the results are reproducible and comparative with previous 
experiments. In the present study, the Human Inflammation BD Cytometric Bead 
Array (BD Biosciences) kit was used to measure the concentrations of the 
released cytokines. The BD CBA kit was utilized to quantitatively measure 
interleukin-8 (IL-8), IL-1β, IL-6, IL-10, tumour necrosis factor (TNF)-α and IL-12p70 
protein levels in a single sample.  The release of cytokines was measured to 
quantify the inflammatory response of the cells in response to various stimuli, as 
cytokines are the messengers that co-ordinate inflammation and give a direct 
representation of cellular response (Morgan et al. 2004).  
To detect the analytes under the flow cytometer, beads of known size and 
fluorescence from the CBA kit were utilized to capture the singular soluble or the 
sets of analytes. The capture beads are each unique and conjugated with a 
specific antibody and a combination of phycoerythrin (PE)–conjugated antibodies 
(BD CBA kit) was used as the detection mixture. This reagent of PE-conjugated 
antibodies gives a fluorescent signal in proportion to the quantity of the bound 
analyte(s).  Following the incubation of the capture beads and PE-reagent with an 
unknown sample, the beads, the analytes in the sample and the PE-conjugated 
antibodies form a complex. These complexes can be measured using flow 
cytometry to identify particles with fluorescence characteristics of both the bead 
and the detector.  
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The FCAP Array analysis software gates on each individual bead population and 
determines the median fluorescence intensity (MFI) for each analyte in the array. 
It generates a standard curve and performs interpolation of sample concentrations 
compared to the standard curve and generates an analysis report in tabular 
format. 
 
 
 
Figure 2.9 Cytometric bead array (CBA) system. CBA beads bind to cytokines in the sample. 
Each capture bead in the array has unique fluorescence intensity and is coated with a capture 
antibody specific for a single analyte. A combination of different beads is mixed with a sample or 
standard and a mixture of detection antibodies that are conjugated to a reporter molecule (PE). 
Following incubation and subsequent washing, the samples are acquired on a flow cytometer and 
analyzed (BDbiosciences, URL). 
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2.9.2 Experimental procedure 
The BD cytometric bead array Human Inflammatory Cytokine kit (551811 BD, 
Biosciences, USA) was used according to the manufacturer’s instructions. Briefly, 
for the experimental procedure, the mixed capture beads (50 µl) were added to 
each of the samples (50 µl) in flow tubes and incubated for 1 h in RT. Then 50 µl 
of the phycoerythrin detection reagent was added to the samples and mixed, 
followed by further 3 h incubation in the dark at RT. Following incubation, washing 
buffer (1 ml) was added to the samples and were then centrifuged at 200xg for 5 
min. The supernatant was carefully discarded, and 300 µl wash buffer was added 
and the sample was resuspended. The samples were analysed using flow 
cytometry, with the data acquired being analysed using the FCAP Array software 
(Becton Dickinson). 
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2.10 HEK-IFN-α/β and HEK IL-1β reporter cells  
HEK IFN(Invivogenwere generated by stable transfection of HEK293 cells 
(human embryonic kidney 293) with the human STAT2 and IRF9 genes to obtain 
a fully active type I IFN signalling pathway. The other genes of the pathway 
(IFNAR1, IFNAR2, JAK1, TyK2 and STAT1) are naturally expressed in sufficient 
amounts. The cells were further transfected with a SEAP reporter gene under the 
control of the IFN-α/β inducible ISG54 promoter. Stimulation of HEK-Blue™ IFN-
α/β cells with human IFN-α or IFN-β activates the JAK/STAT/ISGF3 pathway and 
subsequently induces the production of serum embryonic alkaline phosphatase 
(SEAP). 
 HEK-Blue IL1β cells (Invivogen) enable the detection of IL1β by monitoring the 
activation of the ISGF3 pathway. HEK 293 cells are modified immortal cell lines 
engineered to express (SEAP) in response to the activation of downstream 
signalling cascades induced by IL1-β binding to its cognate receptor IL1R as is 
shown in figure 2.9.1 below depicting IL1-β as a worked example.  
 
Figure 2.10 Mechanism of cytokine detection with reporter cells.  
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Initial incubation of an appropriate population of reporter cells in the presence of 
supernatant from samples of interest will result in the generation of SEAP 
proportional to the concentration of cytokine in the assay. If the particular cytokine 
is absent in the supernatant of interest, no SEAP will be produced by the reporter 
cells. Incubation of the SEAP-containing supernatant with alkaline detection 
reagent results in a light absorbance shift in the supernatant which may be 
quantified by photospectrometry analysis(; Yang et al. 1997). 
Reporter cells and detection reagent were obtained from Invivogen USA. Reporter 
cells specific for IL1-β (HEK) or IFNwere incubated for 24 hr with triplicate 
supernatants reflecting each experiment and associated time-points. The following 
day supernatant was transferred to Eppendorfs containing 150μl QuantiBlue 
alkaline phosphatase detection reagent (catalogue number: rep-qb1), incubated 
for 60 minutes prior to analysis using a Shimadzu Biospec-1601 
DNA/Protein/Enzyme Analyzer (Tokyo, JP) photospectrometer to determine 
cytokine expression at different time points compared to un-stimulated 
supernatants. 
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2.11 Histology  
2.11.1 Underlying principles 
This is a simple method for the staining of tissues/cells to view their structure. The 
most commonly used stains are haematoxylin and eosin (H&E). Haematoxylin 
stains acidic structures, such as DNA, and eosin stains basic structures, such as 
proteins in the cytoplasm. When used together, the haematoxylin indicates nuclei 
in blue and eosin indicates the cytoplasm in pink. It is commonly used to 
investigate the overall structure of tissue, such as the thickness of vessel walls, or 
the presence of tumour tissue. It may also be used to count cells. Prior to H&E 
staining, tissue must have been fixed, embedded and sectioned.  
In the present study, immunohistochemistry (IHC) was utilized to stain the tissue 
sections obtained from the Oxford and UCL Brain Banks. The method of IHC is 
utilized to detect certain antigens in a tissue section and it is widely used by 
laboratories for diagnostic reasons or to identify the expression patterns of various 
proteins.  IHC is based on the property of antibodies to bind specific antigens. For 
example, antibodies recognizing specific antigens of interest, such as primary 
antibodies, are detected using secondary antibodies conjugated to an enzyme or 
a fluorochrome (immunohistofluorescence). The secondary antibody is directed 
against the Fc portion of the primary antibody and is, therefore, specific to the 
species in which the primary antibody was raised in (Duraiyan et al. 2012). 
In the present study, the ImmPRESS Polymerized Reporter Enzyme Staining 
System (Vector Laboratories Ltd, Cambridgeshire, UK) was utilized to detect the 
proteins of interest. This is an enzymatic, non-biotin, one-step detection kit that 
provides high sensitivity with low background staining in immunohistochemical and 
immunocytochemical applications. The ImmPRESS Reagent utilizes a novel 
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approach to conjugate horseradish peroxidase micropolymers to affinity-purified 
secondary antibodies. This conjugation technology avoids the use of large 
dextrans or other macromolecules as a backbone and enables a higher density of 
enzymes per antibody to bind to the target with minimal steric interference. 
Successfully labelling multiple antigens in the same tissue section entails the use 
of detection systems with high sensitivity and low background, and substrate 
choices that produce an ideal colour contrast (ImmPRESS REAGENT manual; 
Vector Laboratories Ltd.). The peroxidase and alkaline phosphatase detection 
systems offered by Vector Laboratories are widely acknowledged for having the 
above qualities, thus they were chosen the applications of this project.  
2.11.2 Immunohistochemical procedure – paraffin fixed tissue 
Sections were heated in an oven maintained at 60oC for 30 min and then emerged 
in xylene for 2 x 20 min, followed by submersion in graded alcohol series (100% 
ethanol: 5 min, 95% ethanol: 5 min, 80% ethanol: 5min, 70 % ethanol: 5 min). 
Slides were washed for 5 minutes in distilled water and then immersed in 1X 
antigen retrieval solution (DAKO UK Ltd.) for 30 min in a 100oC waterbath. Most 
antigens require an antigen retrieval step before antibody binding can occur on 
fixed tissue.  This is due to cross-linking of proteins during fixation which masks 
epitopes. The two methods of antigen retrieval are heat-induced and enzymatic. 
Both methods act by breaking the methylene bridges and exposing the epitopes 
to allow binding of the primary antibody. Heat-induced epitope retrieval is most 
often performed using a pressure cooker or a microwave at maximum power 
(850W). The antigen retrieval was collected and the slides were placed for 5 
minutes in a microwave. Then they were left for 30 minutes at RT. Slides were 
rinsed twice with 1X PBS and appropriate primary antibodies (1ug/ml; diluted in 
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1X PBS/BSA/NaN3/Saponin) were added. Slides were left to incubate in RT for 1-
2 hours, depending on the primary antibody used, and then washed with 1X 
PBS/BSA/NaN3/Saponin. Following washing, the appropriate IMM-PRESS 
secondary antibody (Vector VIP kit) was added and slides were incubated at RT 
for 30 minutes. Slides were washed with1X PBS for 5min at RT and then incubated 
with the appropriate Chromogen buffer (peroxidase substrate solution from the kit) 
for 1-2 minutes. Depending on the enzyme and substrate used, the specific 
antigen on the tissue was coloured either red, blue, or brown.  
Enzyme Substrate Colour 
Horseradish 
Peroxidase (HRP) 
3,3'-Diaminobenzidine (DAB) Brown 
3-Amino-9-ethylcarbazole (AEC) Red 
Alkaline 
phosphatase 
(AP) 
5-Bromo-4-chloro-3-indolyl phosphate:Nitroblue 
tetrazolium (BCIP/NBT) 
Blue 
Vector Blue Blue 
Glucose oxidase Nitroblue tetrazolium (NBT) Blue 
 
Table 2.11.2 Enzyme and substrate used to produce certain colours. 
 
Following incubation, slides were washed with distilled water, counterstained for 
the nucleus with either haematoxylin (blue), nuclear fast red, or methyl green and 
mounted using Vectashield (Vectorlabs, UK) (schematic representation in Figure 
2.11.2). 
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Figure 2.11.2 Multiple antigen labelling using the VECTASTAIN Systems. (Vectorlabs, URL)  
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2.12 Confocal Microscopy  
2.12.1 Underlying principles 
Confocal microscopy is an optical imaging technique utilized to increase the optical 
resolution and contrast of a micrograph by adding a spatial pinhole positioned at 
the confocal plane of the lens to eliminate out-of-focus light. Confocal microscopy 
generates clear images of large specimens or complete cells and was developed 
to enhance immunofluorescence microscopy. This method allows for optical 
sectioning (sets of images at different depths within a specimen) and the 
reconstruction of 3D structures from the obtained images (Hotton et al. 1997; 
Pawley 2006).  
Following the initial concept of the confocal microscope by Marvin Minsky in 1955 
(Minsky 1957; Minsky 1988), confocal microscopy has evolved drastically due to 
technological advances.  At present, there are various types of confocal scanning 
techniques, such as single beam scanning [confocal stage scanning microscopy 
(CSSM) and confocal laser scanning microscopy (CLSM)] and multiple-beam 
scanning. CLSM utilizes a pulsed laser beam of an appropriate wavelength that is 
powerful enough to excite the fluorochrome of interest when it is focused at the 
focal plane of the layer in the specimen. The light emitted by other layers is out-
of-focus and is ignored by the detector due to the confocal pinhole. Molecules 
and/or structures in a cell may be labelled with varied fluorochrome conjugated 
antibodies that emit light of different wavelengths. Simultaneous observation of 
various fluorochromes on different parts of the cells is allowed due to the variety 
of wavelengths of the light utilized (Masters 2006).  
Present day confocal microscopes rely on a dedicated computer for control and 
image storage. The images obtained from the microscope are analysed by a 
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computer that assigns different colours to the various wavelengths, thus allowing 
for image overlap and detection of co-localization of molecules and/or structures 
in a cell. Therefore, confocal microscopy may be used to investigate and assess 
the effect of various stimuli on different components of a cell. In addition, multiple 
labelling of cells with various fluorochrome-conjugated antibodies for antigens of 
interest provides a great insight into the biological processes of cells.   
Figure 2.12.1 Principles of a confocal microscope. Coherent light emitted by the laser system 
(excitation source) passes through a pinhole aperture positioned in a conjugate plane (confocal) 
with a scanning point on the specimen and a second pinhole aperture located in front of the detector 
(a photomultiplier tube). As the laser is reflected by a dichromatic mirror and scanned across the 
specimen in a specific focal plane, secondary fluorescence emitted from points on the specimen 
(in the same focal plane) pass back through the dichromatic mirror and are focused as a confocal 
point at the detector pinhole aperture (Nikon MicroscopyU, URL).  
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The distribution of signals in fluorescence microscopy images may be used to 
determine whether two probes co-distribute with one another or co-localize. A 
confocal microscope is widely used to assess co-localization, as it excites certain 
fluorophores and gate a specific wavelength of emitted light to produce an image 
of colour-labelled antigens, such as green, red, or blue.  The location of specific 
antigens on a cell is revealed due to the fluorochrome-conjugated antibodies, thus 
merging the images of numerous fluorochrome-labelled antigens in the same cell 
location could suggest a possible co-localization upon colour change. 
Fluorescence co-localization analysis is more appropriately used to determine 
whether two molecules associate with the same structures. For example, to 
determine whether a particular protein associates with endosomes (Babey et al. 
2006), mitochondria (Lynch et al. 1996) or microtubules (Nicolas et al. 2008) or 
whether two proteins associate with the same sub-nuclear structures (van 
Steensel et al. 1996). Evaluating co-localization at this scale is still susceptible to 
the limits of resolution. For example, an overlap in fluorescence does not 
necessarily indicate co-localization of two probes in the same cellular structure. 
However, the observation of repeated coincidence of two probes in multiple 
structures throughout a cell increases the confidence that the two occupy the same 
structures.  
Quantitative assessment of the images is required to verify co-localization. A 
number of factors, such as pixels of overlaid images, may indicate to be in close 
proximity and appear to the human eye as overlapping when they are not. To 
eliminate user bias and provide a quantitative value of the extent of co-localization, 
the images obtained were automatically thresholded and the interdependency of 
the red and green channels was measured. A correlation coefficient was used to 
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calculate the interdependence of the two variables, which equates to the extent of 
co-localization that may be occurring. 
2.12.2 Dual labelling via indirect immunofluorescence 
To prepare the slides, 10,000 astrocytes cells were seeded on coverslips or labtek 
slides (10,000 cells per well). The slides were then incubated until they reached 
desired confluency. And then stimulated as required at certain time points.  The 
cells were fixed to prevent potential re-organisation of the `proteins during the 
experiment. Cells were permeabilised using PBS/0.02% BSA/0.02% Saponin and 
labelled with antibodies for NLRP3, C9, Amyloid, or TLR4 (2g) (listed in Table 
2.1.2a). Followed by an appropriate species specific secondary antibody (2g) 
conjugated to Alexa 488, Alexa546 or Alexa 647 (listed in Table 2.1.2b). We have 
validated our confocal experiments with isotype control antibodies as well as with 
only secondary antibody. 
In the Instances of dual labelling, secondary antibodies conjugated to Alexa488 
and Alexa546 were used and Topro-3 (1/10,000 dilution) was the selected nuclear 
stain since it has far-red fluorescence (Excitation/Emission: 642/661nm) similar to 
Alexa 647. 
To reduce photobleaching slides were mounted using Slowfade antifade reagent 
(Fischer Scientific, UK) or Vectashield (Vector labs).  
Cells were imaged on a Carl Zeiss, Inc. LSM510 META confocal microscope (with 
an Axiovert 200 fluorescent microscope) using a 1.4 NA 63x Zeiss objective. The 
images were analysed using LSM 2.5 image analysis software (Carl Zeiss, Inc.). 
To quantify the degree of co-localization, we used ImageJ software 
(MacBiophotonics). The analysis uses Costes’ approach. This allows for the 
calculation of Pearson’s correlation coefficient R(obs), which also accounts for any 
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random overlay of pixels by generating the mean correlation coefficient R(rand) 
between n images that have identical average pixel intensity to the original images, 
but a random distribution of pixels. 
2.12.3 ImageJ and JACoP analysis 
Statistical software programmes have been developed to quantify co-localization. 
By considering pixels individually in separately gated images, these programs 
accurately quantify the amount of co-localization between two fluorescent labels. 
In the current study, ImageJ (version 1.43) analysis software and the JACoP plugin 
were utilized to assess co-localization. ImageJ allows for the analysis of the co-
localization of two images using a number of standard analysis methods 
simultaneously. For the purposes of the current study, the Costes` randomization 
method (Pearson`s correlation coefficient) was utilized to quantify the co-
localization of fluorochrome-labelled antigens. 
The images obtained were converted to TIF files to be accessed by ImageJ and 
JACoP. ImageJ (ImageJ, URL) is an open source image processing and analysis 
software designed for scientific multidimensional images. The JACoP (Just 
Another Colocalisation Plugin) (available from ImageJ Plugins, URL) plug-in is a 
compilation of co-localization tools (Bolte and Cordelieres, 2006), that calculates 
a set of commonly used co-localization indicators, including the Pearson's 
coefficient.  
2.12.4 Pearson`s correlation coefficient  
The Pearson`s correlation coefficient (Rr) calculates the covariance between the 
intensities of the corresponding pixels in each gated image. The images are then 
analysed as grey for consistency and the statistical analysis is independent of the 
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image background. Furthermore, Rr is independent of pixel intensities due to the 
thresholds being automatically created for each gated image (Manders et al. 
1993). The maximum intensity of an image was used to set the image threshold, 
with the resulting Rr ranging from -1 to 1. Rr is equal to 1 for 100% co-localization 
(i.e., the 2 images compared are the same), 0 for random overlap of proteins and 
-1 indicates full anti-correlation (i.e. no red where there is green). Negative values 
of Rr were not used for co-localization, as they indicate an anti-co-localized 
situation where a pixel is bright in one channel and dim in the other. The fact that 
that Rr is invariant to background or intensity scales makes the correlation 
coefficient a robust estimator for co-localization. Furthermore, a more biologically 
meaningful set of coefficients are the proportion of each protein co-localized with 
the other (Manders et al. 1993).  
2.12.5 Mander’s overlap coefficient 
Mander’s overlap coefficient is measured from the Pearson’s coefficient. It is 
sensitive to background intensity, however, it is an easier method to interpret than 
Pearson’s coefficient. The data obtained range from 0 (total negative correlation) 
to 1 (total positive correlation). Mander’s co-localization coefficients (M1 and M2) 
demonstrated the extent of green pixels in one channel overlapping red pixels in 
the other channel, and vice versa. The data obtained indicate the percentage of 
the total pixels in each channel that overlap with pixels in the other channel 
(Manders et al. 1993). 
2.12.6 Costes’ randomisation method  
The Costes` method evaluates the statistical significance of the Rr obtained. The 
Rr coefficient measures the amount or degree of co-localization, however, initially 
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there was no comparison to understand the meaning of this coefficient. Therefore, 
Sylvain Costes designed a statistical significance test to assess the probability that 
the measured value of Pearson's correlation Rr between the two-colour channels 
is significantly greater than values of Rr that would be calculated if there was only 
random overlap of the same information.  The result of these tests indicates 
whether the Pearsons’ Rr and Manders' coefficients measured are better than pure 
chance or not. 
The Costes’ method compares the Rr observed from the original two images, 
r{obs}, with an average Rr obtained from randomized images of the two original 
images, r{rand}, which have been created by shuffling pixels’ blocks (Figure 
2.12.6). The Costes’ randomisation method then compares r{obs} and r{rand} to 
obtain a significance (p-value) expressed as a percentage, that is inversely 
correlated to the probability of getting r(obs) by chance. Results obtained from this 
analysis range from 0 (total negative correlation) to 1 (total positive correlation) 
(Costes et al. 2004). 
 
 
 
 
 
 
 
 
Figure 2.12.6 Randomized image of two original images, r{rand}, created by shuffling pixels’ 
blocks. r{rand} is the average of a comparison of 1000 pairs of scrambled original images and 
represents the events occurring due to chance. 
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2.13 Fluorescence resonance energy transfer (FRET) 
2.13.1 Underlying principles 
Fluorescence (or Förster) resonance energy transfer (FRET) is a technique that 
enables the quantification of the association among fluorescently labelled 
molecules between 1 and 10 nm apart. It is a biophysical method probing the 
proximity of molecules on the cell surface, under conditions very close to the 
physiological state of the cells, thus it is a useful tool for investigating molecular 
associations. FRET may be used to reveal interactions between proteins or 
structural changes within a molecule. This method measures the non-radiative 
transfer of photon energy from an excited fluorophore (the donor) to another 
fluorophore (the acceptor), and it is one of few tools available for measuring 
nanometre scale distances and the changes in distances, both in vitro and in vivo 
(Wu and Brand 1994; Ankerhold 2001).  
FRET is utilized to investigate molecular level interactions, due to its sensitivity to 
distance changes, thus uncovering cellular localizations which were previously 
undetectable. The present technological advances assisted in developing 
qualitative and quantitative enhancements for the method, such as distance range, 
increased spatial resolution and sensitivity. However, FRET requires the donor 
emission spectrum to overlap the excitation spectrum of the acceptor to work 
correctly and only specific pairs of fluorophores are eligible. Fluorescence 
microscopy techniques rely upon the absorption by a fluorophore of light at one 
wavelength (excitation), followed by the emission of secondary fluorescence at a 
longer wavelength. The mechanism of FRET includes a donor fluorophore in an 
excited electronic state, which may transfer its excitation energy to a neighbouring 
(1-10 nm) acceptor, that subsequently emits light (Kenworthy and Edidin 1999). 
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Fluorescent proteins (FPs), such as the green-fluorescent-protein (GFP), are 
usually used for FRET experiments. FPs may be genetically fused to proteins of 
interest and expressed in cells making them an excellent reporter system for gene 
expression and protein localization. Numerous enhanced FP variants with different 
spectral properties are commercially available, and CFP (cyan-coloured) is used 
as the donor, whereas YFP (yellow-coloured) is used as the acceptor.  
Figure 2.13.1 The principles of fluorescence resonance energy transfer (FRET). ex, 
excitation; CFP, cyan-coloured fluorescence protein; YFP, yellow-coloured FP; em, emission 
(Ankerhold 2001). 
2.13.2 FRET detection methods 
FRET detection methods are able to identify living cells or interactions between 
proteins in fixed cells, and has been utilized to detect the activation process of 
enzymes in apoptosis in real time (Xu et al. 2009), to analyze the function of 
transcriptional proteins (Camuzeaux et al. 2005) or investigate the activation of 
gene transcription (Liu et al. 2006). The detection methods of FRET are: sensitized 
emission (seFRET), acceptor bleaching (abFRET) and lifetime measurements. 
These methods have different properties depending on the sample tested (Diaspro 
2010). The abFRET method is performed on most fluorescence microscopes by 
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emitting the excitation light (of a certain wavelength to excite the donor and not the 
acceptor) on samples with and without the acceptor fluorophore, and then monitor 
the donor fluorescence. abFRET is a quantitative approach that does not require 
sophisticated and expensive instrumentation and was initially introduced to 
determine transfer efficiency on a pixel-by-pixel basis in a microscope (Jovin and 
Arndt-Jovin 1989).  
For the successfully implementation of FRET, three factors are required: 1) the 
emission spectrum of the donor must overlap with the excitation spectrum of the 
acceptor; 2) the distance between the donor and the acceptor must be sufficiently 
small and; 3) the dipoles of the donor and the acceptor must have a certain spatial 
orientation (Lam et al. 2012; Cardullo 2013). The rate of energy transfer is 
inversely proportional to the sixth power of the distance between the donor and 
acceptor (Kenworthy et al. 1998). The efficiency of energy transfer (E) is defined 
with respect to r and R0, the characteristic Förster distance, using the following 
formula: 
 
 
 
where E is the FRET effect; r is the distance between fluorophores and R0 is the 
distance between the donor and acceptor fluorophores when the energy transfer 
effect is 50% (Kenworthy et al. 1998).   
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2.13.3 Experimental procedure 
In the present study, FRET was quantified as previously described (Kenworthy 
and Edidin 1999). Briefly, the change in donor (Cy3) emission following the 
acceptor (Cy5) bleaching was measured. Bleaching of the acceptor eliminates the 
light excitation of the fluorophore and FRET would not occur between donor-
acceptor, therefore the donor emission will not be sequestered. If the 
donor/acceptor pair is ≤10nm apart the donor emission will increase after 
bleaching of the acceptor. Scaling factor of 10,000 was used to expand E to the 
scale of the 12-bit images.  
Astrocytes cells were seeded on 8 well glass slides (Nunc Lab-Tek II Chamber 
Slide System; ThermoFisher Scientific, Inc.). Cells labelled only with the 26ic-Cy5 
probe were used to determine the minimum time required to bleach Cy5. Cy5 was 
bleached by continuous excitation with an arc lamp using a Cy5 filter set for 10 
minutes. Under these conditions, Cy3 was not bleached. FRET images were 
calculated from the increase in donor fluorescence subsequent to the acceptor 
photobleaching using the following formula:  
E(%) x 100 = 10,000 x [(Cy3 postbleach – Cy3 prebleach)/Cy3 postbleach]. 
Fluorsecent probes against TLR4, TLR2, NLRP3, ASC, NLRP1, C9 have been 
generated by Dr Martha Triantafilou as Fab fragments conjugated to specific 
fluorophores (Triantafilou et al. 2001; Triantafilou et al. 2000). These probes were 
kindle provided for labelling in my FRET experiments. 
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Figure 2.13.3 Indication of the excitation and emission wavelength of Cy3 and Cy5. 
  
Astrocytes were labelled with 100 µl of a mixture of donor conjugated antibody 
(Cy3) and acceptor conjugated antibody (Cy5). The cells were then rinsed twice 
in PBS/BSA/NaN3, prior to fixation with 4% PFA for 15 min. Cells were imaged on 
a Carl Zeiss LSM510 confocal microscope (with an Axiovert 200 fluorescent 
microscope) using a 1.4 NA 63x Zeiss objective (Carl Zeiss, Inc.). The images 
were analysed using the LSM 2.5 image analysis software (available from Zeiss, 
URL), and Cy3 (Excitation/emission: 548/561nm) and Cy5 (Excitation/emission: 
647/665nm) were detected using the appropriate filter sets. Using typical exposure 
times for image acquisition (<5 sec), no fluorescence was observed from the Cy3-
labelled specimen using the Cy5 filters, nor was Cy5 fluorescence detected using 
the Cy3 filter sets.  
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2.14 Statistical Analysis 
Data were evaluated by analysis of variance and the Dunnett multiple-comparison 
test using the GraphPad Prism Software (San Diego, CA). Where appropriate 
(comparison of two groups only), two-tailed t-tests were performed. Statistical 
differences were considered significant at the level of P<0.05. Experiments were 
performed in triplicate samples and were performed three times or more to verify 
the results. 
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Chapter III 
Involvement of PRRs in the innate 
immune sensing of fibrillar Aβ 
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3.1 Introduction 
 Dementia is the primary result of Alzheimer’s disease (AD) and is commonly 
characterised by the presence of amyloid plaques (NPs) and neurofibrillary tangles 
(NFTs). NTs are structures deposited extracellularly containing a fibrillar amyloid-
beta (Aβ) core which is highly insoluble (Iversen 1995). This is formed of fragments 
39-42 amino acids which are surrounded by reactive astrocytes, dystrophic 
neurites and microglia produced as a biproduct of neuronal degenerative 
processes.  
Astrocytes create the brain environment and provide for brain defence. In the 
hippocampus, ~60 % of all axon-dendritic synapses are surrounded by astroglial 
membranes (Sofroniew and Vinters, 2010). The presence of Aβ in microglia and 
astrocytes is a primary contributing factor in the development of AD progression, 
leading to deteriorating neuronal cells. An innate immune response is elicited due 
to the presence of these plaques and deposits; a series of cellular events resulting 
in a robust inflammatory response (Akiyama et al, 2000).  These events result in 
the production of nitric oxide (NO), reactive oxygen species (ROS) and a plethora 
of pro-inflammatory cytokines. This may eventually lead to deleterious effect and 
neuronal cell death (Kitazawa et al, 2004). 
During the early stages of AD, activated astrocytes are located in two regions: the 
inner layer of the cerebral cortex and near the amyloid deposits below the 
pyramidal cell layer. The pathological changes leading to the activation of 
astrocytes in AD are not fully understood, however it has been demonstrated that 
the presence of amyloid activates astrocytes. Microglia and astrocytes have been 
reported to play a central role as moderators of Aβ clearance and degradation. 
Upon activation, astrocytes may phagocytose and degrade amyloid. This suggests 
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that astrocytes may contribute to the removal of accumulated Aβ (Ries and Sastre, 
2016). Astrocytes are activated through TLR-dependent pathways, thus causing 
local inflammation that eventually could intensify neuronal death (Halassa and 
Haydon, 2010; Henneberger et al., 2010). Cellular infection and stress are 
causative agents for activating molecular platforms called inflammasomes. 
Inflammasomes are responsible for the production and maturation of pro-
inflammatory cytokines, such as IL 1-β and IL-18. For the release of these 
cytokines, that leads to potential inflammation, two signals are required: priming 
(signal 1), and activation and assembly of the inflammasome (signal 2) (Latz E, 
2010; Bauernfeind et al, 2009; Bauernfeind et al, 2011; Embry et al, 2011). Several 
sterile inflammatory diseases are caused by the excessive secretion of interleukin 
(IL)-1β, such as type 2 diabetes, atherosclerosis, and AD (Sheedy et al, 2013). 
Increased production may cause or potentiate the neurodegeneration, specifically 
upon a prolonged exposure as in the AD brain.  
In addition, the fibrillar amyloid-β (fAβ) in senile AD plaques, or amyloid-containing 
amylin/islet amyloid polypeptide (IAPP) on pancreatic β-cells in T2D3 is a hallmark 
of AD (Sheedy et al, 2013). Recent studies demonstrated that that these specific 
materials cause inflammation by recruiting cytosolic sensors, such as NLRP3 
(Duewell et al, 2010; Halle et al, 2008; Masters et al, 2010; Rajamaki et al, 2010).  
A previous study demonstrated that injection of Aβ oligomeric forms into the 
retrosplenial cortex of rats lead to astrocyte activation. The results revealed 
activation of the transcription factor NF-κ B and demonstrated the presence of 
inflammatory mediators, such as tumour necrosis factor (TNF-α) and IL-1β 
(Carrero et al., 2012). NF-κB controls chemokine and adhesion molecules 
secretion in astrocytes, increasing the inflammatory response (Moynagh, 2005). 
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The continuation of this process results in a self-regulating mechanism, which 
leads to neurodegeneration. 
In this chapter, we shed some light on how PRRs, such as the NOD proteins and 
TLR play a role in eliciting inflammation by recruitment of inflammasome and 
otherwise. In addition, we investigated how amyloid aggregates cause such a form 
of innate immune response resulting in neuronal inflammation and AD 
pathogenesis.  
3.2 Aβ induced cytokine secretion in astrocytes 
To test our hypothesis that Aβ triggers pattern recognition receptors in the brain 
leading to neuroinflammation and AD pathology, we initially investigated what 
cytokine response is triggered in astrocytes by Aβ. Fibrillar Aβ (amino acids 1-42), 
as well as control non-fibrillary peptide (identical sequence in reverse order) was 
obtained from AnaSpec Inc. Fremont (USA) and prepared as previously described 
by Gasque and colleagues (Gasque P. et al, 1997).  
Different concentrations of Aβ (5uM, 10uM, 15uM) were utilised to determine the 
optimum concentration of Aβ which would be used. Cells were stimulated at 
different time points (6h and 8h) and cell viability was also tested. The 
concentrations used did not affect cell viability.  The 10uM concentration were 
chosen for our subsequent stimulations since it triggered a similar response of 
IL1 seen with the higher concentration (Figure 3.2.1)  
The astrocytes were stimulated with 10uM Aβ1-42, and HEK-IFN-α/β sensor cells 
and HEK IL-1β sensor cells were used to identify the Human Type I IFN and IL-1β 
response (Figure 3.2.2). Reporter cell lines were incubated with the supernatant 
from unstimulated, Aβ1-42 stimulated and scrambled peptide stimulated astrocytes  
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Figure 3.2.1 IL-1secretion levels in astrocytes stimulated with different concentrations of 
Aβ. 
 
for 24 hours. The next day, supernatants from reported cell lines were collected 
and incubated with HEK-Blue detection medium and the expression levels of IFN-
α/β and IL-1β were detected using a spectrophotometer at a wavelength of 650 
nm.  
Results indicate that amyloid Aβ1-42 triggers a type I interferon response which is 
specific since there is no IFN secretion in the unstimulated cells or cells in the 
presence of the scrambled peptide. IFN secretion is probably via TLRs since it is 
known that an alternative pathway exists to induce IFNβ downstream of 
TLR4 in an MyD88-independent manner (Sato et al. 2003; Noppert et al. 2007).  
As for IL-1β, higher levels of activation were observed indicating secretion, when 
cells were stimulated with amyloid compared with the unstimulated cells, thus 
confirming inflammasome activation in the presence of amyloid.   
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Figure 3.2.2 IFN-α/β and IL-1β activation in HEK-Blue sensor cells stimulated with 
supernatants from unstimulated, Aβ1-42 stimulated and scrambled peptide (10ug) stimulated 
astrocytes. Supernatant was added to HEK IFNβ/ and HEK IL-1β reporter cells and incubated for 
24 hours. Quanti-Blue was added and the levels of SEAP were measured using a 
spectrophotometer at 630 nm. The SEAP levels correspond to the expression levels of IFNβ/IL1β. 
*P<0.05, **P<0.01 and ***P<0.001 vs. unstimulated. The results are presented as the mean + 
standard deviation, and are representative of three independent experiments. 
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3.3 Involvement of PRRs in Aβ detection 
To determine which PRRs are involved, we initially investigated changes in the 
expression levels of TLRs, NLRs and complement receptors in response to 
different concentrations of fibrillar Aβ and scrambled peptide in human astrocytes. 
Immunological techniques, such as immunofluorescence and flow cytometry, were 
employed to determine the expression levels of different TLRs (TLR2, TLR4), 
NLRs (NLRP1, NLRP3) and complement receptors (CD55, CD59, C5aR1, C3aR, 
CR1, CR3) at different time points following stimulation. The same techniques 
were employed to determine the expression levels of different TLRs (TLR2, TLR4), 
NLRs (NLRP1, NLRP3 and NLRC5) and complement receptors (CRs; C5aR1, 
C3aR, CR1, CR3, CD55, CD59 and Factor H) before and after A stimulation at 
different time points following fixation with paraformaldehyde (PFA). 
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3.3.1 Does PFA fixation prior to antibody incubation have an 
adverse effect on fluorescence intensity?  
PFA (4%) was used in this occasion to fix the cell monolayers at the end of each 
time point to avoid receptor re-organization. To determine whether our fixation 
method had an adverse effect on the receptor expression levels, live cells were 
incubated with primary antibodies and then with the specific secondary antibodies, 
followed by PFA fixation at the end (Fig 3.3.1-B). Cells were also fixed and then 
labelled with primary antibodies followed by the appropriate secondary antibodies 
(Fig 3.3.1-A). Rabbit IgG, polyclonal (Isotype Control) (ab27478, abcam, UK) was 
also used as a control.  Flow cytometry was used to analyse receptor surface 
expression levels. Our results demonstrated no difference in the two methods.  
 
Figures 3.3.1 Basal level of PPRs surface expression in astrocytes with PFA fixation prior 
to antibody staining and PFA fixation after antibody staining. Astrocytes were harvested, 
incubated for 30 minutes with primary antibodies against the receptors of interest, followed by a 
30-minute incubation with the appropriate secondary antibody conjugated to FITC. Astrocytes were 
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fixed with 4% PFA either prior, or after antibody staining (experimental processes run on ice).  The 
graph compares the two methods and the fluorescence was detected by flow cytometry using a 
FACSCalibur (BectonDickinson). P>0.05 (ns), *P<0.05 vs. the respective isotype control. The 
results are presented as the mean + standard deviation, and are representative of three 
independent experiments. 
3.3.2 PRRs expression in response to fibrillar Aβ1-42 
Immunofluorescence and flow cytometry was employed to determine the total 
expression levels of different TLRs (TLR2, TLR4), NLRs (NLRP1, NLRP3 and 
NLRC5) and complement receptors (CRs; C5aR1, C3aR, CR1, CR3, CD55, CD59 
and Factor H) before and after Aβ1-42 stimulation at different time points in human 
astrocytes. At 2-hour stimulation (Figure 3.3.2), there is an upregulation of NLRP3, 
C5aR1 as well as Factor H (FH) receptor. At 6-hour incubation there is no 
significant upregulation observed in the receptors of interest (Figure 3.3.2). 
 
Figure 3.3.2 Comparison of expression levels of PRRs before and after 2 and 6 hours 
stimulation with Aβ1-42. Basal level of PPRs expression in unstimulated and Aβ1-42 stimulated 
astrocytes. Astrocytes were stimulated with 10 ug/ml of Aβ1-42 for 2 and 6 hours and subsequently 
were harvested, fixed, permeabilised with 4% PFA and incubated with primary antibodies against 
the receptors of interest, followed by an appropriate secondary antibody conjugated to FITC. 
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Fluorescence was detected by flow cytometry using a FACSCalibur (BectonDickinson). P>0.05 vs. 
the respective unstimulated cells. The results are presented as the mean + standard deviation, and 
are representative of three independent experiments. 
3.3.3 Signalling cascades triggered by A 
To determine which signalling cascades are triggered in response to A, 
astrocytes were either not stimulated, stimulated with 10 ug/ml A or 10 ug/ml 
scrambled peptide for 2 and 6 hours and subsequently lysed and analysed for the 
presence of phospho-IkB and caspase-1 p10. Phospho-IκB is indicative of 
activated NF-κB which is a result of TLR activation upstream of the signalling 
cascade. Presence of phospho-IκB was investigated to determine whether Aβ 
triggers TLR activation. Similarly, caspase-1 p10 activation acts downstream of 
inflammasome (NLR) activation, therefore caspase-1 p10 detection was also 
investigated to determine whether A triggers inflammasome activation. Western 
blot analysis of phospho-IkB and caspase-1 p10 expression in unstimulated, 
scrambled peptide stimulated and Aβ1-42 stimulated astrocytes was performed. 
 
            kDa    Marker     Un-stim.   Scrambled    Aβ1-42 
45   
31 
 
 
Figure 3.3.3.1 Detection of phospho-IkB expression on astrocytes by western blot analysis. 
Astrocytes were prepared and incubated as described in Chapter 2, Material and Methods. Cell 
lysates from astrocytes stimulated with Aβ1-42 for 2h and 6h were collected and analysed for 
phospho-IκB using SDS-PAGE gel electrophoresis and western blot. Primary antibodies specific 
for phospho-IκB were used followed by the appropriate secondary antibodies conjugated to HRP. 
The bands were visualised using the ECL procedure. The data is a representative of four 
independent experiments.   
phospho-I-kB 
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Figure 3.3.3.2 Detection of caspase-1 p10 expression on astrocytes by western blot 
analysis. Astrocytes were prepared and incubated as described in Chapter 2, Material and 
Methods. Cell lysates from astrocytes stimulated with Aβ1-42 for 2h and 6h were collected and 
analysed for caspase-1 p10 using SDS-PAGE gel electrophoresis and western blot. Primary 
antibodies specific for caspase-1 p10 were used followed by the appropriate secondary antibodies 
conjugated to HRP. The bands were visualised using the ECL procedure. The data is a 
representative of four independent experiments. 
 
 
 
 
 
 
 
Caspase-1 p10 
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3.4 Involvement of inflammasome in the innate immune 
response to Aβ 
3.4.1 Aβ-induced inflammatory responses via TLRs, NLRs and 
CRs 
To determine the involvement of TLR4, TLR2, NLRP3, NLRP1 and complement 
in Aβ recognition, silencing and confocal microscopy were used. RNA interference 
was utilised to knock down the expression of TLRs and NLRs involved in Aβ 
recognition during the expression experiments mentioned above. 
Astrocytes were silenced for TLR4, TLR2, NLPR3 and NLRP1. I also looked at the 
effect of NLRP3 silencing as a control on other NLRs. Thus, the expression of 
NLRC5 or NLRP1 was also investigated. The results showed that NLRP3 silencing 
was specific and did not affect the expression of other NLRs. siRNA with 
scrambled sequence was also used as a control which showed that the 
transfection had no effect on NLRP1, NLRP3, TLR2 or TLR4 (Fig 3.4.1.1). 
Once knock-down of the receptors of interest was confirmed in human astrocytes, 
we proceeded to stimulate the cells with different concentrations of Aβ and 
measure pro-inflammatory cytokines secretion using CBA. 
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Figure 3.4.1.1 Human astrocytes silenced for TLR4, TLR2, NLRP3, NLRP1 and NLRC5. 
Astrocytes were silenced for (A) TLR4, (B) TLR2, (C) NLPR3, (D) NLRP1 and percentage of 
knockdown was compared to wild type astrocytes. The effect of NLRP3 silencing (E) as a control 
on NLRC5 or NLRP1 expression levels is shown on panel F and G, respectively, and β-actin 
expression is also depicted as a control. Panel H shows different gels showing the expression of 
TLR4, TLR2, NLRP3, NLRP1 when psiRNA with scrambled sequence was used. The data is a 
representative of four independent experiments. 
  
Astrocytes are a major inducible source of IL-6. Many factors have been 
demonstrated to induce IL-6 expression. IL6 is is a marker of inflammation with no 
direct role in inflammasome (McGeough et al. 2012). IL-6 is consistently detected 
in the brains of patients with AD, but not in the brains of non-demented elderly 
persons. IL-6 immunoreactivity was established in diffuse Aβ plaques from AD 
patients and it was demonstrated to regulate neuronal survival and function. In 
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addition, IL-1β is a key player associated with the development and onset of AD 
(Wang, et al.2015).  
To determine whether Aβ triggers pro-inflammatory cytokine secretion, we 
measured the secretion of IL-1β (Figure 3.4.2-A) and IL-6 (Figure 3.4.2-B) using 
the cytometric bead array system (CBA; Becton Dickinson). Cytokine secretion 
was observed in response to Aβ1-42 stimulated astrocytes at 2, 4 and 6 hours. In 
the presence of scrambled peptide, the secretion of cytokines was minor, 
indicating that cytokine production occurred only in response to Aβ1-42 stimulation. 
To further determine the role of PRRs in Aβ recognition, we investigated the 
secretion of IL-6 and IL-1β in astrocytes silenced for NLRP1, NLRP3, TLR2 or 
TLR4. The data demonstrated a significant reduction in IL-1β secretion (Figure 
3.4.2-A) when NLRP3, TLR2 or TLR4 activity was silenced, while there was no 
significant change observed in IL-1β secretion when NLRP1 activity was silenced 
(Figure 3.4.2-A). 
Concerning IL-6 secretion, when TLR2 was silenced there was a decrease in IL-
6. TLR4 silencing resulted to a more pronounced reduction of IL-6. NLRP3 and 
NLRP1 silencing as expected, since they do not play a role in IL-6 activation and 
secretion, had no effect on IL-6 production (Figure 3.4.2-B).  
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A.  
 
B. 
 
Figure 3.4.1.2 Cytokine production in response to Aβ1-42 stimulation. Astrocytes silenced for 
NLPR1, NLRP3, TLR2 or TLR4 and wild type astrocytes were stimulated with Aβ1-42 and scrambled 
peptide. Supernatant was collected at 2, 4 and 6 hours post incubation and analysed for IL-1β (A) 
and IL-6 (B) using CBA on a FACSCalibur (Becton Dickinson). *P<0.05, **P<0.01 and ***P<0.001 
vs. respective unstimulated. The results are presented as the mean + standard deviation, and are 
representative of three independent experiments. 
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3.4.2 Aβ1-42 triggers NF-kB pathway (Signal 1) 
To determine which signalling cascades are triggered in response to A, wild type 
and astrocytes silenced for TLR4 and TLR2 were either not stimulated, stimulated 
with 10 ug/ml A or 10 ug/ml scrambled peptide for 2, 4 and 6 hours (Figure 
3.4.3 A and B). Cells were subsequently lysed and analysed for the presence of 
phospho-IkB by western blotting. As NF-kB activation acts downstream of TLR 
activation, presence of phospho-IkB was investigated to determine whether A 
triggers TLR activation. 
Figure 3.4.2 Western blot analysis of silenced astrocytes. Cell lysates were analysed for the 
presence of phospho-IkB by western blotting when TLR4 was silenced and cells were stimulated 
with A and scrambled A for 2h, 4h and 6h (A) when TLR2 was silenced and cells were stimulated 
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with A and scrambled A (B). Furthermore, the presence of phospho-IkB was investigated when 
NLRP3 was silenced and cells were stimulated with A and scrambled A as well as LPS as a 
positive control (C). Beta actin loading controls are also shown. The gels are representatives of 
three independent experiments. 
 
The data shows that A stimulation resulted in phospho-IkB production while the 
scrambled peptide had no effect. When TLR2 and TLR4 were silenced. there was 
inhibition of phospho-IkB. Probably because Aβ1-42 is a PAMP recognized by TLR2 
and TLR4 and thus resulting in NF-kB activation. When NLRP3 was silenced and 
cells were stimulated with Aβ1-42 or LPS which is the PAMP for TLR4 there was 
phospho-IkB production which is what we expected since NLRP3 has no direct 
role in NF-kB activation and it is known that it cannot recognize PAMPs/ligands 
directly. Therefore, TLR2 and TLR4 seem to recognize Aand trigger NF-kB 
activation and cytokine production. 
3.4.3 Aβ1-42 triggers inflammasome activation (Signal 2) 
To investigate whether PRRs play a role in inflammasome activation, 
inflammasome activation was assessed by western blotting, probing for caspase-
1 p10 in astrocytes silenced for TLR4, TLR2, NLRP3 and NLRP1 (Figure 3.4.3). 
Caspase-1 p10 is present in Aβ1-42 stimulated wild type astrocytes, at all time 
points, indicating inflammasome activation. The data demonstrated a reduced 
signal for caspase-1 p10 activation in Aβ1-42 stimulated shTLR2. However, no 
signal was detected for caspase-1 p10 in Aβ1-42 stimulated shTLR4 at all time 
points. This demonstrated that TLR2 and TLR4 play a role in the inflammasome 
activation through Aβ1-42 recognition as a PAMP which is consistent with the 
phospho-IKB production already seen previously, thus acting as signal 1 for 
inflammasome.  Knockdown of NLRP3 abrogates caspase-1 p10 production 
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indicating that NLRP3 is vital in detection of amyloid by inflammasomes triggering 
signal 2 which leads to the cleavage and activation of caspase1 and resulting in 
IL1 secretion. 
 
Figure 3.4.3 Western blot analysis of silenced astrocytes. Cell lysates were analysed for the 
presence of phospho-IkB by western blotting when TLR4 was silenced and cells were stimulated 
with A and scrambled A for 2h, 4h and 6h (A) when TLR2 was silenced and cells were stimulated 
with A and scrambled A (B). Furthermore, the presence of phospho-IkB was investigated when 
NLRP3 was silenced and cells were stimulated with A and scrambled A as well as LPS as a 
positive control (C). Beta actin loading controls are also shown. The gels are representatives of 
three independent experiments. 
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3.4.4 Aβ and NLRP3 presence in the AD brain 
 To determine if Aβ is present in the AD brain, AD patients’ tissue sections were 
stained for Aβ using immunohistochemistry. Amyloid plaques were observed in 
the brain of the AD patients. To determine whether NLRP3 is present in the Aβ 
plagues in the AD brain, patients’ tissue was stained for NLRP3 and Aβ (Figure 
3.4.4). In these experiments the peroxidase substrate yields a grey/blue stain and 
the DAB label a brown stain enabling the two primary antibodies to be visualised 
on the same slide in different colours. 
 
Figure 3.4.4 Tissue staining demonstrating NLRP3 activation in the AD brain. Paraffin wax 
sections (original magnification x400) of hippocampus of normal controls and AD patients 
immunolabelled with anti an Amyloid-β mAb (brown) to detect plaques and an anti NLRP3 rabbit 
IgG (blue), The active plaque shows the presence of amyloid and NLRP3. 
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3.4.5 NLRP3-MAC association in AD  
To determine whether MAC triggers NLRP3 activation in the AD brain, patients’ 
tissue was stained for NLRP3 and C9 neoepitope [signifies the presence of the 
membrane attack complex (MAC) in the human brain] using 
immunohistochemistry. Dual labelling via indirect immunofluorescence was also 
used to determine whether there is NLRP3 activation in the AD brain. Brain tissue 
from normal and AD patients was stained for NLRP3, ASC (its adaptor molecule 
once activated) and C9. It was shown that NLRP3 and ASC are present in the 
brain of AD patients and not in healthy controls (Figure 3.4.5-A). 
 Furthermore, results demonstrated that NLRP3 colocalizes with C9 in the amyloid 
plagues, suggesting that there is inflammasome-complement interaction in the AD 
brain (Figure 3.4.5-B). 
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Figure 3.4.5 Tissue staining demonstrating NLRP3 and C9 activation in the AD brain. (A) 
Paraffin wax sections (Original magnification x400) showing specific cytoplasmic cell staining 
(brown, Vector DAB) on brain tissue of AD patient for amyloid using an Amyloid-β mAb, for NLRP3 
using a rabbit anti-NLRP3 antibody and for C9 using a mouse monoclonal antibody anti-C9 
neoantigen with Haematoxylin (blue) counterstain. The presence of NLRP3 and ASC and NLRP3 
and C9 in tissue sections of AD patients and normal controls is also shown (B). Tissue was stained 
for NLRP3 using a primary goat anti-NLRP3 with secondary donkey anti-goat conjugated to Alexa 
546 and for C9 using a mouse monoclonal antibody anti C9 neoantigen with secondary donkey 
anti-mouse conjugated to Alexa 647. Amyloid was labelled with a rabbit anti amyloid antibody 
followed by donkey anti rabbit secondary conjugated to Alexa 488.  Cells were imaged using a 
Zeiss 510 confocal microscope. (Scale bar 100um). The arrows on figure depict the amyloid 
plague. 
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3.4.6 Aβ interacts with NLRP3  
Aβ and NLRP3 were shown to be present in brain tissue of AD patients. To 
investigate if Aβ associates with NLRP3 in astrocytes, we stimulated wild type 
astrocytes with Aβ for 4h and 6h when there is the peak of IL1 secretion this 
confirming inflammasome activation. Cells were then labelled with primary 
antibodies against NLRP3, ASC and Aβ and secondary antibodies conjugated to 
Alexa fluorophores. (Figure 3.4.6). 
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Figure 3.4.6 NLRP3 and amyloid interactions on astrocytes. Confocal images of astrocytes 
stimulated with Aβ for 4h are shown. NLRP3 was labelled using a rabbit anti NLRP3 antibody 
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followed by a donkey anti-rabbit secondary conjugated to Alexa 488 while ASC was stained using 
a goat anti ASC antibody followed by a secondary donkey anti-goat conjugated to Alexa 546 (A) 
Aβ was stained using a primary mouse monoclonal anti-amyloid-β with secondary donkey-anti 
mouse conjugated to Alexa 546 and NLRP3 was labelled using a rabbit anti NLRP3 antibody 
followed by a donkey anti-rabbit secondary conjugated to Alexa 488 (B) Aβ was stained using a 
primary mouse monoclonal anti-amyloid-β with secondary donkey-anti mouse conjugated to Alexa 
546 and ASC was stained using a goat anti ASC antibody followed by a secondary donkey anti-
goat conjugated to Alexa 488 (C). Cells were imaged using a Zeiss 510 confocal microscope. Bars 
shown are 10um. Histograms indicating 3D representation of the image generated by ZEN blue 
software are also shown. The data presented are a representation of three independent 
experiments. The merged images show apparent localized interaction R(obs) between NLR3 and 
ASC, NLRP3 and amyloid as well as ASC and amyloid, determined using ImageJ software analysis 
via the Costes’ method. 
 
In our imaging experiments ASC and NLRP3 were used as a positive control which 
returned R(obs) of 0.930 which are close to the theoretical maximal value 
confirming these co-localizations are highly significant (Fig. 3.4.6 A). The statistical 
significance of NRP3 and amyloid co-localisation, was calculated by Costes’ 
approach, by using ImageJ which returned R(obs) of 0.880, therefore suggesting 
that these co-localizations are significant (Fig. 3.4.6 B). 
Our data showed as expected since amyloid colocalises with NLRP3 that ASC 
interacts with amyloid as well R(obs) of 0.865 (Fig. 3.4.6 C) confirming these co-
localizations are significant.  
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3.5 Investigating Aβ internalization 
3.5.1 The endosomal pathway 
Early endosomes are the initial station of the endocytic pathway and often located 
in the periphery of the cell. These endosomes receive most vesicles originating in 
the cell surface and are primarily sorting organelles where many ligands dissociate 
from their receptors in the acid pH of the lumen (Lundmark et al. 2008; Mellman 
1996). This is the site for receptors to separate into the transcytotic pathway to 
late components (via vesicular component, which form multivesicular bodies, or 
endosomal carrier vesicles). 
Internalized materials en route to the lysosomes, from early endosomes in the 
endocytic pathway, the trans-Golgi network in the biosynthetic pathway or the 
phagosomes in the phagocytic pathway, travel via the late endosomes (Mukherjee 
et al. 1997). The late endosomes have numerous membrane vesicles and proteins 
characteristic of lysosomes, such as glycoproteins, and are believed to mediate 
the final events prior to delivery of materials to the lysosomes. 
The final part of the endocytic pathway is the lysosomes. The primary function of 
lysosomes is to break down cellular waste products, fats, carbohydrates, proteins, 
and other macromolecules into simple compounds. These compounds are then 
returned to the cytoplasm as new cell-building materials. To accomplish this, 
lysosomes use different types of hydrolytic enzymes, all of which are 
manufactured in the endoplasmic reticulum and modified in the Golgi apparatus 
(Luzio et al. 2000).  
To investigate whether the internalization and trafficking of Aβ was crucial for 
triggering a pro-inflammatory response, we utilized confocal microscopy. Briefly, 
following the internalization of molecules from the plasma membrane, they fuse 
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with early endosomes, sent to late endosomes (degradation), and destroyed in 
lysosomes. Along with Aβ, we investigated TLR4 and CR3 to identify whether a 
co-localization occurs, hence Aβ traffics via either of these receptors.  
 
Figure 3.5.1 The endosomal pathway (adapted from 
www.theartofmed.tumblr.com/post/119579864277).  
3.5.2 TLR4 internalization 
The best characterized TLR, in terms of its key function in both innate immunity 
and signal transduction, is TLR4. TLR signalling consists of at least two distinct 
pathways: a MyD88-dependent pathway that leads to the production of 
inflammatory cytokines, and a MyD88-independent pathway associated with the 
stimulation of IFN-β and the maturation of dendritic cells. Previous studies 
demonstrated that TLR4 is the main sensor of LPS from Gram-negative bacteria 
and senses endogenous molecules causing inflammation and cell damage. TLR4 
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traffics to early endosomes from the plasma membrane and activates IRF3, and 
then traffics to late endosome, where it undergoes degradation.  
3.5.3 TLR4 interactions with cell surface PRRs in response to Aβ 
To determine whether Aβ interacts with different cell surface PRRs, we employed 
fluorescence resonance energy transfer (FRET), a biophysical method probing the 
proximity of molecules on the cell surface, under conditions very close to the 
physiological state of the cells. FRET occurs over distances of 1-10nm and is a 
useful tool for investigating molecular associations. Using FRET, we investigated 
TLR4 heterotypic associations on the cell surface of human astrocytes in response 
to Aβ. The results demonstrated that subsequent to Aβ stimulation, TLR4 co-
clustered with TLR2 (E = 25 ± 2.1%), to some extent with C5aR1 (E = 14 ± 1.2%) 
and with CR3 (E = 24 ± 2.1%). TLR4 interactions with MHC class I were used as 
a negative control (E = 5 ± 0.9%), while interactions between two different epitopes 
of TLR4 were used as our positive control (E = 38 ± 1.5%) (Figure 3.5.3 A).  
Following the identification of these PRRs associated on the cell surface in 
response to Aβ, we investigated their interactions upon internalization. We utilised 
confocal microscopy to visualize in which compartment (endosomes, lysosomes, 
or cytoplasm) these associations take place and in what time frame. To determine 
the internalization route of the PRRs in response to Aβ, the PRRs of interest (TLR4 
and CR3) and the endosomal compartments (early, late, recycling) were labelled 
using fluorescent antibodies/dyes in the presence of Aβ at 30 min, 2h and 4h. The 
astrocytes were imaged on an LSM710 ELYRA P1 confocal microscope using a 
1.4NA 100x Zeiss objective (Carl Zeiss, Inc.) and the images were then analysed 
with the ZEN Black image analysis software (Carl Zeiss, Inc.). 
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The results demonstrated that Aβ traffics through the endosomal/lysosomal 
pathways (Figure 3.5.3). Furthermore, Aβ had internalised along with TLR4 and 
CR3 into the early endosome (EEA1: early endosome marker) within 30 min 
(Figure 3.5.3 B and C), and within 2h into the late endosome containing Rab7 
(Figure 3.5.3 D). In addition, co-localisation of Aβ with CR3 in the lysosomal 
pathway (LAMP1: lysosome marker) was observed after 4h (Figure 3.5.3 E).  
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Figure 3.5.3 PRR associations induced in the presence of Aβ and Αβ internalization. (A) 
FRET measurements between TLR4 and different receptors in response to Aβ. Human astrocytes 
were stimulated with Aβ for 30 min and subsequently fixed. Energy transfer between TLR4 (Cy3) 
and the different receptors (Cy5), was measured from the increase in donor (Cy3) fluorescence 
following acceptor (Cy5) photobleaching. Fab fragments from two different antibodies for TLR4 
(targeting different epitopes) one conjugated to Cy3 and one to Cy5 were used as a positive control. 
W6/32 (antibody specific for MHC- class-I) Fab fragments conjugated to Cy3 and anti TLR4 Fab 
fragments conjugated to Cy5 were used respectively as probes for MHC- class-I and TLR4 as 
negative control since MHC –class- I does not associate with TLR4.  The percentage of energy 
transfer (E%) and standard deviation were calculated from three independent experiments (A). 
Human astrocytes were stimulated with Aβ for 30 min (panel B), 1h (panel C), 2h (panel D) or 4h 
(panel E). The cells were fixed and labelled with primary and secondary antibodies with the 
appropriate fluorescent dye, and the nucleus was stained with TOPRO-3. Images were collected 
using a Zeiss 710 confocal microscope and are representative of three independent experiments. 
Aβ was stained using a primary mouse monoclonal anti-amyloid-β with secondary donkey-anti 
mouse conjugated to Alexa 488 and TLR4 was labelled using a mouse monoclonal antibody 
followed by a donkey anti-mouse secondary conjugated to Alexa 48. EEA1 was stained using a 
goat anti EEA1 antibody followed by a secondary donkey anti-goat conjugated to Alexa 546 Rab7 
was stained using a goat anti RAb7 followed by a secondary donkey anti-goat conjugated to Alexa 
546.  LAMP1 was stained using a goat anti LAMP1 followed by a secondary donkey anti-goat 
conjugated to Alexa 546. CR3 was stained using a mouse monoclonal with secondary donkey-anti 
E. 
A TOPRO LAMP1 Merged 
CR3 TOPRO LAMP1 Merged 
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mouse conjugated to Alexa 488. Cells were imaged using a Zeiss 510 confocal microscope. Bars 
shown are 10um. The data presented are a representation of three independent experiments. The 
statistical significance of receptor co-localisation was calculated by Costes’ approach, by using 
ImageJ. 
3.6 Conclusion 
Alzheimer’s disease (AD) is a neurodegenerative disorder and the most common 
cause of dementia in the elderly. Patients show a gradual onset and progression 
of memory loss and other cognitive deficits. It is widely accepted that the 
extracellular accumulation of Aβ in senile plaques is a principal event in the 
pathogenesis of Alzheimer’s disease (Weiner HL and Frenkel D 2006), but the 
cellular events leading to plaque-induced neuronal dysfunction are still unclear. 
Genetic factors have been suggested to either cause or predispose to AD 
including mutation in amyloid precursor protein (APP), which generates Aβ by 
proteolytic processing, mutation in presenilins 1 and 2 as well as polymorphism to 
apolipoprotein A and Complement receptor 1 (CR1) (Weiner HL and Frenkel D 
2006). It is our hypothesis that deposition of Aβ peptide can activate the innate 
immune system via PRRs, including complement, and evoke Alzheimer's 
pathology initiating a pro-inflammatory cascade that results in the release of 
cytokines, complement, proteases and other acute phase proteins, ultimately 
causing neurodegeneration.  
The precise roles of PRRs in detecting and mounting responses against Aβ, and 
their roles in AD are not clear. To determine which PRRs are involved, the 
expression levels of TLRs as well as NLRs and complement receptors in response 
to fibrillar Aβ were investigated in cultures of astrocytes. A concern over the use 
of fixation prior to antibody staining was raised, thus a further comparison of cells 
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fixed prior to antibody staining and after was performed to determine receptor 
surface expression. The results showed that the two methods were comparable, 
thus we proceeded to determine total expression of receptors at different time 
points using PFA fixation and permeabilization with Saponin prior to antibodies 
staining. 
Furthermore, the results showed that in un-stimulated astrocytes all the PRRs of 
interest such as TLRs (TLR2, TLR4), NLRs (NLRP1, NLRP3 and NLRC5) as well 
as complement receptors (CRs; C5aR1, C3aR, CR1, CR3, CD55, CD59 and 
Factor H) were present albeit at low levels (Figure 3.3.2) suggesting that these 
cells are able to detect and respond to a wide range of PAMPs and DAMPs. When 
we examined PRRs expression following 2h-stimulation with Aβ1-42, we observed 
up-regulation for some of them. From the NLRs, NLPR3 had a high expression 
level and from the CRs, C3aR, C5aR1, CD59 and Factor H were found to be highly 
expressed.  The results suggested there was a difference in expression level at 
various time points, thus different time points of stimulation were studied as well 
to give us a better picture of PRR expression following Aβ stimulation.  
Inflammation has been shown to be present in AD patients and IL-6 and TNF-a 
have been demonstrated in cerebrospinal fluid samples from AD patients, when 
compared to their age-matched healthy controls (Blum-Degen D et al. 1995) 
whereas IL-6 immunoreactivity is established in diffuse Aβ plaques from AD 
patients (Gadient et al. 1997). In addition, increased levels of IL-1β have been 
shown in the circulation of AD patients (Licastro et al 2000). 
To determine which PRRs are involved in neuroinflammation, we investigated 
inflammasome activation since IL-1β secretion have been linked with AD (Licastro 
et al 2000) as well as the involvement of TLRs and complement. The data 
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demonstrated that Aβ can trigger cytokine secretion (IL1, as well as non 
inflammasome cytokines IL6 and IFN NF-kB activation (which was detected by 
the presence of Phospho-IKKb) as well as cleavage to caspase 1 p10 which 
results in inflammasome assembly. 
To determine the role of TLRs and NLRs in Aβ recognition, we utilised RNA 
interference to knock down expression of TLRs and NLRs. Knockdown of TLR2 
and TLR4 not only significantly decreased levels of TLR2 and TLR4 protein in 
astrocytes, but also resulted in reduced NF-kB activation (determined by the 
presence of phospho-Ikkb by western blotting), as well as decreased caspase-1 
protein levels in response to Aβ. IL-6 secretion which is TLR dependent as well as 
IL-1 secretion was also inhibited. These findings suggest that TLR2 and TLR4 
could be linked to the upstream’ activation’ of inflammasome assembly.  
Since inﬂammasomes have been shown to be triggered by diverse ligands, it has 
been suggested that two or potentially more signals are required for full activation. 
The ﬁrst, or priming signal, can by triggered from a transcriptionally active PRR or 
cytokine receptor, this leads to transcriptional activation of the genes encoding 
pro-IL1β and pro-IL18 (Martinon et al. 2009). The second signal is triggered in 
response to various stress signals associated with damaged self resulting in NLR 
assembly (Bauernfeind et al. 2009). Thus, it seems that A is detected by TLR2 
and TLR4 which provide the priming signal since knocking down these TLRs 
resulted in a reduction in expression of IL-1β and IL-6. 
To determine which NLR is involved in the inflammasome assembly, NLRP3 and 
NLRP1 were knocked down using shRNA in astrocytes and cells were stimulated 
with A. When IL-1 secretion and caspase 1 expression were examined, the data 
showed a signiﬁcant reduction in IL-1 secretion and a reduction in caspase 1 p10 
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expression when NLRP3 was knocked down, whereas there was no signiﬁcant 
change in IL-1b or caspase 1 when NLRP1 was knocked down. 
 To confirm the role of NLRP3 in amyloid induced neuroinflammation, AD brain 
samples from patients were used and stained for A to visualize the plagues, as 
well as NLRP3 and MAC (C9). A study by our group has demonstrated that 
following sublytic MAC attack, there is an increase in intracellular Ca2+ 
concentration leading to Ca2+ accumulation in the mitochondrial matrix and loss of 
mitochondrial transmembrane potential. This triggers NLRP3 inflammasome 
activation and IL-1β release, demonstrating as association of NLRP3 and MAC 
(Triantafilou K et al. 2013). Thus, to identify NLRP3 and complement interaction in 
the AD brain, AD brain tissue was stained for NLRP3 and MAC (C9) (Figure 3.4.5). 
NLRP3 and MAC co-localize in amyloid plaques of the AD brain, further indicating 
an inflammasome-complement interaction. The data points that our hypothesis is 
right and neuroinflammation is due to the PRRs and complement. 
In addition to neuroinflammation, we also looked at Aβ trafficking to determine the 
intracellular route that Aβ follows to enter cells. When cells were stimulated with 
Aβ FRET studies showed associations of TLR4 with TLR2 as well as CR3 and 
C5aR1. To determine whether Aβ internalizes with these receptor cluster, we 
labeled intracellular organelles for early and late endosome as well as lysosome 
at different time points since previous studies have shown that the lysosomal 
system can play a role in A trafficking (Zheng et al. 2012). Our results showed 
that A internalises via early endosomes (EEA1) and associates with TLR4 and 
CR3 and then accumulates in lysosomes (LAMP1). This is constant with other 
studies since Aβ has been shown to accumulate within lysosomes, apparently 
promoting neuronal death through lysosomal destabilization (Nixon et al. 2000; 
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Ditaranto 2001). It is possible that the Aβ accumulation in the lysosome could be 
triggering oxidative stress and since inflammasome activation is triggered in 
response to various stress signals that’s why there is inflammasome assembly in 
the A plagues. 
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Chapter IV 
Amyloid internalises along with the 
complement membrane attack complex 
within Rab5+ endosomes and triggers 
non-canonical NF-kB signalling resulting 
in NLRP3 inflammasome activation  
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4.1 Introduction 
Alzheimer’s disease (AD) is a neurodegenerative disorder and the most common 
cause of dementia in the elderly. Amyloid β (Aβ) accumulation in senile plaques is 
a principal event in the pathogenesis of Alzheimer’s disease (Weiner and Frenkel 
2006; Meyer-Luehmann et al. 2008), but the cellular events leading to plaque-
induced neuronal dysfunction are still unclear. Genetic factors have been 
suggested to either cause or predispose to AD including mutation in β-amyloid 
precursor protein (APP) (Goate et al. 1991), which is the protein that generates Aβ 
by proteolytic processing, mutation in presenilins 1 and 2 (Sherrington et al. 1995; 
Rogaev et al. 1995), as well as polymorphism to apolipoprotein A and Complement 
receptor 1 (CR1) (Lambert et al. 2009). In addition to genetic factors, studies have 
suggested that inflammatory and immunological processes are not just mere 
bystanders, but that microglia and invading bone marrow derived mononuclear 
phagocytes are central in the initiation and progression of Alzheimer’s disease 
(Weiner and Frenkel 2006). Therefore, it is now accepted that the innate immune 
system plays a crucial role in the development of the disease. 
The innate immune system has been primarily viewed as the first line of defence 
against “danger” acting quickly by mounting an inflammatory response and 
eliminating the intruders. It employs pattern recognition receptors (PRRs), such as 
Toll like receptors (TLRs), Nod-like receptors (NLRs) and complement to detect 
“danger”. The precise roles of PRRs in detecting and mounting responses against 
Aβ, and their roles in AD are not clear. TLR expression is upregulated in the AD 
brain, and in murine models of AD, TLR2 and TLR7 were found to be upregulated 
compared to controls (Letiembre et al. 2009). Furthermore, multiple TLR genes (1-
8) were found to be present in microglia in post-mortem tissue from AD patients, 
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with varying levels of expression (Bsibsi et al. 2002). The increased expression of 
TLRs in AD has positioned them as potential key players in neurodegenerative 
mechanisms and disease progression.  
The TLR4 gene has emerged as a candidate for susceptibility for AD. A common 
miss-sense polymorphism resulting in an adenine to guanine substitution 896 
nucleotides downstream of the transcription start site causes the replacement of 
glycine for aspartic acid at amino acid 299 (Asp299Gly) and alters the extracellular 
structural domain of TLR4. This mutation attenuates TLR4 signalling in response 
to LPS (Arbour et al. 2000). Since its discovery, this polymorphism has been 
associated with decreased cardiovascular disease risk (Balistreri et al. 2004), 
aging (Balistreri et al. 2009) as well as decreased risk of late-onset AD in an Italian 
cohort (Minoretti et al. 2006; Balistreri et al. 2008), suggesting that pro-
inflammatory responses triggered via TLR4 are crucial for disease progression. 
Recently, Tang et al. (Tang et al. 2008) using primary neuronal cultures from TLR4 
mutant mice have shown that neurons expressing TLR4 have an increased 
sensitivity to Aβ and are vulnerable to degeneration in AD. 
In addition to the implication of TLR4 in susceptibility to neurodegeneration, recent 
studies have suggested that TLR4 activation is required for clearance of Aβ in AD. 
Mice carrying a point mutation in TLR4 exhibit augmented deposition of Aβ in both 
the neocortex and hippocampus (Tahara et al. 2006). The mechanism by which 
TLR activation aids Aβ clearance is unclear. 
The complement system is another pattern recognition arm of the innate immune 
system, providing protection from infection and resolution of injury. It recognises 
PAMPs; it tags them and eliminates the pathogen. It is one of the innate immune 
mechanisms considered to play a role in the death of the brain neurons in patients 
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with AD. Evidence for complement mechanisms in microglial responses to Aβ has 
been reported, but may not been fully appreciated. Microglia and other brain cells 
express the genes and/or proteins for virtually all classical and alternative pathway 
components (Walker et al. 1995; Walker and McGeer 1992). Both the classical 
and alternative pathways are directly activated by Aβ in an antibody-independent 
fashion (Daly and Kotwal 1998). The classical pathway has been shown to be 
directly activated in AD by both fibrillar Aβ deposits and neurofibrillary tangles 
(Shen et al. 2001; Rogers et al. 1992). All components of the classical pathway 
(Shen et al. 1997) and the alternative pathway (Strohmeyer et al. 2000) have been 
identified in neurons of the AD brain. The end product of the terminal pathway, the 
membrane attack complex (MAC), was also found in neuronal membranes of the 
AD brain (Webster et al. 1997). The presence of MAC in the AD brain suggests 
that C5a has been released since the formation of MAC is initiated by C5b, which 
is generated when C5a is cleaved from C5 by C5 convertase from either the 
classical or alternative pathways. These studies suggest the involvement of C5a 
as well as its receptor, C5aR1 in the neuroinflammation observed in AD. The 
expression of the C5aR1 in microglia cells of human and rodents supports this 
hypothesis (Gasque et al. 1997). A recent study by Fonseca et al. (Fonseca et al. 
2009) has demonstrated that treatment with a C5aR1 antagonist decreases 
pathology and enhances behavioural performance in murine models of AD, 
suggesting that C5aR1 is a novel therapeutic target for AD. 
Long before TLRs and complement had been implicated in autoimmune diseases, 
studies had demonstrated that neuroinflammation plays a key role in 
neurodegeneration in AD. Both complement and TLRs are swiftly activated in 
response to infection or danger and there is increasing evidence for extensive 
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bidirectional cooperation between the two systems, shaping the immune response 
through both synergistic and antagonistic crosstalk (Hajishengallis et al.  2010; 
Hajishengallis and Lambris 2016). TLRs and complement have been individually 
linked to AD. Aβ linked with AD can activate both types of pattern recognition 
sensors, but whether and how these two innate immune systems interact with 
each other in the context of AD has not been studied before. In this study, I aimed 
to answer some of the key questions that arise: 1) whether interplay between 
complement and TLR receptors is the key to the chronic inflammatory response 
observed in AD; 2) how are PRRs involved in Aβ clearance; and 3) whether the 
internalization and trafficking of Aβ is crucial for triggering a pro-inflammatory 
response.  
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4.2 Aβ-induced inflammatory responses in the presence 
of complement 
To address the question whether the interplay between complement and TLR/NLR 
receptors is the key to the chronic inflammatory response observed in AD, we 
initially investigated what cytokine response is triggered in astrocytes by Aβ in the 
presence and absence of complement. Fibrillar Aβ (amino acids 1-42), as well as 
control non-fibrillary peptide (identical sequence but in reverse order) was 
obtained from American Peptide (USA) and prepared as previously described 
(Moore et al. 2002). Utilising an astrocytic cell line for these experiments, we 
stimulated astrocytes by incubating the cells with different concentrations of Aβ. 
Following incubation, supernatants were collected and frozen until they were 
analysed for their cytokine content. Pro-inflammatory cytokines were analysed 
using cytometric bead arrays (CBAs) from BectonDickinson. As demonstrated in 
the previous chapter (Figure 3.4.1.2), it was shown that IL-1β as well as IL-6 were 
triggered in response to Aβ (Figure 4.2 A and B). This response was greatly 
enhanced in the presence of normal human serum (NHS) as a source of 
complement, especially in the case of IL-1β, suggesting that complement 
augments Aβ-induced IL-1β secretion. An NHS titration was performed and 10% 
NHS was found to be the optimum concentration to be used. To verify complement 
activation, flow cytometry was used in order to confirm the presence of the MAC 
through positive staining for C9 neoepitope after activation of complement (Figure 
4.2 C, open histogram), whereas cells treated with the equivalent concentration of 
heat-inactivated NHS (HI-NHS) were negative for MAC staining (Figure 4.3 C, grey 
histogram). 
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Furthermore, to confirm complement-involvement in the Aβ-induced IL-1β 
secretion, we stimulated the cells with Aβ in the presence of NHS depleted for 
complement terminal components. It was shown that when HI-NHS or C5-depleted 
NHS was used, the augmented IL-1β response was not observed, suggesting a 
role for the terminal pathway of complement components. In contrast IL-6, which 
is not dependent on inflammasome activation, was marginally enhanced by the 
addition of NHS, and there was not a significance difference when incubated with 
either heat inactivated NHS or C5-depleted NHS, suggesting that the terminal 
pathway of complement components does not play a role in IL-6 responses. 
 
Figure 4.2 Aβ-induced inflammatory responses in the presence of complement. Human 
astrocytes were incubated with fibrillar Aβ in the presence and absence of normal human serum 
(NHS) for 6 h. The supernatants were harvested and assayed for cytokine contents using the 
Cytometric Bead Array (CBA) system (Becton Dickinson) (A, B). The level of MAC deposition at 
different doses of serum was revealed by mean fluorescence intensity upon staining for the anti-
C9 neoepitope (white histogram) using flow cytometry (C). Fluorescence was detected using a 
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FACSCalibur (BectonDickinson). The data presented are the mean ± standard deviation (n=3) from 
three independent experiments. *P<0,05, **P<0,01, ***P<0,001 vs respective unstimulated. 
 
4.3 Aβ triggers inflammatory responses via TLR2, TLR4 
and NLRP3 
To determine which PRRs are involved in triggering the inflammatory responses 
observed, we utilised RNA interference to knock down expression of TLRs and 
NLRs. Once we had confirmed knock-down of the receptors of interest in 
astrocytes cells, we proceeded to stimulate the cells with different concentrations 
of Aβ and measure pro-inflammatory cytokine using CBAs and compared the 
cytokine profile of normal and knocked down cells (Figure 4.3). TLR2, TLR4 and 
NLRP3 knock down reduced the Aβ induced IL-1β while NLRP1 knock down had 
no effect (as previously shown in 3.4.1.2. at times between 2-6 h). When cells were 
co-incubated with Aβ and NHS, knockdown of NLRP1 had no effect on IL-1β 
secretion, while knockdown of NLPP3 completely abrogated the induced IL-1β 
secretion. Knockdown of TLR2 and TLR4 only partially reduced the IL-1 secretion. 
Co-incubation of heat inactivated serum or C5-depleted serum with Aβ, resulted 
in a similar pattern of IL-1β secretion as incubation with Aβ on its own. 
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Figure 4.3 RNA interference reveals PRR involved in Aβ-induced IL-1β secretion. RNA 
interference was used to knock down expression of TLRs and NLRs, and subsequently the cells 
were stimulated with Aβ in the presence and absence of complement. The supernatants were 
harvested and assayed for cytokine contents using the CBA. The data presented are the mean ± 
standard deviation (n=3) from three independent experiments carried out in triplicate. *P<0,05, 
**P<0,01, ***P<0,001 vs respective unstimulated. 
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4.4 PRR associations induced in the presence of Aβ and 
complement 
To shed light into PRR and Aβ interactions we utilised fluorescence resonance 
energy transfer (FRET). FRET is a non-invasive imaging technique used to 
determine molecular proximity. FRET can occur over 1-10 nm distances, and 
effectively increases the resolution of light microscopy to the molecular level 
(Stryer 1978). It involves non-radiative transfer of energy from the excited state of 
a donor molecule to an appropriate acceptor. FRET was measured in terms of 
dequenching of donor fluorescence following complete photo-bleaching of the 
acceptor fluorophore.  
Using FRET, we investigated TLR4 heterotypic associations on the cell surface of 
human astrocytes in response to Aβ. We found that following Aβ stimulation, TLR4 
co-clustered with TLR2 (E = 25 ± 1.1%) and to some extent C5aR1 (E = 16 ± 
1.2%), which was enhanced in the presence of complement (NHS) (E = 32 ± 0.5 
and 35 ± 0.9%, respectively) (Figure 4.5). C5 depleted serum did not enhance the 
effect of Aβ, suggesting the involvement of activation of the terminal pathway of 
Complement. 
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Figure 4.4 PRR associations induced in the presence of Aβ and complement. FRET 
measurements between TLR4 and different receptors in response to Aβ. Human astrocytes were 
stimulated with Aβ for 30 min and subsequently fixed. Energy transfer between TLR4 (Cy3) and 
the different receptors (Cy5), was measured from the increase in donor (Cy3) fluorescence 
following acceptor (Cy5) photobleaching. The percentage of energy transfer (E%) and standard 
deviation were calculated from three independent experiments performed in triplicate. 
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4.5 Aβ in the presence of complement triggers non-
canonical NF-kB signalling 
In Chapter 3, the internalization of Aβ was investigated. It was shown that Aβ 
internalizes in endosomal compartments. In order to determine whether signalling 
is triggered from these locations, Rab5+ containing endosomes were labelled 
using fluorescent antibodies/dyes as well as signalling molecules in the presence 
of Aβ. Interestingly, it was shown that NF-kB-inducing kinase (NIK) which leads to 
the activation of the non-canonical NF-kB pathway, was recruited to Rab5+ 
containing endosomes in response to Aβ and complement (10% NHS) (Figure 4.5 
A, top row), but not when cells were stimulated with Aβ and 10% HI-NHS (Figure 
4.5A, bottom row). To verify these findings, astrocytes were stimulated with Aβ in 
the presence of complement and lysed to perform western blotting. Western 
blotting confirmed that following Aβ stimulation in the presence of 10% NHS as a 
source of complement, non-canonical NF-kB signalling is triggered (Figure 4.5 B). 
NIK could only be detected in the presence of NHS, whereas when the 
complement terminal components were removed from the serum, NIK activation 
was inhibited (Figure 4.5 B), suggesting that it is only recruited in the presence of 
complement. 
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Figure 4.5 Aβ in the presence of complement triggers non-canonical NF-kB signalling. (A) 
Human astrocytes were stimulated with Aβ, in the presence of 10% NHS or HI-NHS for 30 min. 
The cells were fixed and labelled with primary and secondary antibodies with the appropriate 
fluorescent dye (A) or lysed and analysed using western blotting (B). Fluorescent images were 
collected using a Zeiss 710 Confocal microscope. The data are representative of three independent 
experiments.  
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4.6 Clearance of fibrillar Aβ through its internalization 
and trafficking, is crucial for triggering a non-canonical 
NF-kB signalling via Rab5+ containing endosomes 
To investigate the recruitment of NIK to Rab5+ containing endosomes, we labelled 
human astrocytes that had been stimulated with Aβ in the presence of NHS for 
PRRs, NIK and Rab5+. It was shown that within 30 min following Aβ stimulation, 
C9, a component of the membrane attack complex (MAC), was found to co-
localise with NIK within the Rab5+ containing endosomes (Figure 4.6, top row). In 
addition, TLR4 and Aβ were found to localised in these endosomes at the same 
time (Figure 4.6, middle and bottom row). In the presence of HI-NHS (Figure 4.6, 
second row), there was no MAC deposition/internalization and neither was co-
localisation of NIK in endosomal vesicles.  
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Figure 4.6 Internalization of Aβ in the presence of complement triggers non-canonical NF-
kB signalling. Human astrocytes were stimulated with Aβ, either in the presence of 10% NHS or 
10% HI-NHS for 30 min. The cells were fixed and labelled with primary and secondary antibodies 
with the appropriate fluorescent dye. Fluorescent images were collected using a Zeiss 710 
Confocal microscope. The data are representative of three independent experiments. Bars 10 µm. 
The data represent the means of three independent experiments. Co-localization coefficients 
[R(obs)] were calculated using Costes’ approach. 
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4.7 Conclusion 
Aβ linked with AD can activate TLRs/NLRs and complement, but whether and how 
these two parts of the innate immune systems interact with each other in the 
context of AD has not been studied before.  
In this study, we set out to investigate the effect of the complement system in Aβ-
induced inflammasome activation. Initially we investigated whether Aβ could 
trigger IL-1β responses and it was shown that Aβ could trigger some 
inflammasome activation. Interestingly, this activation was enhanced in the 
presence of human serum as a source of complement, which seemed to be 
dependent of the terminal pathway activation, since serum depleted for C5 did not 
enhance the Aβ-induced IL-1β response. This is in agreement with recent 
publications, demonstrating how crystal aggregates (An et al. 2014; Samstad et 
al. 2014; Pilely et al. 2016), such as MSU or cholesterol crystals, can trigger 
inflammasome activation in the presence of complement and in particular C5a. 
Since inflammasomes seem to require two signals for activation, one signal via a 
PRR that leads to the production of pro-IL-1β and pro-IL-18 in the cytosol and a 
second signal that leads to the assembly of the oligomeric inflammasome structure 
that activates caspase-1 leading to the processing of pro-IL-1β/18 into IL-1βand 
IL-18 (Stutz et al. 2009); we proceeded to investigate which PRRs are involved in 
triggered Signal 1 and Signal 2 of inflammasome activation in the presence of Aβ 
and complement. 
Using RNA interference, we demonstrated that both TLR4 and TLR2 are able to 
contribute to Signal 1 of inflammasome activation, whereas NLRP3 seems to be 
the NLR that forms the inflammasome in response to Aβ and complement. This is 
in agreement, with recent literature where complement components have been 
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shown to be able to enhance innate immune responses and induced 
inflammasome activation and in particular NLRP3 activation (An et al. 2014; 
Samstad et al. 2014; Pilely et al. 2016; Laudisi et al. 2013; Triantafilou et al. 2013). 
Thus, NLRP3 seems to be the NLR that is involved in most complement-induced 
inflammasome responses. 
Since RNA interference had demonstrated the involvement of TLR2 and TLR4 on 
the cell surface, we proceeded to investigate the molecular interactions of these 
PRR on the cell surface following stimulation with Aβ in the presence of 
complement. For these experiments, we utilised fluorescence resonance energy 
transfer (FRET), to study molecular associations. Interestingly, Aβ in the presence 
of NHS induced heterotypic association of TLR2 and C5aR1 with TLR4, NHS on 
its own had no effect, but when co-incubated with Aβ, it enhanced the effect of Aβ. 
C5 depleted serum did not enhance the effect of Aβ, suggesting the involvement 
of activation of the terminal pathway of the complement system. 
We proceeded to investigate using confocal microscopy, what happens to the 
oligomeric structures that are formed in response to Aβ+NHS on the cell surface. 
It was shown that TLR4/ C5aR1/Aβ complexes internalized within 30 min and are 
targeted to Rab5+ containing endosomes, stabilising NF-kB-inducing kinase (NIK) 
and leading to the activation of the non-canonical NF-kB pathway, suggesting that 
internalization and signalling are interlinked in the case of Aβ. Surprisingly, 
complement was found to internalize along with Aβ and TLR4 in Rab5+ 
endosomes, and recruited NIK to these endosomes. This recruitment of the non-
canonical NF-kB pathway appeared to be complement-dependent as it was 
inhibited in the absence of terminal complement components. This is in agreement 
with a recent paper that has demonstrated that MAC complexes activate an 
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Akt+NIK+ signalosome (Jane-Wit et al. 2015) in human endothelial cells. Our 
study, is the first study to identify such signalosomes in Rab5+ endosomes in 
response to complement and Aβ, suggesting new possible therapeutic targets for 
Aβ-induced neuroinflammation. 
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Chapter V  
Inhibition of inflammatory responses 
by antagonising PRRs involved in 
neuroinflammation  
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5.1 Introduction 
Astrocytes and microglia express various immune receptors, including Toll-like 
receptors (TLRs) and complement receptors, to identify pathogen-associated 
molecular patterns (PAMPs) on invading organisms and mediate the immune 
response of the host. The activation of TLRs leads to the production of cytokines, 
which may either assist in the protection of the central nervous system (CNS) from 
pathogens (Pan et al. 2011), or have a damaging effect on neurons. For example, 
HIV1-associated dementia is characterized by neuronal apoptosis which is 
believed to be the result of cytokine secretion, such as interleukin (IL)-1β, IL-6 and 
tumour necrosis factor (TNF)-α, by astrocytes and microglia (Kaul 2009). 
Furthermore, an immune response in the CNS was demonstrated by a previous 
study to be involved in the neurodegeneration of certain neurological diseases, 
such as Alzheimer’s disease (AD) (Whitney et al. 2009). The accumulation of 
extracellular fibrils of amyloid-β (fAβ) and intracellular neurofibrillary tangles in 
neurons lead to the formation of senile plaques. These events result in the 
neurodegeneration observed in AD (Weiner and Frenkel 2006).  
For certain cytokines, it may be beneficial to inhibit their activity. For example, IL-
1β may induce excito-neurotoxicity by activating the tyrosine phosphorylation of 
N-Methyl-D-aspartate (NMDA) receptors, leading to an increase in the levels of 
intracellular Ca2+ and loss of cultured hippocampal neurons (Viviani et al. 2006). 
On the other hand, the IL-6 cytokine was demonstrated to have a neuroprotective 
role against an NMDA-induced death of the cerebellar neurons (Wang et al. 
2009a). These data indicate that pro-inflammatory cytokines may be either 
neuroprotective or neurotoxic via the modulation of neurotransmission. fAβ 
activates the classical and alternative pathways of complement with consequent 
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C3 activation, C5a production and membrane attack complex (MAC) formation 
(Bradt et al. 1998). The role of the complement system in the removal of the 
infectious pathogen occurs through the activation of a variety of receptors 
including CR1, CR3 and C5aR1, and certain of these receptors serve a prominent 
role in the inflammatory response induced in AD (Crehan et al. 2012); not to 
mention the pro-inflammatory effects that complement might be contributing to 
neuroinflammation. 
As already mentioned, IL-1β seems to be playing a critical role in 
neuroinflammation but how it is triggered in AD is unclear. Aβ could be triggering 
inflammasome activation (mainly Signal 1), but the questions that remain are what 
is the crosstalk of complement with inflammasome in AD and in particular what 
could be triggering Signal 2 for inflammasome activation? Several ions have been 
suggested to be able to trigger Signal 2, Reactive oxygen species (ROS) and Ca2+ 
are at least two of those (Dostert et al. 2008; Segovia et al. 2012). Both ions can 
be linked to AD, but the question remains whether they are involved in Aβ-induced 
responses in the presence of complement. 
ROS is produced in numerous normal and abnormal processes in humans, 
including asthma, cancer, and aging. In addition, the basal levels of ROS 
production in cells may be associated with other physiological functions, such as 
cell proliferation, apoptosis, and homeostasis (Lambeth 2004). Excessive ROS 
production (above basal levels) impairs and oxidizes DNA, lipids, sugars, and 
proteins, thus leading to the dysfunction of these molecules and cell apoptosis. A 
leading theory of the cause of aging indicates that free radical damage and 
oxidative stress serve an important role in the pathogenesis of AD. This is because 
the brain utilizes 20% more oxygen than other tissues that also undergo 
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mitochondrial respiration. Cellular oxidative stress, including augmentation of 
protein oxidation, was demonstrated in AD in response to Aβ, and it is believed 
that treatment with anti-oxidant compounds may provide protection against 
oxidative stress and Aβ toxicity (Park et al. 2005). 
Furthermore, Ca2+ serves an important role in the normal functioning of cells. 
Deregulation of Ca2+-mediated signalling has been implicated in numerous 
neurodegenerative diseases, including AD. The amyloid precursor protein (APP) 
was demonstrated to alter the Ca2+ homeostasis, and lead to synaptic dysfunction 
and dendritic spine loss in neurons (Carafoli 1991). Aβ and the presenilins 
identified in AD have an effect on Ca2+ homeostasis during the early stages of the 
disease development. Thus, the synaptic transmission and function is affected 
prior to the neurotic plaque development. An alteration in the Ca2+ may provide 
Signal 2 for inflammasome activation and induce inflammatory responses, protein 
modifications and neuronal degeneration. As functional synapses and synaptic 
transmission are fundamental processes in memory formation, alterations in these 
processes may result in neuronal dysfunction and memory deficit, such as 
observed in AD (LaFerla 2002). It is thus important to identify whether a Ca2+ 
inhibition, in combination with other inhibitors has a beneficial effect in astrocytes 
in response to Aβ. 
At present, there are no drug treatments that can cure AD or any other common 
type of dementia. To be able to develop AD-specific therapeutic interventions, we 
need to decipher the exact molecular mechanisms that are involved in Aβ-induced 
inflammatory responses. So far, our study has demonstrated that complement and 
in particular the terminal pathway can augment Aβ-induced responses, but which 
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part of the terminal pathway plays a role in triggering Signal 1 or 2 of 
inflammasome activation is something that we have to address.  
In this chapter, we aim 1) to decipher which part of the terminal pathway of the 
complement system contributes to the enhanced Aβ-induced inflammasome 
responses; 2) how is Signal 2 being triggered in the presence of NHS+Aβ; and 3) 
how can we inhibit the NHS+Aβ-induced inflammasome response as a potential 
therapeutic intervention.  
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5.2 C5a augments Aβ-induced IL-1β production 
Our data so far suggested complement-inflammasome interactions both in vitro 
(astrocytes) and in vivo (AD brain tissue). In the AD brain, we demonstrated 
NLRP3, C9 and amyloid co-localization (see Chapter III). We have shown that Aβ 
is capable of delivering signal 1 (NF-kB activation) and non-canonical NF-kB in the 
presence of complement (see Chapter IV), but which complement components are 
involved in triggering Signal 1? Since they co-localize, could complement 
component(s) released upon complement activation also be potential triggers? We 
therefore focused on the effect of C5a, the most potent anaphylatoxin, on 
inflammasome activation in astrocytes. To determine the role of C5a in Aβ 
recognition, we investigated the secretion of IL-1β in astrocytes upon a 6-h 
stimulation with C5a, Aβ and combinatory treatment of C5a+Aβ (Figure 5.2). The 
results demonstrated that C5a stimulation resulted in increased IL-1β secretion 
compared with the unstimulated astrocytes. Furthermore, an augmented effect 
was observed in the combinatory treatment of C5a+Aβ compared with the 
individual treatments of C5a or Aβ (Figure 5.2). This was even more pronounced 
if cells were “primed” (or pre-treated) with C5a 30 min prior to exposure to Aβ 
(Figure 5.2); thus, demonstrating that the effect is synergistic, rather than additive. 
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Figure 5.2 Aβ-induced production of IL-1β. To determine the role of C5a in Aβ recognition, the 
secretion of IL-1β in human astrocytes was investigated upon stimulation with C5a, Aβ and a 
combination of C5a+Aβ. Human astrocytes were stimulated with 50ng/ml C5a and 10mg/ml Aβ for 
6h.  Cells were either pretreated with C5a for 30 min and subsequently Aβ was added, or both C5a 
and Aβ were added simultaneously. The supernatants were harvested and assayed for cytokine 
contents using the Cytometric Bead Array (CBA) system (Becton Dickinson). The data presented 
are the mean ± standard deviation (n=3) from three independent experiments carried out in 
triplicate. *P<0,05, **P<0,01, ***P<0,001 vs respective unstimulated. 
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5.3 C5a triggers Signal 1 
To identify whether C5a triggers signal 1, we run western blots probing for pro-IL-
1β. Human astrocytes were stimulated with C5a, Aβ and a combinatory treatment 
of C5a and Aβ for 6 hours. Membranes were probed with Pro-IL-1β to identify 
whether Signal 1 was activated. 
 
 
 
 
 
 
 
 
Figure 5.3 C5a triggers Signal 1. To identify whether C5a triggers Signal 1, western blotting was 
utilized, probing for pro-IL-1β. Human astrocytes were stimulated with 50ng/ml C5a and 10mg/ml 
Aβ for 6 hours. Pro-IL-1β was present in C5a-, Aβ- and C5a + Aβ-stimulated astrocytes, and not 
in unstimulated astrocytes. This is a representative from three independent experiments. 
 
The results demonstrated that Pro-IL-1β was present in the C5a-, Aβ- and 
C5a+Aβ-stimulated astrocytes, and not in unstimulated astrocytes. Therefore, C5a 
was able to trigger Signal 1. 
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5.4 C5a-induced IL-1β release is C5aR1 and caspase-1-
dependent 
To determine whether the effect of C5a is through the C5aR1 and not the C5aR2, 
anti-C5aR1 (10μg/ml; Cambridge Biosciences), as well as control mouse IgG (7ug; 
Cambridge Biosciences; relevant IgG added as control) was used. Cells were pre-
treated for 30 min with the blocking antibody prior to challenge with C5a as well as 
C5a+Aβ (Figure 5.4). The data clearly demonstrates that the effects observed are 
C5aR1 dependent, as pre-treatment with the blocking antibody inhibited C5a-
induced responses, whereas the control IgG had no effect. 
In addition, we proceeded to investigate whether the C5a effects observed are 
caspase-1 dependent. Z-YVAD-FMK (10μM; Abcam; irreversible caspase-1 
inhibitor, cell-permeable) was utilized to determine whether the secretion of IL-1β, 
following C5a and Aβ stimulation, was caspase-1-dependent. The inhibitor was 
added (at the concentrations mentioned above) to the human astrocytes for 30 
minutes prior to the addition of C5a and/or Aβ for 6 hours. A viability test was 
performed using Trypan blue (see Chapter II) to verify that the selected 
concentrations of the inhibitors did not kill off the cells. Cells remained unaffected 
when the inhibitors were used in the concentrations mentioned above. 
It was shown that Z-YVAD-FMK was able to inhibit IL-1β responses triggered by 
either C5a, Aβ, or a combination of both, demonstrating that the inflammasome 
activation observed is caspase-1-dependent.  
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Figure 5.4 C5a-induced IL-1β release. Inhibitors (anti-C5aR1, control hIgG and Z-YVAD-fmk) 
and PBS were added for 30 min to the human astrocytes and then accordingly C5a, Aβ and 
C5a+Aβ were added for a total of 6 h. The supernatants were harvested and assayed for cytokine 
contents using the Cytometric Bead Array (CBA) system (Becton Dickinson). The data presented 
are the mean ± standard deviation (n=3) from three independent experiments carried out in 
triplicate. *P<0,05, **P<0,01, ***P<0,001 vs respective unstimulated. 
 
The results demonstrated that following C5a stimulation, the Ca2+ inhibition using 
BAPTA as well as the ROS inhibition with DPI reduced IL-1β secretion significantly 
compared with the PBS treatment (Figure 5.4). In contrast, the CA-074 Me 
treatment had no effect on the IL-1β secretion compared with the PBS treatment. 
In contrast in Aβ (alone) stimulation, BAPTA and DPI treatments had no effect on 
the IL-1β secretion, compared with the PBS treatment. However, treatment with 
CA-074 Me inhibiting Cathepsin B resulted in decreased levels of IL-1β compared 
with the other treatments (Figure 5.4), suggesting that Aβ must be triggering Signal 
2 via lysosomal damage and Cathepsin B release. 
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As expected, in the combinational treatments with both C5a+Aβ stimulation, ROS, 
Ca2+ as well as Cathepsin B inhibition seemed to be effective in reducing IL-1β 
secretion compared with the PBS treatment (Figure 5.4). Cathepsin B had the 
highest effect, with ROS inhibition being the least effective of the three inhibitors, 
suggesting that Cathepsin B and Ca2+ are the main triggers of Signal 2 for 
inflammasome activation.   
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5.5 C5a-induced IL-1β release following Signal 2 
stimulation: Ca2+ and lysosomal damage 
Thus far, C5a was demonstrated to augment Aβ-induced IL-1β production, trigger 
Signal 1 (pro-IL-1β activation) and be caspase-1-dependent (caspase inhibitor 
blocked IL-1β production). To further investigate whether C5a triggers Signal 2, 
we utilized certain inhibitors, as follows: (i) BAPTA-AM, membrane-impermeable 
Ca2+ chelator, (ii) DPI (NADPH oxidase inhibitor diphenylene iodonium chloride), 
reactive oxygen species (ROS) inhibitor, and (iii) CA-074 Me, cathepsin B inhibitor 
(lysosomal damage). Previous studies utilized inhibitors that reportedly 
discriminate between cathepsin B and related lysosomal cysteine proteinases, and 
have implicated the enzyme in a wide range of physiological and pathological 
processes. The most popular substance to selectively inhibit cathepsin B in vivo is 
CA-074 Me, the methyl ester of the E-64 derivative CA-074.  
Similar to the above experiments, the inhibitors Cathepsin B (CA-074; 100 μM), 
DPI (20 μM) and BAPTA (30 μM; all from Sigma-Aldrich) were added to the human 
astrocytes for 30 minutes, and then added accordingly C5a and/or Aβ for a total 
of 6 hours.  
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Figure 5.5 C5a-induced IL-1β release. Inhibitors (BAPTA, DPI and CA-074 Me) and PBS were 
added for 30 min to the human astrocytes, and then accordingly C5a, Aβ and C5a+Aβ were added 
for a total of 6 h. The supernatants were harvested and assayed for cytokine contents using the 
Cytometric Bead Array (CBA) system (Becton Dickinson). The data presented are the mean ± 
standard deviation (n=3) from three independent experiments carried out in triplicate. *P<0,05, 
**P<0,01, ***P<0,001 vs respective unstimulated.  
 
The results demonstrated that following C5a stimulation, the Ca2+ inhibition using 
BAPTA as well as the ROS inhibition with DPI reduced IL-1β secretion significantly 
compared with the PBS treatment (Figure 5.4). In contrast, the CA-074 Me 
treatment had no effect on the IL-1β secretion compared with the PBS treatment. 
In contrast in Aβ (alone) stimulation, BAPTA and DPI treatments had no effect on 
the IL-1β secretion, compared with the PBS treatment. However, treatment with 
CA-074 Me inhibiting Cathepsin B resulted in decreased levels of IL-1β compared 
with the other treatments (Figure 5.4), suggesting that Aβ must be triggering Signal 
2 via lysosomal damage and Cathepsin B release. 
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As expected, in the combinational treatments with both C5a+Aβ stimulation, ROS, 
Ca2+ as well as Cathepsin B inhibition seemed to be effective in reducing IL-1β 
secretion compared with the PBS treatment (Figure 5.4). Cathepsin B had the 
highest effect, with ROS inhibition being the least effective of the three inhibitors, 
suggesting that Cathepsin B and Ca2+ are the main triggers of Signal 2 for 
inflammasome activation. 
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5.6 Therapeutic interventions for AD: the MCC950 
inhibitor and PMX53 antagonist  
Following the identification of the PRRs involved and the signalling cascades, the 
next step was to target them therapeutically. We decided to test inhibitors for 
inflammasome, complement and combinations of both in vitro. A previous study 
demonstrated the development of MCC950, an inhibitor of NLRP3, and the 
possibility of being used as a potential therapeutic for inflammatory diseases (Coll 
et al. 2015). This inhibitor blocks canonical and non-canonical NLPR3 activation 
at nanomolecular concentrations, possibly by interacting directly with NLRP3. 
PMX53 (complement inhibitor), which has already been shown to be beneficial for 
AD (Fonseca et al. 2009), was also utilized for the experiments. PMX53 belongs 
to a class of selective small cyclic peptides, which potently inhibit C5a effects. For 
example, PMX53 inhibits C5a-induced myeloperoxidase release from human 
neutrophils (March et al. 2004). This antagonist of C5aR1 is also effective in 
numerous inflammatory disease models in mice and rats in which the 
physiopathology depends on complement system activation, such as rheumatoid 
arthritis (Woodruff et al. 2002), inflammatory bowel disease (Woodruff et al. 2003) 
and neurodegeneration (Woodruff et al. 2006). It is possible that if PMX53 is used 
in combination with TLR/NLR antagonists, such as MCC950, it will be more 
beneficial. Since the activation appears to involve multiple receptors, the therapy 
should be combinational and not targeting single molecules. MCC950 was not 
demonstrated by Coll et al. (2015) to block K+ efflux or Ca2+ flux and targeting the 
NLRP3 may present certain advantages over the use of biologic inhibitors of IL-
1β. 
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 Figure 5.6 Complement-inflammasome inhibitors. Human astrocytes were incubated with 10% 
normal human serum (NHS), fibrillar Aβ and a combinatory treatment of NHS+Aβ, and heat-
inactivated (HI)-NHS+Aβ for 6 h. PBS, 10 µM MCC950 (NLRP3 inflammasome inhibitor, Sigma, 
UK), 10 nM PMX53 (complement inhibitor, TOCRIS, UK) or a combinatory treatment of 
MCC950+PMX53 were added to the cells for 6 h.  The supernatants were harvested and assayed 
for cytokine contents using the Cytometric Bead Array (CBA) system (Becton Dickinson). The data 
presented are the mean ± standard deviation (n=3) from three independent experiments carried 
out in triplicate. *P<0,05, **P<0,01, ***P<0,001 vs respective unstimulated. 
MCC950 inhibition of NLRP3 had no effect on the NHS induced IL-1β secretion, 
while it largely prevented the Aβ induced IL-β secretion in all treatments containing 
Aβ, however the NHS+Aβ induced IL-1β secretion was least affected (Figure 5.5). 
In contrast PMX53, the C5aR1 antagonist, prevented the NHS and NHS+Aβ 
induced IL-1β secretion but not the Aβ induced secretion, demonstrating that C5a 
generated in the NHS was responsible. PMX53 had a stronger effect on the 
NHS+Aβ than expected. We were expecting that only the NHS component would 
have been affected, but it seemed to have a very strong inhibition, possibly 
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because the response is synergistic and not additive, it is possible that the 
complement component is contributing more to the inflammatory response. 
A combination of both MCC950 and PMX53 was able to inhibit IL-1β secretion in 
response to any of the stimulations (Aβ alone or in combination with complement) 
(Figure 5.5), suggesting that a combinational therapeutic intervention targeting 
both the inflammasome and the complement system might be the most beneficial.  
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5.7 Conclusion 
The pathogenesis of AD and other neurodegenerative diseases is characterised 
by inflammatory processes, which may be triggered by molecules of the NOD-like 
receptor (NLR) family, such as NLRP3. NLRP3 may form the inflammasome 
complex and upon activation leads to a cascade of events resulting in the secretion 
of cytokines, such as IL-1β. The irregular activation of the inflammasome is 
observed in cases of AD patients, hence targeting the specific molecule is of great 
interest. 
Previous studies identified NLRP3 inhibitors, however the MCC950 inhibitor is 
more potent and specific than other NLRP3 inhibitors and has several advantages 
which are listed below. Coll et al. (2015) demonstrated that the MCC950 inhibitor 
overcomes the side effects of other anti-inflammatory drugs commonly used and 
observed that it blocks the production of inflammatory factors in blood samples 
from patients with a severe inflammatory disorder. In addition, MCC950 may be 
orally administered, hence has pharmaceutical potential as a therapeutic drug. 
IL-1β maturation may be mediated by a number of different enzymes, such as 
serine proteases (Latz et al. 2013). MCC950 was demonstrated to not block the 
major antimicrobial inflammasomes NLRC4 and NLRP1, therefore a specific 
targeting of NLRP3 will not result in the complete blockade of IL-1β in vivo during 
infection (Coll et al. 2015). MCC950 may have less immunosuppressive effects 
compared with biologics, such as canakinumab, and a shorter half-life (Dinarello 
and van der Meer 2013). Thus, it may be withdrawn should unwanted effects, such 
as infections, occur. Furthermore, MCC950 is a small molecule and may be more 
cost effective compared with other biologic agents (Fautrel 2012). In conclusion, 
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the clinical progression of MCC950 or other derivatives may lead to the 
development of novel anti-inflammatory therapies for Alzheimer’s disease. 
In the case of complement, over the last decades, its role in the genesis of the 
inflammatory process and inflammatory diseases, including AD, has been gaining 
increasing attention (Sarma et al. 2006). One of the main effector components of 
the complement system is the anaphylatoxin C5a: one of the most potent 
inflammatory peptide mediators binding to its G-protein-coupled receptor (C5aR1) 
present in inflammatory cells (Werfel et al. 1992). C5a is a potent neutrophil 
chemoattractant and induces an increase in oxidative burst, phagocytosis, and 
release of granule enzymes (Hetland et al. 1998).   
In the current study, the data demonstrated the importance of C5a in Aβ-induced 
inflammasome responses, supporting the hypothesis that the inhibition of C5a-
induced inflammation via its receptor, C5aR1, reduces the secreted IL-1β levels. 
C5a was found to be able to “prime” the cells, especially when added prior to the 
addition of Aβ, and subsequently augment the inflammasome response. 
Therefore, the interaction of C5a+Aβ seems to be synergistic and not additive. 
Single 1 (priming) of inflammasome activation is delivered via C5a- C5aR1 axis, 
whereas Signal 2 seems to be calcium and Cathepsin-B dependent. Calcium must 
most likely be triggered by C5a, since it has been shown that C5a stimulates 
calcium influx (Monk and Partridge 1993). In the case of Cathepsin-B release, we 
believe that it must be attributed to the Aβ. Internalization of Aβ must eventually 
result in lysosomal damage and Cathepsin B release into the cytosol (Halle et al. 
2008), thus both calcium and Cathepsin B release must be delivering Signal 2 of 
inflammasome activation.  
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Since both complement and Aβ contribute to the inflammasome activation 
observed, it would be beneficial for therapeutic interventions to be targeting both 
pathways. Thus, in this study, we tested inhibiting the complement system, the 
inflammasome and both. PMX53, which is a C5aR1 antagonist, was able to 
potently inhibit NHS+Aβ responses. It had a stronger effect on the NHS+Aβ than 
expected, as we were expecting that only the NHS component would have been 
affected, but it seemed to also affect the Aβ; possibly suggesting there is a 
synergistic effect of NHS+Aβ when added together (and the effect is not simply 
additive), that once you remove the complement component, you reduce most of 
the inflammation. This is in agreement with recent literature, that demonstrates 
that C5a in particular primes the cells for inflammasome activation (An et al. 2014; 
Samstad et al. 2014) and subsequently addition of crystals or aggregates (as it is 
in this case with the Aβ), further trigger the inflammasome response. 
The secretion of IL-1β was further reduced in the combinatory treatment of 
PMX53+MCC950, indicating an interplay between complement and 
inflammasome, which agrees with the current literature as mentioned above. 
Therefore, suggesting that combinatory treatments to tackle the effect of Aβ in 
cells would be beneficial. This combinatory therapeutic approach is attractive due 
to the specificity of the pathways being inhibited, the potential for oral delivery for 
both drugs, the already successful Phase 1 testing of PMX53 in humans, and the 
fact that these drugs could be prescribed following clinical diagnosis of early stage 
AD. In conclusion, further investigation is required to identify the potential 
combinatory use of a C5a receptor antagonist and an NLRP3 specific inhibitor as 
a therapeutic for AD in humans. 
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Chapter VI 
Discussion 
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Alzheimer’s disease is a neurodegenerative disorder and the most common cause 
of dementia in the elderly. Patients show a gradual onset and progression of 
memory loss and other cognitive deficits. It is widely accepted that the extracellular 
accumulation of Aβ in senile plaques is a principal event in the pathogenesis of 
Alzheimer’s disease (Meyer-Luehmann et al. 2008), but the cellular events leading 
to plaque-induced neuronal dysfunction are still unclear.  
The innate immune system has been primarily viewed as the first line of defence 
against “danger” acting quickly by mounting an inflammatory response and 
eliminating the intruders, thus buying the adaptive immune system time to pick up 
momentum. The innate immune system employs PRRs, such as Toll like receptors 
(TLRs) and complement to detect “danger”. Both complement and TLRs are swiftly 
activated in response to infection or danger and have both been linked to 
neuroinflammation in the AD brain. Neuroinflammation is proposed to play a key 
major role in AD pathogenesis. Neuroinflammation is concentrated at sites of Aβ 
plaques, which exhibit increased levels of pro-inflammatory cytokines, 
complement components and proteases (Akiyama et al. 2000; McGeer et al. 
2006). Aβ plaques are surrounded and infiltrated by activated astrocytes and 
microglia, which are believed to be the major source of local inflammatory 
components (Akiyama et al. 2000). TLRs and complement have been individual 
linked to AD, but currently, there is increasing evidence for extensive bidirectional 
cooperation between the two systems, shaping the immune response through both 
synergistic and antagonistic crosstalk.  
The complement system is a well-known powerful effector mechanism of the 
innate immune system, providing protection from infection and resolution of injury. 
It recognises PAMPs, quickly tags them and eliminates the pathogen. It is one of 
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the innate immune mechanisms considered to play a role in the death of the brain 
neurons in patients with AD. Evidence for complement mechanisms in microglial 
responses to Aβ has been reported, but may not been fully appreciated. Microglia 
and other brain cells express the genes and/or proteins for virtually all classical 
and alternative pathway components (Walker et al. 1992; Walker et al. 1995). As 
demonstrated by Linton and Morgan (1999) and Hawlisch et al. (2004), the 
complement system is involved in numerous inflammatory conditions. The 
effectors of the complement were originally believed to be mediators due to their 
capability of enhancing phagocytosis, hence protecting the host from pathogens 
(van Beek et al. 2003). As demonstrated later, the complement served a role in 
the physiopathology of numerous acute and chronic inflammatory diseases. For 
example, the complement can recruit and activating leukocytes in various 
diseases, including rheumatoid arthritis, primarily via C5a (Weissmann 2006). 
The classical and alternative pathways are directly activated by Aβ in an antibody-
independent fashion (Daly and Kotwal 1998). In particular, the classical pathway 
has been shown to be directly activated in AD by both fibrillar Aβ deposits and 
neurofibrillary tangles (Shen et al. 2001; Rogers et al. 1992). All components of 
the classical pathway (Shen et al. 1997) and the alternative pathway (Strohmeyer 
et al. 2000) have been identified in neurons of the AD brain. The end product of 
the terminal pathway, the membrane attack complex (MAC), was also found in 
neuronal membranes of the AD brain (Webster et al. 1997).  
Long before TLRs and complement had been implicated in autoimmune diseases, 
studies had demonstrated that neuroinflammation plays a key role in 
neurodegeneration in AD. Both complement and TLRs are swiftly activated in 
response to infection or danger and there is increasing evidence for extensive 
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bidirectional cooperation between the two systems, shaping the immune response 
through both synergistic and antagonistic crosstalk. TLRs and complement have 
been individually linked to AD. Aβ linked with AD can activate both types of these 
receptors, but whether and how these two innate immune systems interact with 
each other in the context of AD has not been studied before. It is our hypothesis 
that deposition of Aβ peptide can activate both the TLR and complement systems 
and evoke Alzheimer's pathology.  
The cells of the innate immune system can recognize molecules shared by groups 
of related microbes, PAMPs, which are essential for the survival of the invading 
organisms. Similarly to microglia, astrocytes have an essential role in the immune 
response against CNS pathogens. They are a major source of inflammatory 
chemokines, and TLRs have been proved to exist in astrocytes (Bsibsi et al. 2002; 
Bowman et al. 2003; Carpentier et al. 2005; Farina et al. 2005). It has been 
previously demonstrated that primary astrocytes express low levels of TLR2, 
TLR3, TLR5 and TLR9, while the expression of each TLR homolog was rapidly 
up-regulated, following exposure to its corresponding ligand (Kielian 2006). In 
addition, certain microbial components have been shown to up-regulate the 
expression of other TLR homologs instead of their corresponding TLR homologs 
(Jack et al. 2005; Konat et al. 2006), whereas the exposure of astrocytes to 
inflammatory cytokines may also augment TLR expression. The results of the 
above studies imply that cell activation by microbial components and/or 
inflammatory cytokines could possibly sensitize astrocytes by increasing the 
expression of PRRs. Therefore, subsequent to CNS damage or infection, this 
could increase the immune responses of astrocytes (Konat et al. 2006). 
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Furthermore, IL-1β is a key player associated with the development and onset of 
AD. It can be released by glial cells and activates the NF-kB pathway to up-
regulate cytokine production. Increased levels of cytokines such as IL-1β, IL-6 and 
TNF-a have been previously demonstrated in cerebrospinal fluid samples of 
patients with AD, when compared to their age-matched healthy controls (Blum-
Degen et al. 1995). In addition, increased levels of IL-1β have been observed in 
the circulation of AD patients (Licastro et al. 2000). IL-6 immunoreactivity was 
established in diffuse Aβ plaques of patients with AD by a previous study, and it 
was demonstrated to regulate neuronal survival and function (Gadient et al. 1997). 
Increased production of inflammatory compounds may lead to the 
neurodegeneration observed in AD. In the present study, IL-1β production was 
investigated in response to inflammasome activation induced by Aβ in astrocytes. 
Silencing different NLRs and TLRs allowed us to discover their involvement in 
inflammasome activation. 
Initially we demonstrated that all PRRs of interest were present albeit at low levels 
in wt astrocytes, therefore astrocytes were able to detect and respond to a wide 
range of PAMPs and DAMPs. Our data demonstrated an increase of IL-1β in 
response to Aβ stimulation in wt astrocytes. Upon silencing the activity of NLRP3, 
TLR2 or TLR4, a decrease in IL-1β secretion was observed at 2, 4 and 6 h time 
points, compared to the level of secretion of either Aβ-stimulated wt or Aβ-
stimulated shNLRP1 astrocytes. This further indicated the key role of NLRP3, 
TLR2 and TLR4 activity in the activation of the inflammasome and the recognition 
of Aβ. 
One of the signalling cascades that can be triggered by Aβ is the NF-kB pathway. 
NF-kB resides in the cytoplasm and is associated with its inhibitory protein IkB. 
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Once stimulated, IkB is phosphorylated leading to proteasomal degradation. NF-
kB then becomes free and is translocated into the nucleus leading to the 
transcription of cytokines. This is an essential step in inflammasome activation, as 
a Signal 1 (priming signal) is needed to produce pro-IL-1β and pro-IL-18 in the 
cytosol. TLRs act upstream of NF-kB activation and to identify whether the 
pathway was activated we probed for phospho-IkkB. In our study, it was shown 
that activation of TLR2 and TLR4 was essential to trigger Signal 1 of Aβ-induced 
inflammasome activation. This agrees with previous studies that have shown that 
TLR4 is linked to Aβ recognition. 
The other signalling cascade that can be triggered by Aβ is Signal 2, leading to 
the activation of caspase-1 and the secretion of IL-1β and IL-18. To investigate 
whether inflammasome activation) we probed for caspase-1 p10. It was shown 
that NLRP3 was essential in activating the inflammasome in response to Aβ. The 
experiments confirmed that NLRP3, TLR2 and TLR4 play a major role in the 
recognition of Aβ, which agrees with recent studies that have shown that Aβ is 
linked to the NLRP3 inflammasome (Halle et al. 2008).  
AD brain samples from previous studies have demonstrated increased expression 
of caspase-1 and activated NLRP3 inflammasome. In the present study, we 
observed that subsequent to stimulations with Aβ, NLRP3 was activated and 
neuroinflammation was present in the AD brain, as demonstrated by confocal 
microscopy. To identify NLRP3 and complement interaction in the AD brain, AD 
brain tissue from patients with AD and healthy controls was stained for NLRP3 and 
MAC (C9), demonstrating that NLRP3 and MAC co-localize in amyloid plaques of 
the AD brain, further indicating an inflammasome-complement interaction. The 
data indicated that our hypothesis was right and neuroinflammation is due to the 
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PRRs and complement. These findings are extremely novel, as the interaction of 
NLRP3 and C9 in the brain of individuals with AD has never been demonstrated 
before. This finding is significant as the link of inflammasome-complement 
interactions in the amyloid plaque demonstrates that both parts of the innate 
immune system are linked with AD, but questions remain as to which parts of the 
complement system are responsible for this interaction, how is Signal 1 and Signal 
2 triggered and how can we inhibit it. Therefore, we proceeded to analyse further 
the exact molecular mechanisms that are involved. 
When we started to investigate the innate immune responses in the presence of 
both Aβ and complement, it was demonstrated that Aβ-induced responses were 
augmented in the presence of complement. Aβ in the presence of complement 
appeared to induce the heterotypic interactions of TLR4 and C5aR1 on the cell 
surface, triggering Signal 1 of inflammasome activation. 
These heterotypic complexes (TLR4/ C5aR1/Aβ) complexes internalized within 30 
min and were found to be targeted to the Rab5+ containing endosomes. 
Interestingly, this internalization step was crucial for triggering signalling, as 
signalling molecules were found to be recruited to the endosome. In particular, the 
NF-kB-inducing kinase (NIK), which results in the activation of the non-canonical 
NF-kB pathway, was recruited to the endosomes, and was found to co-localise 
with Aβ, TLR4 and C5aR1, suggesting that internalization and signalling are 
interlinked in the case of Aβ – especially in the presence of complement. In 
addition, we demonstrated that complement internalized along with Aβ and TLR4 
in Rab5+ endosomes, and recruited NIK to these endosomes, which is a finding 
that is extremely novel. 
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Although we had demonstrated a synergistic interaction between NHS as a source 
of complement and Aβ we had to decipher which part of the complement system 
was responsible for triggering the response. When we utilised C5-depleted serum, 
the IL-1b response was reduced, suggesting the terminal pathway of complement 
is the one responsible for augmenting the response. More specifically, when we 
utilised C5a purified complement components to stimulate the cells in the 
presence of Aβ, the results demonstrated that C5a stimulation resulted in 
increased IL-1β secretion compared with the unstimulated astrocytes. 
Furthermore, an augmented effect was observed in the combinatory treatment of 
C5a+Aβ compared with the individual treatments of C5a or Aβ. This was even 
more pronounced if cells were “primed” (or pre-treated) with C5a 30 min prior to 
exposure to Aβ; thus, demonstrating that the effect is synergistic, rather than 
additive.  
C5a is the most potent anaphylatoxin and chemoattract and it has been implicated 
in many inflammatory conditions, thus it is not surprisingly that it seems to 
contribute to Aβ-induced inflammation. C5a triggers its functional effects by 
binding to two receptors, C5aR1 and C5aR2. It is thought that most functional 
effects of C5a occur via C5aR1 and the role of C5aR2 is a bit unclear (Llee et al. 
2008). In our study, we wanted to identify which C5a receptor are the functional 
effects triggered by. Using function-blocking mAbs, it was demonstrated that the 
effects that we observed are triggered via the C5a- C5aR1 axis. Thus C5aR1, 
along with TLR2 and TLR4 is one of the receptors involved in triggering Signal 1 
of inflammasome activation. 
As already mentioned, the inflammasome requires two signals for activation, a 
priming signal (Signal 1) coming from an activated PRR (in this case TLR2/TLR4, 
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C5aR1) and an activating signal (Signal 2), which activates caspase-1 and 
catalyses the processing of pro-IL-1β into IL-1β. Although it is easier to determine 
Signal 1, Signal 2 seems to be rather diverse. It has been demonstrated to be 
triggered by K+/Na+ fluxes, as well as Ca2+ imbalances and the generation of 
reactive oxygen species (ROS). To determine the mechanism of inflammasome 
activation by Aβ in the presence of complement in our study we investigated 
various inhibitors that affect ion homeostasis in the cell. The inhibitors that we 
utilized are as follows: (i) BAPTA-AM, membrane-impermeable Ca2+ chelator, (ii) 
DPI (NADPH oxidase inhibitor diphenylene iodonium chloride), reactive oxygen 
species (ROS) inhibitor, and (iii) CA-074 Me, cathepsin B inhibitor (lysosomal 
damage).  
The results demonstrated that following C5a stimulation, the Ca2+ inhibition using 
BAPTA as well as the ROS inhibition with DPI reduced IL-1β secretion significantly 
compared with the PBS treatment. In contrast, the CA-074 Me treatment had no 
effect on the IL-1β secretion compared with the PBS treatment. 
In Aβ (alone) stimulation, BAPTA and DPI treatments had no effect on the IL-1β 
secretion, compared with the PBS treatment. However, treatment with CA-074 Me 
inhibiting Cathepsin B resulted in decreased levels of IL-1β compared with the 
other treatments, suggesting that Aβ must be triggering Signal 2 via lysosomal 
damage and Cathepsin B release. 
As expected, in the combinational treatments with both C5a+Aβ stimulation, ROS, 
Ca2+ as well as Cathepsin B inhibition seemed to be effective in reducing IL-1β 
secretion compared with the PBS treatment. Cathepsin B had the highest effect, 
with ROS inhibition being the least effective of the three inhibitors, suggesting that 
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Cathepsin B and Ca2+ are the main triggers of Signal 2 for inflammasome 
activation. 
Following the identification of the PRRs involved and the signalling cascades, the 
next step was to target them therapeutically. Since the irregular activation of the 
inflammasome was observed in cases of patients with AD, we decided to target 
specific molecules of interest. The presence of MAC in the AD brain suggests that 
C5a has been released since the formation of MAC is initiated by C5b, which is 
generated when C5a is cleaved from C5 by C5 convertase from either the classical 
or alternative pathways. Previous studies suggested the involvement of C5a as 
well as its receptor, C5aR1 in the neuroinflammation observed in AD. The 
expression of the C5aR1 in microglia cells of human and rodents supports this 
hypothesis (Gasque et al. 1997). A recent study by Fonseca et al. (Fonseca et al. 
2009) has demonstrated that treatment with a C5aR1 antagonist decreases 
pathology and enhances behavioural performance in murine models of AD, 
suggesting that C5aR1 is a novel therapeutic target for AD.  
Since both complement and Aβ contribute to the inflammasome activation 
observed, it would be beneficial for therapeutic interventions to be targeting both 
pathways. Thus, in this study, we tested inhibiting the complement system, the 
inflammasome and both. PMX53, which is a C5aR1 antagonist, was able to 
potently inhibit NHS+Aβ responses. It had a stronger effect on the NHS+Aβ than 
expected, as we were expecting that only the NHS component would have been 
affected, but it seemed to also affect the Aβ; possibly suggesting there is a 
synergistic effect of NHS+Aβ when added together (and the effect is not simply 
additive), that once you remove the complement component, you reduce most of 
the inflammation. This is in agreement with recent literature, that demonstrates 
224 | P a g e  
 
that C5a in particular primes the cells for inflammasome activation (An et al. 2014; 
Samstad et al. 2014) and subsequently addition of crystals or aggregates (as it is 
in this case with the Aβ), further trigger the inflammasome response. 
The secretion of IL-1β was further reduced in the combinatory treatment of 
PMX53+MCC950, indicating an interplay between complement and 
inflammasome, which is in agreement with the current literature as mentioned 
above. Therefore, suggesting that combinatory treatments to tackle the effect of 
Aβ in cells would be beneficial. This combinatory therapeutic approach is attractive 
due to the specificity of the pathways being inhibited, the potential for oral delivery 
for both drugs, the already successful Phase 1 testing of PMX53 in humans, and 
the fact that these drugs could be prescribed following clinical diagnosis of early 
stage AD. 
The last decade has witnessed an impressive growth of knowledge regarding the 
signaling pathways regulating glial biology and pathophysiology. In the present 
study we focused on some of the important examples, such as complement and 
inflammasome pathways, calcium efflux, reactive oxygen species (ROS) presence 
and lysosomal damage leading to inflammasome activation. These factors serve 
essential and multifaceted roles in maintaining homeostasis in brain cells. In 
addition, they have an impact on neurodegenerative processes in a complex and 
context-dependent manner, depending on their unique neuron–glial signalling 
profile or the cross-talk among TLRs and complement pathways.  
Based on the results of the present study, we proposed a model of activation, as 
detailed in Figure 6.1. 
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Figure 6.1 Proposed model of activation. TLR2 and TLR4 were demonstrated to be involved in 
Aβ recognition (see Chapter III). Data suggests that a synergistic interaction between complement 
receptors and the TLR pathway may be an important mechanism by which complement promotes 
inflammation. Preliminary data from FRET indicated that C5aR1 clusters with TLRs 2 and 4 (see 
Chapter IV). The canonical pathway is initiated by receptors on cell surface and the non-canonical 
pathway by the endosomes (see Chapter IV).  
 
Astrocytes were the glial cells of interest in the current study, as being a 
specialized type of glial cells they outnumber neurons by over fivefold. They 
contiguously tile the entire central nervous system (CNS) and exert many essential 
complex functions in the healthy CNS (Sofroniew and Vinters 2009). A vital 
question arises, however, as to how many types of astrocytes exist in the CNS. 
Furthermore, the morphological and molecular signatures of astrocytes have not 
been fully elucidated, particularly the way these signatures may alter during aging 
and in pathological conditions. There is a possibility that different types of 
astrocytes exist in the hippocampus and frontal lobe (areas primarily affected in 
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AD) and have different responses to brain stimuli/insults. In addition to astrocytes, 
future work should focus on the use of microglia compared to astrocytes in order 
to see the importance of microglial cells in complement-inflammasome 
interactions. It has not been possible to use such cells for comparison in this study, 
but in the future with the generation of iPSC (induced pluripotent stem cells)-
derived microglia-like macrophage microglial cells, there would be an opportunity 
to compare the results.  
Future work should also include testing the inhibitors that we have used in vitro in 
an in vivo model of Alzheimer’s (such as J20 mouse, or the 3Tg mouse strains). It 
would be very interesting to try to inhibit the inflammasome (using MCC950), the 
complement system (with PMX53 or even Compstatin) and a combination of both 
in a mouse model of Alzheimer’s. In addition to testing the pro-inflammatory profile 
of the mice throughout the time of the experiment, as well as, performing 
immunohistochemistry of the brain tissue, it would be beneficial to image the mice 
using MRI and PET (using antibodies against NLRP3 and complement 
components) to assess any changes in their brain. Behavioural studies in order to 
establish whether there is cognitive impairment should also be conducted.  
Our studies and others have confirmed the inflammatory nature of Aβ. We have 
moved the field a step further forward in deciphering the molecular mechanisms 
involved, by demonstrating that there is complement-inflammasome crosstalk. 
Only by targeting these pathways can we hope to be able to develop a therapeutic 
intervention for Alzheimer’s for the future. 
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